Huston vs. Cleveland Clinic

Deposition of Howard Muntz, M.D.

June 22, 2002



1326 Fifth Avenue, Suite 721 Seattle, Washington 98101 (206) 287-9066 Fax: (206) 287-9832 e-mail: lisabuell@aol.com х. У

(?) 京

\$

IN THE COURT OF COMMON PLEAS CUYAHOGA COUNTY. OHIO	DEPOSITION OF HOWARD MUNTZ, M.D. EXAMINATION INDEX
JOHN M. HUSTON, Executor,) Plaintiff,)) JUDGE COYNE vs) No 439194) THE CLEVELAND CLINIC) FOUNDATION, et al.,)) Defendants) DEPOSITION UPON ORAL EXAMINATION OF HOWARD MUNTZ, M.D. Taken at 1326 Fifth Avenue Seattle, Washington	EXAMINATION BY PAGE Ms. Nissenberg 4 EXHIBIT INDEX EXHIBITS FOR IDENTIFICATION PAGE 1 Curriculum Vitae 4
DATE TAKEN: JUNE 22,2002 REPORTED BY: JOLENE C. HANECA, RPR, CCR HANECAJC2741	
<section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><text><text><text></text></text></text></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header>	 Page 4 1 Seattle, Washington; JUNE 22, 2002 2 9:00 3oOo 4 (Exhibit No. 1 marked.) 5 6 HOWARD MUNTZ, M.D., witness herein, having been 7 first duly sworn on oath, 8 was examined and testified 9 as follows: 10 11 E X A M I N A T I O N 12 BY MS. NISSENBERG: 13 Q. Would you state and spell your name for the 14 record, please. 15 A. Howard Muntz, H-O-W-A-R-D M-U-N-T-Z. 16 Q. And you are a medical doctor? 17 A. Yes. 18 Q. We're here today because you've been designated 19 as one of the defense experts in this case. We're here 20 to get your deposition as to all the opinions that you 21 have formed in this case that you intend to offer at 22 trial. 23 Have you ever had your deposition taken before? 24 A. Yes. 25 Q. Approximately how many times?

1 (Pages 1 to 4)

$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\end{array} $	 Page 5 A. Probably four or five times. Q. With what were those in connection, specifically? A. There was one malpractice case when I was a fellow in Boston that involved nursing error for the administration of chemotherapy. So I was deposed in that case as a fact witness, I suppose is the best way to describe that. And I've done a few medical malpractice cases as an expert witness for both plaintiff and defense. Q. Did any of those involve ovarian cancer? A. Yes. Q. What type of cases were those? A. Oh, one case was a young woman with an immature teratoma, which is a highly malignant type of ovarian cancer. That was a failure-to-diagnose-type malpractice case. That was only the case, if I'm recalling correctly, that was ovarian cancer specifically. Q. And, in that case, did you testify on behalf of the defense? A. No, it was on behalf of the plaintiff. 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\end{array} $	 Page 7 If you answer the question, I will assume that you understood it as asked. All right? A. All right. Q. How many times have you been named as an expert witness, to the best of your knowledge? A. Oh, probably less than half a dozen. Q. And of the depositions that you have given, the four to five times, have most of those been in the last five years? A. Yes. Q. How often during the year are you asked to review medical negligence matters? A. Probably only about once per year. Q. What percentage of your clinical time is used in reviewing cases? A. Infinitesimal. Small amount. Q. I wasn't going to tell Virginia Mason. That's okay. Have you ever given any talks or speeches regarding medical negligence litigation? A. No. Q. And have you ever worked with any defense firms
22	Q. Do you recall what the gist of your opinions	23	in Ohio before?
23	were in that case?	24	A. Yes, actually, I have.
25	A. In that situation, the woman had been seen in	25	Q. What firms were those?
1 2	Page 6 the emergency room, was misdiagnosed with irritable bowel syndrome and sent home, only to have her ovarian cancer	1 2	Page 8 A. I can't remember the name of the firm. I'm
2 3 4	rupture a few months later and developed disseminated disease.	3 4	just drawing a total blank on that.Q. Do you remember what city?A. It would have been in the general Cleveland
5 6 7	Q. Teratoma, is that part of the staging system, the FIGO staging system? Does that appear in there for ovarian?	5 6 7	area. Q. Did you actually give a deposition in that case?
8 9 10 11 12	 A. An immature teratoma is a germ cell malignancy of the ovary. So it simply represents one of the three broad categories of ovarian cancer, and as such, it would be staged according to the FIGO system. Q. And there's a substrata of people diagnosed with early germ cell tumors of the ovary that, in fact, 	8 9 10 11 12 13	 A. I did do a deposition, but that case did not go to trial, or if it did, I'm drawing a blank on that, also. Q. In that case, were you working on behalf of the plaintiff or the defense? A. I was a defense expert for that case. Q. And you don't remember the name of the firm?

	Page Q		Page 11
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 9 Mr. Bonezzi was the counsel for the defense. Q. Is that the same case that you were just telling me about? A. No. It was a different case. Q. Where was that filed, what state? A. That was also in Ohio. Q. So that's two cases that you have given testimony in in Ohio? MR. BONEZZI: Excuse me. Listen to his answers and remember your question. You asked him if he has given testimony as a defense witness. MS. NISSENBERG: No, I didn't. MR. BONEZZI: Yes, you did. MS. NISSENBERG: I asked if he has given deposition testimony. MR. BONEZZI: I'm going to ask you, seriously, Merel, to listen to his answers, because you're already starting to ask the same question where he has already provided you the answer. BY MS. NISSENBERG: Q. I asked you how many times you have given deposition testimony or worked with firms in Ohio, and I think you said once in the general Cleveland area?	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\21\end{array} $	 Page 11 A. Okay. Three cases in Ohio; two are for plaintiffs, one was for defense. Q. In the cases in which you testified A. Actually, I haven't finished. Q. I'm sorry. A. Three yielded depositions and one went to trial, at which I did testify. That was for the plaintiff. One plaintiff case was settled before it went to trial. And then the third case for the defense went to trial, but I was not required to testify at trial. Q. Have you ever testified on behalf the case in which you testified for the defense, that did not involve Mr. Bonezzi's firm, correct? A. No, it did not. Q. Do you know personally any of the GYN oncologists at the Cleveland Clinic? A. No, I do not. Q. Have you ever discussed any aspect of this case with the GYN oncologists at the Cleveland Clinic? A. No, I have not. Q. May I look at the file that you brought with you today?
23 24	Is it more than once?	24	A. Yes. There's a copy of the letter that I
25	A. We can probably clarify matters by talking	25	provided Mr. Bonezzi back in March, when I was first
	Page 10		Page 12
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 about three different scenarios. One is when I'm asked to review a case. The second is when it moves forward to an actual deposition. And then last, which is the most infrequent of the situations, is when I'm actually called to Ohio to give trial testimony. Q. And in the case that you referenced earlier, you said it either didn't go to trial or you don't have any recollection? A. Let me pause for a moment and just collect my thoughts on that, so that I can give you a chapter-and-verse account of that. (Telephonic interruption.) MR. BONEZZI: Go ahead. (Discussion off the record.) A. I think I can give you the information you want Q. Great. A in a concise way without doing the 20 questions, which then confused me, because some of your legal language in terms of what is testimony, I think of 	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 asked to review this case. Q. This is the opinion letter that you furnished. Is there anything else in your file? A. No, blank paper. Q. Did you make any notes when you reviewed anything that you did review to give your opinions in this matter? A. I'm sure I had a working draft of this, but that's no longer available, since it would have been discarded as I created my final document. Q. Have you ever discussed this case or any aspect of this case with any GYN oncologist at Virginia Mason or anywhere else? A. No. Q. Do you know any of the pathologists at the Cleveland Clinic? A. No. Q. What is your understanding of the nature of the plaintiffs claim in this case? A. Failure to diagnose ovarian cancer. Q. Do you have an understanding as to any
22 23 24 25	that being trial testimony, but what I'm realizing now is you're also talking about deposition as being testimony. Am I correct? Q. Correct.	22 23 24 25	 particular physicians with whom the plaintiff is unhappy? A. I understand that she's unhappy with the Cleveland Clinic in general, but I do not know which physicians in particular the claim is being filed

3

١

r	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	1	
	Page 13		Page 15
2 3 fa 4 s 5 th 6 7 8 th 9 o 10 11 th 12 13 da 14 15 16 17 18 2' 19 ba 20 21 22 23	 against. Q. And with respect to the plaintiffs claim of ailure to diagnose ovarian cancer, can you be more specific, if you have a more specific understanding of heir claim? A. I'm not sure I understand the question. Q. You understand the plaintiff's claim to be that he Cleveland Clinic failed to make a timely diagnosis of ovarian cancer. Is there anything else that you understand heir claim to consist of, any more specifics? A. That pretty much covers the complete case, loesn't it? Q. When were you first contacted in this case? A. I don't remember. Q. Was it in the year 2002? A. I can assume that if I'm writing a letter March 7, 2002, that I would have been contacted a month or two effore then. Q. Do you recall who contacted you? A. Someone from Mr. Bonezzi's office. Q. Was it Mr. Bonezzi? A. No. I doubt that Mr. Bonezzi and I would have poken about the case immediately. I think, as you're familiar, the usual routine 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 depositions were done just this week and might have not even been transcribed yet. Q. Which depositions did you receive subsequent to forming your opinions that appear in your letter? A. I have honestly lost track. MR. BONEZZI: I will tell you. It was Drs. Biscotti, Gramlich and Levin. Q. Mr. Bonezzi has indicated that you were provided with the depositions of Dr. Gramlich, Dr. Levin and Dr. Biscotti. Do you recall receiving those depositions? A. Yes, I do. Q. Did you have an opportunity to read those depositions? A. Yes, I did. Q. Were you ever provided with the deposition of Dr. Braherd, the cytopathologist who read the pelvic washings in this case? A. Yes, I did, although that is one of the depositions I received several months ago. Q. What about the deposition of Julie Shorie, S-H-O-R-I-E? A. I don't think I received that one. Can you describe to me MR. BONEZZI: No, you didn't see that. We
2 av 3 de 4 re 5 6 th 7 8 w 9 10 re 11 12 le 13 14 w 15 ac 16 A 17 Te 18 de 19 Br 20 21 22 th 23 24 so	 Page 14 an office staff member contacts me to see if I'm vailable, No. 1; and then, No. 2, after a brief escription of the case, to see if I'm interested in epresenting or, I should say, helping with the defense. Q. Did you request certain materials at the time hat you had this first contact? A. I would not have requested materials, but they yould have been provided to me automatically. Q. What materials did you receive for your initial eview? A. That's listed in the first paragraph of my etter back to Mr. Bonezzi. Q. So we can assume that you have provided you you rere provided with the clinical records of Mrs. Huston's dmission to the Cleveland Clinic from April '99 through august 2000, the first summary statement of Dr. William ench, the statement of Dr. Weiss, and only four epositions, those of Drs. Prayson, Kennedy, Markman and rainerd; is that correct? A. That's correct. Q. Is there anything else that you received from the defense firm for your review? A. Subsequent to this, I have received copies of one of the other depositions, although not all of them are arrived for my review. And I understand that some 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Page 16 didn't send you that. Q. Did you request at any time any additional records or deposition transcripts from the defense firm? A. I've never requested anything, obviously. I'm simply provided with material as it becomes available. Q. And the two volumes of records you have in front of you, those are the medical records that you have referenced in the letter already, correct? A. That's correct. Q. Have you seen the pathology slides in this case? A. No, I have not. Q. Did you ever request to see them? A. No, I have not. Q. Prior to today, did you have an opportunity to meet with defense counsel? A. Yes, I have. Q. Approximately how many times? A. Just once. Q. Was that before or after your opinion letter? A. It was after my opinion letter. Q. And what was discussed during that conversation? A. We reviewed the case and discussed in general the content of my letter from the end of March.

1			noward Multi2, Wil
	Page 17		Page 19
1	Q. Did you ever receive the second of Dr. Tench's	1	the pathology interpretation for this case.
2	expert reports?	2	Q. That's what he told you Dr. Robboy testified?
3	A. No, I have not.	3	A. That is probably a gross oversimplification.
4	Q. Were you aware that one exists?	4	Dr. Robboy has, of course, given extensive deposition
5	A. I don't think I knew one existed. Did it	5	testimony, and that's one of the transcripts that I have
6	change?	6	not had a chance to review.
7	MR. BONEZZI: That's the one I showed you	7	Q. What did Mr. Bonezzi tell you Dr. Tench
8	yesterday.	8	testified to at his deposition on Wednesday?
9	A. Did it change substantively from his first	9	A. I don't recall that he spoke specifically about
10	opinion?	10	what Dr. Tench said, other than to review
11	Q. Ijust want to know if you've seen it.	11	MR. BONEZZI: Actually, you have it backwards.
12	MR. BONEZZI: This one.	12	We spoke about Dr. Tench as opposed to Robboy.
13	A. I guess not to be difficult, but there's a	13	THE WITNESS: Okay. BY MS. NISSENBERG:
14	difference between crossing my retina and getting into my	14	
15 16	cortex. Could I compare this with his first? I don't see that there's any substantive	15 16	Q. Now that Mr. Bonezzi has refreshed your recollection, you spoke about Dr. Tench's testimony and
10	difference between these two reports.	10	not about Dr. Robboy's testimony? Is that your
17		17	recollection?
10	Q. Is today the first time that you have reviewed that second report?	10	A. I honestly don't recall precisely which
20	A. Mr. Bonezzi has reminded me that we actually	20	pathologist we were talking about.
20	looked at this together yesterday evening.	21	O. As you sit here today, do you have any
22	O, That brings up my next question. Did you have	22	information as to how Dr. Robboy at Duke testified on
23	a meeting with Mr. Bonezzi prior to today's deposition,	23	Tuesday of this week?
24	other than the one you already told us about?	24	A. I don't know the details of his testimony.
25	A. No, the one meeting yesterday.	25	O. What do you know about his testimony?
			e i i
	Page 18		Page 20
1	• I think you already told ma that you mat with		
1. 1	() I think you alleady told life that you lifet with	1	A. But I do know that he feels that the material
	Q. I think you already told me that you met with him at some point after you did the report.	1 2	A. But I do know that he feels that the material is very difficult to evaluate, and that probably most
2 3		[is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the
2	him at some point after you did the report. Is that what you were talking about, yesterday's meeting?	2	is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing
2 3	him at some point after you did the report. Is that what you were talking about,yesterday's meeting?A. No, one meeting yesterday.	2 3	is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical
2 3 4 5 6	him at some point after you did the report. Is that what you were talking about,yesterday's meeting?A. No, one meeting yesterday.Q. And then yesterday?	2 3 4 5 6	is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some
2 3 4 5 6 7	him at some point after you did the report. Is that what you were talking about,yesterday's meeting?A. No, one meeting yesterday.Q. And then yesterday?A. No, one meeting, which was yesterday.	2 3 4 5 6 7	is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign.
2 3 4 5 6 7 8	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. 	2 3 4 5 6 7 8	is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report?
2 3 4 5 6 7 8 9	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written 	2 3 4 5 6 7 8 9	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi.
2 3 4 5 6 7 8 9 10	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. 	2 3 4 5 6 7 8 9 10	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony
2 3 4 5 6 7 8 9 10 11	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. 	2 3 4 5 6 7 8 9 10 11	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi?
2 3 4 5 6 7 8 9 10 11 12	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken 	2 3 4 5 6 7 8 9 10 11 12	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct.
2 3 4 5 6 7 8 9 10 11 12 13	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? 	2 3 4 5 6 7 8 9 10 11 12 13	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is
2 3 4 5 6 7 8 9 10 11 12 13 14	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations 	2 3 4 5 6 7 8 9 10 11 12 13 14	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. And we probably would have just confirmed that 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the ins and outs of the pathology review, including all the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. And we probably would have just confirmed that he had received my original correspondence, and that was 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the ins and outs of the pathology review, including all the difficulties of sorting out cytology versus histology,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. And we probably would have just confirmed that he had received my original correspondence, and that was pretty much it. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the ins and outs of the pathology review, including all the difficulties of sorting out cytology versus histology, were all revolving around Dr. Tench's testimony.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. And we probably would have just confirmed that he had received my original correspondence, and that was 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the ins and outs of the pathology review, including all the difficulties of sorting out cytology versus histology,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. And we probably would have just confirmed that he had received my original correspondence, and that was pretty much it. Q. When you met yesterday with him, did he tell 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the ins and outs of the pathology review, including all the difficulties of sorting out cytology versus histology, were all revolving around Dr. Tench's testimony. Q. And what you just told me about Dr. Robboy's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. And we probably would have just confirmed that he had received my original correspondence, and that was pretty much it. Q. When you met yesterday with him, did he tell you the nature of the testimony of Dr. Robboy at Duke? A. Yes, we did speak about that. Q. What did he tell you Dr. Robboy testified? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the ins and outs of the pathology review, including all the difficulties of sorting out cytology versus histology, were all revolving around Dr. Tench's testimony. Q. And what you just told me about Dr. Robboy's testimony.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 him at some point after you did the report. Is that what you were talking about, yesterday's meeting? A. No, one meeting yesterday. Q. And then yesterday? A. No, one meeting, which was yesterday. Q. Okay. A. And that includes after the report was written and before today. Q. So after you submitted this report to Mr. Bonezzi for utilization in this case, you have not spoken to him about this case prior to yesterday? A. Oh, I assume that we had some conversations just as we were getting ready for the deposition, conversations, most of them revolving around scheduling issues. And we probably would have just confirmed that he had received my original correspondence, and that was pretty much it. Q. When you met yesterday with him, did he tell you the nature of the testimony of Dr. Robboy at Duke? A. Yes, we did speak about that. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 is very difficult to evaluate, and that probably most importantly he is of the opinion that if he had seen the original 1999 material himself as a practicing pathologist, without knowing her subsequent clinical history, that he would more probably than not, or some words to that effect, signed out the case as benign. Q. Where did you learn that? From his report? A. No, from speaking with Mr. Bonezzi. Q. So then you did discuss Dr. Robboy's testimony with Mr. Bonezzi? A. Correct. Q. So then the correct testimony of you today is that you discussed both Dr. Tench's testimony and Dr. Robboy's testimony both educed this week, correct? A. That is correct, but what Mr. Bonezzi has clarified is that the more extensive discussion about the ins and outs of the pathology review, including all the difficulties of sorting out cytology versus histology, were all revolving around Dr. Tench's testimony. Q. And what you just told me about Dr. Robboy's testimony. is that ail that you know about it from his deposition this week?

	Page 21		Page 23
$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Dr. Robboy testified with respect to whether or not there were malignant cells in the pelvic washing? MR. BONEZZI: Objection to the characterization of that testimony. Go ahead and answer. A. I think it's unclear to me how to answer that question, particularly when you realize I have not reviewed the testimony. In other words, I have not had a chance to see that deposition. Q. I understand that, but you did discuss Dr. Robboy's testimony, albeit briefly, with Mr. Bonezzi when you met with him yesterday, correct? A. Correct. MR. BONEZZI: Objection to the characterization. Go ahead. Q. Maybe it wasn't briefly, but you met and discussed with Mr. Bonezzi Dr. Robboy's testimony yesterday, correct? MR. BONEZZI: Objection to the way in which that is phrased. Go ahead and answer. A. Correct. Q. And you told me that your understanding of how Dr. Robboy testified is that it was very difficult to read the slides, and that if he had been reading the slides at the time, he would have signed them out as no problem or normal or whatever, however you described it; 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 clinical decisions for the patient, correct? A. Correct. Q. And you're aware that Dr. Kennedy testified to the same effect in his deposition; is that right? A. Yes. Q. Is it your understanding that the plaintiff is unhappy with Dr. Kennedy for some reason? A. I don't have any understanding of what the plaintiff is unhappy about, other than the understandably sad outcome of the clinical case. Q. I only ask you that because you go on quite extensively in your opinion letter about how, in your opinion, Dr. Kennedy acted appropriately. I thought that maybe you considered that that was part of their claim. A. Is he part of the lawsuit? Q. Only in so much as he was an employee of the clinic at the time. A. So he's part of the lawsuit. Q. But my question is, are you aware or do you think that the plaintiff is unhappy with Dr. Kennedy's actions in this case? A. Whether the plaintiff is happy or unhappy with Dr. Kennedy is irrelevant to me, if he's part of your
	Page 22		Page 24
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	 is that correct? A. I think that's a fair summary of the gist of all the pathology review. Q. And that particular aspect of Dr. Robboy's testimony you gleaned from Mr. Bonezzi yesterday? MR. BONEZZI: Objection. A. Yes. Q. Is there anything else from Dr. Robboy's testimony? 1know you haven't read the transcript yet, but anything else about Dr. Robboy's testimony that he gave this week that you gleaned from Mr. Bonezzi yesterday? MR. BONEZZI: Objection. Go ahead and answer. A. No, I don't think there is anything of any substantive importance. Q. As part of your clinical practice, how often do you personally review GYN slides? A. All the time. Q. And as a GYN surgeon, you rely on the pathology lab to correctly analyze surgical specimens and pelvic washing slides that are submitted for evaluation, correct? A. That is correct. Q. So it's critical for those interpretations to be accurate, since you rely on them in making important 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 lawsuit. Q. Would you agree with Dr. Prayson at the Cleveland Clinic that carcinoma of the ovary typically would demonstrate more cytologic atypia than low-grade or benign lesions? MR. BONEZZI: Would you read that back, please, because you're reading awfully fast. MS. NISSENBERG: I can slow down. I can repeat it, because I don't think you got it either. Q. Would you agree with Dr. Prayson at the Cleveland Clinic that, quote, carcinoma of the ovary typically would demonstrate cytologic atypia than low-grade or benign lesions, end quote? A. Could you repeat that again? Q. Would you agree with Dr. Prayson of the Cleveland Clinic that, quote, carcinoma of the ovary typically would demonstrate more cytologic atypia than low-grade or benign lesions? A. I think that's a normal statement of fact describing any pathological process involving cancer. Q. Then you agree? A. Correct. Q. Is it fair to say that whatever opinions you have regarding the accuracy of the interpretation of the surgical specimen slides of April '99, as well as the

			·
	Page 25		Page 27
	-		-
	pelvic washing slides, is based solely on the deposition	1	Q. Since you read GYN slides in the course of your
2	testimony that you read, as well as the medical records,	2	clinical practice, why is it that you never asked to see
3	since you have never seen the slides yourself?	3	the original either surgical specimen slides or pelvic
4	A. I would not limit my opinion in that way,	4	washing slides in this case?
5	simply because as a practicing gynecologic oncologist, I	5	A. Because I'm here predominantly as the clinical
6	have had a lot of experience dealing with these difficult	6	gynecologic oncologist to try and make sense out of this
7	endometriosis cases that develop either atypical changes	7	confusing case from really a patient care standpoint.
8	that are not yet malignant or have actually evolved all	8	The pathology aspect of this case is, in my
9	the way into a malignancy associated with endometriosis.	9	opinion, very well represented already by experts on both
10	So I would say that I'm filtering this	10	sides, both by you and by Mr. Bonezzi.
11	information through my clinical experience to render my	11	Q. But wouldn't you think that since you're going
12	opinion.	12	
13	Q. But in this case, you've never seen either the	13	of the interpretation of these slides, that it would have
14	surgical slides or the pelvic washing slides, correct?	14	been important for you to see the original slides?
15	A. It is true that I have never seen them with my	15	A. No. Partly because I can read these different
16	own two eyes, but courtesy of this extensive deposition	16	reports and, again, putting it through my filter as a
17	process, I have read many, many descriptions of both the	17	clinician almost be a one-manjury for deciding how this
18	cytology slides, as well as the histology slides, and	18	dispute about the pathology slides should be resolved.
19	since I am familiar with pathology terminology, I have	19	Q. Now, you said that you read Dr. Kennedy's
20	very a good picture in my mind of what these slides look	20	deposition. That's referenced in your letter, correct?
21	like.	21	A. Correct.
22	Q. When you wrote your original opinion dated	22	Q. Then you're aware that Dr. Kennedy testified
23	March 27, 2002, in which you state basically that you	23	that Dr. Biscotti had identified for him in person a
24	disagreed that these slides were misread, even though you	24	small focus of high-grade cancer in the original B6
25	have never seen the slides, because of reading these four	25	slide, correct?
	Page 26		Page 28
· 1		1	
1	depositions that we talked about, two of the depositions,	1	A. You are misquoting, I think, some of the
2	depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and	2	A. You are misquoting, I think, some of the conversations that they had.
2	depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in	2 3	A. You are misquoting, I think, some of the conversations that they had.Q. I would be happy to show you the quote.
2 3 4	depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case?	2 3 4	A. You are misquoting, I think, some of the conversations that they had.Q. I would be happy to show you the quote.A. I know the quote you're going to show me.
2 3 4 5	depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case?A. The full text of my letter is as follows:	2 3 4 5	A. You are misquoting, I think, some of the conversations that they had.Q. I would be happy to show you the quote.A. I know the quote you're going to show me. The difficulty is jumping all the way forward
2 3 4 5 6	depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case?A. The full text of my letter is as follows:Quote, Drs. Tench and Weiss, comma, in opinions written	2 3 4 5 6	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking
2 3 4 5 6 7	depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case?A. The full text of my letter is as follows:Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the	2 3 4 5 6 7	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial.
2 3 4 5 6 7 8	depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case?A. The full text of my letter is as follows:Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and	2 3 4 5 6 7 8	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr.
2 3 4 5 6 7 8 9	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 	2 3 4 5 6 7 8 9	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him
2 3 4 5 6 7 8 9 10	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, 	2 3 4 5 6 7 8 9 10	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted
2 3 4 5 6 7 8 9 10 11	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. 	2 3 4 5 6 7 8 9 10 11	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer?
2 3 4 5 6 7 8 9 10 11 12	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these 	2 3 4 5 6 7 8 9 10 11 12	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition.
2 3 4 5 6 7 8 9 10 11 12 13	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. 	2 3 4 5 6 7 8 9 10 11 12 13	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing
2 3 4 5 6 7 8 9 10 11 12 13 14	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because 	2 3 4 5 6 7 8 9 10 11 12 13 14	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. Q. Okay. Doctor, going back to my question that I 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it is not as dramatic in its atypia or other atypical
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. Q. Okay. Doctor, going back to my question that I had asked about two minutes ago, isn't it true that the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it is not as dramatic in its atypia or other atypical findings as the original B6 that is missing, correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. Q. Okay. Doctor, going back to my question that I had asked about two minutes ago, isn't it true that the four depositions that you of the four depositions that 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it is not as dramatic in its atypia or other atypical findings as the original B6 that is missing, correct? A. That is correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. Q. Okay. Doctor, going back to my question that I had asked about two minutes ago, isn't it true that the four depositions that you of the four depositions that you had read prior to writing your opinion letter, two of 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it is not as dramatic in its atypia or other atypical findings as the original B6 that is missing, correct? A. That is correct. Q. And are you aware as you sit here today that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. Q. Okay. Doctor, going back to my question that I had asked about two minutes ago, isn't it true that the four depositions that you of the four depositions that you had read prior to writing your opinion letter, two of those were of the cytopathologist and pathologist, whose 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it is not as dramatic in its atypia or other atypical findings as the original B6 that is missing, correct? A. That is correct. Q. And are you aware as you sit here today that Dr. Robboy testified that the pelvic washings contain
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. Q. Okay. Doctor, going back to my question that I had asked about two minutes ago, isn't it true that the four depositions that you of the four depositions that you had read prior to writing your opinion letter, two of those were of the cytopathologist and pathologist, whose very interpretation of the slides are at issue in this 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it is not as dramatic in its atypia or other atypical findings as the original B6 that is missing, correct? A. That is correct. Q. And are you aware as you sit here today that Dr. Robboy testified that the pelvic washings contain atypical cells, atypical cell clusters, irregular nuclei,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 depositions that we talked about, two of the depositions, isn't it true, were of the pathologist and cytopathologist, whose very interpretation is at issue in this case? A. The full text of my letter is as follows: Quote, Drs. Tench and Weiss, comma, in opinions written for the plaintiffs attorney, comma, allege that the Cleveland Clinic pathology department negligently and I will emphasize "negligently" misread the April 1999 histology and cytology material, period. I disagree, period, end quote. I am disagreeing with the allegation that these slides were negligently misread. Q. Are you emphasizing "negligently" because you're saying they might have been misread but it wasn't negligently? Is that where you're going with this? A. I think that's where I'm going with this. Q. Okay. Doctor, going back to my question that I had asked about two minutes ago, isn't it true that the four depositions that you of the four depositions that you had read prior to writing your opinion letter, two of those were of the cytopathologist and pathologist, whose 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A. You are misquoting, I think, some of the conversations that they had. Q. I would be happy to show you the quote. A. I know the quote you're going to show me. The difficulty is jumping all the way forward and saying high-grade cancer, when what we may be talking about is atypial. Q. My question to you was, do you recall Dr. Kennedy testifying that Dr. Biscotti pointed out to him in person an area in the original B6 that he interpreted to be a small focus of high-grade cancer? A. Yes. That is in that deposition. Q. You're aware that the original B6 is missing from the Cleveland Clinic? A. I figured that out by reading the depositions. Q. And are you aware further that Dr. Biscotti states that in looking at the first recut of B6, that it is not as dramatic in its atypia or other atypical findings as the original B6 that is missing, correct? A. That is correct. Q. And are you aware as you sit here today that Dr. Robboy testified that the pelvic washings contain

Buell Realtime Reporting (206) 287-9066

7 (Pages 25 to 28)

Huston vs. Cleveland Clinic Foundation

$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Page 29 Dr. Robboy testified to that? MR. BONEZZI: Objection to that. Go ahead and answer the question. A. Again, I have not seen Dr. Robboy's transcript of his deposition. I would also be concerned that you are stating all that in a way that is perhaps overly dramatic in terms of its content. Q. My question I can say it in sotto voce. My question just is, are you aware that Dr. Robboy testified to that? A. I think the simple answer to that question is no, I'm not aware, because I have not seen the deposition transcript. Q. And you're aware that in Dr. Brainerd's original report that she signed out, there is no mention of atypia, correct? A. That is correct. Q. You are aware that there is not only no mention of any type of epithelial cells, but that she testified that there are no epithelial cells present in the pelvic washings? Do you recall that from her testimony? A. That I actually do not recall. Q. Is there anything else that you recall from reading Dr. Biscotti's testimony relative either to the 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	Page 31 original B6 to show you, do we? MR. BONEZZI: Objection. A. We have, I think, a very honest recollection by Dr. Biscotti of what the original B6 looked like. And I would say that, as I read his testimony, he's been very forthright in acknowledging that the recut is underrepresentative of what he saw on the original. Q. You're aware that Dr. Kennedy testified at his deposition that he believes that on April 29th, 1999, there was cancer developing within endometriosis in Mrs. Huston's ovary? A. I would substitute the word "in" let me rephrase that. I would drop the word "in" the ovary and substitute the phrase "on" the ovary, and once we change it, I would agree completely with what you said. MR. BONEZZI: What page are you looking at? MS. NISSENBERG: I'm looking at page 39 of Dr. Kennedy's deposition, wherein he states at line 3: I think she had cancer develop MR. BONEZZI: Hang on. MS. NISSENBERG: In response to my question, as you sit here today, do you believe that Mrs. Huston had cancer on April 29, 1999, which is on page 38, and then on 39, Dr. Kennedy states MR. BONEZZI: Because I wanted you to complete	
$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Page 30 pelvic washings or the original B6 that we haven't covered? MR. BONEZZI: Objection. Go ahead. A. It's a fairly open-ended question. The point I would emphasize, again, is the importance for this case of not using language in a careless fashion. For instance, high-grade carcinoma is a phrase that should be avoided when discussing very small biopsy material and minute pelvic washings, because with the amount of cellular material present, the most you could say is atypia, because you do not have the diagnosiic material necessary to state anything about, quote, high-grade carcinoma, end quote. Q. You're referring to a biopsy. What biopsy is that? A. The ovarian tissue from 1999, as well as the cell block and thin-prep cytology material from 1999. Q. And you're saying that of the amount of tissue that was taken from the surgical specimens, that would not be adequate to make a diagnosis of ovarian cancer? A. Correct. MR. BONEZZI: Objection. A. Because the tissue was quite plentiful, but the area of abnormality was extremely small. Q. And, again, we don't have the benefit of the 	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	Page 32 that line. MS. NISSENBERG: That's why I went back to read the question. Let me start over again. Q. Question to Dr. Kennedy: As you sit here today, today being February 4th, 2002, do you believe that Mrs. Huston had cancer on April 29th, 1999? Answer: Ido. And then on page 39, beginning at line 3, he states: I think she had cancer developing within, comma, in the endometriosis of the ovary. Did you recall that testimony? A. Yes. And, in fact, like most deposition testimony, it gets tortured when it's read back by the court reporter. What Dr. Kennedy is saying is that she had cancer developing within endometriosis. Q. Did he say in the ovary? Yes or no. A. Endometriosis is everywhere in the pelvis, including on the ovary. MR. BONEZZI: Excuse me. He says "of" the ovary, not "in." He says in the endometriosis "of' the ovary, not "in." He says in the endometriosis "of' the ovary. MS. NISSENBERG: Okay, within. MR. BONEZZI: No, within the endometriosis MS. NISSENBERG: Wait. Excuse me, Bill. MR. BONEZZI: No, I don't want you to misphrase	

Ţ

	Page 33		Page 35
1	that. He did not say in the ovary. I'm reading it.	1	O. How important is it to you as a GYN oncologist
2	MS. NISSENBERG: It says within, comma, in the	2	when you're caring for a patient with an ovarian mass to
3	endometriosis of the ovary.	3	learn whether or not the mass is cancerous?
4	THE WITNESS: No.	4	A. It is very important.
5	Q. I'm reading you the direct quote, Doctor. Within, comma, in the endometriosis of the	5 6	Q. And that would be the same whether it's primary
6	ovary. Is that the quote?	7	ovarian or in an endometriosis implant on the ovary, correct?
8	A. That is the deposition transcript.	8	A. That is correct.
9	Q. Is the transcript inaccurate?	9	Q. Would you agree that with most solid tumors,
10	A. I think it is.	10	the earlier you diagnose a cancer, i.e., when the tumor
11	Q. You don't think Dr. Kennedy stated that?	11	burden is smallest, the better prognosis for a patient in
12	A. If he verbalized that, it was with the typical	12	general?
13	hesitation or stutter that we all have during	13	A. That is a correct general statement.
14 15	depositions, but I would rephrase that as follows: Quote, I think she had cancer developing within	14 15	Q. And how important would it be for you as a GYN oncologist caring for a patient with a diagnosed ovarian
15	endometriosis of the ovary.	15	cancer to know whether or not it is high-grade, i.e.,
17	Since I, for instance, dictate all of my clinic	17	well-differentiated, versus low-grade or poorly
18	notes and my operative reports, I'm very familiar with	18	differentiated?
19	how a good transcriptionist can slightly tilt some of the	19	A. In general
20	meaning of our phrase by simple matters such as putting	20	Q. I've got it backwards. High-grade or poorly
21	in a comma or the extra "in." I think that should be	21	differentiated versus low-grade or highly differentiated.
22	dropped out, and then the sentence to me as a clinician	22	A. I was quite ready to agree with you just on
23 24	makes perfect sense.	23 24	general principles that, of course, this information is important to a managing clinician.
24	Q. Are you aware of Dr. Kennedy if Dr. Kennedy made any corrections to his transcript when he had an	24	O. With epithelial tumors, isn't it true that
· · ·			
· · ·	Page 34		Page 36
*· •· 1	opportunity to read it and make corrections?	1	frankly malignant tumors are characterized partly by
2	opportunity to read it and make corrections? A. In all of these deposition transcripts,	2	frankly malignant tumors are characterized partly by dissection into stromal planes?
2	opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such	2 3	frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me,
2 3 4	opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax	2 3 4	frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it.
2 3 4 5	opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was	2 3 4 5	frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a
2 3 4	opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant	2 3 4	frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing.
2 3 4 5 6	opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript.	2 3 4 5 6	frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that
2 3 4 5 6 7 8 9	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 	2 3 4 5 6 7 8 9	frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing.
2 3 4 5 6 7 8 9 10	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? 	2 3 4 5 6 7 8 9 10	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote.
2 3 4 5 6 7 8 9 10 11	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his 	2 3 4 5 6 7 8 9 10 11	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote, but it's a
2 3 4 5 6 7 8 9 10 11 12	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. 	2 3 4 5 6 7 8 9 10 11 12	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could
2 3 4 5 6 7 8 9 10 11 12 13	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change 	2 3 4 5 6 7 8 9 10 11 12 13	frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her.
2 3 4 5 6 7 8 9 10 11 12 13 14	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the 	2 3 4 5 6 7 8 9 10 11 12 13 14	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with
2 3 4 5 6 7 8 9 10 11 12 13	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change 	2 3 4 5 6 7 8 9 10 11 12 13	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. What do you meant by that? A. The endometriosis, I believe, was on the surface of the ovary, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it. Q. In what way do you disagree? A. I guess I want to have clarification from you, since it sounds like this is your own language, what you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. What do you meant by that? A. The endometriosis, I believe, was on the surface of the ovary, Q. Are you aware that Dr. Kennedy told the Hustons 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it. Q. In what way do you disagree? A. I guess I want to have clarification from you, since it sounds like this is your own language, what you mean by stroma.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. What do you meant by that? A. The endometriosis, I believe, was on the surface of the ovary, Q. Are you aware that Dr. Kennedy told the Hustons that there was cancer found in review of the ovarian 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it. Q. In what way do you disagree? A. I guess I want to have clarification from you, since it sounds like this is your own language, what you mean by stroma. Q. What is your understanding of stroma?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. What do you meant by that? A. The endometriosis, I believe, was on the surface of the ovary, Q. Are you aware that Dr. Kennedy told the Hustons that there was cancer found in review of the ovarian endometriosis from April of 1999? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it. Q. In what way do you disagree? A. I guess I want to have clarification from you, since it sounds like this is your own language, what you mean by stroma. Q. What is your understanding of stroma? MR. BONEZZI: Objection. Go ahead.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. What do you meant by that? A. The endometriosis, I believe, was on the surface of the ovary, Q. Are you aware that Dr. Kennedy told the Hustons that there was cancer found in review of the ovarian endometriosis from April of 1999? A. I was not aware that he had that conversation, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it. Q. In what way do you disagree? A. I guess I want to have clarification from you, since it sounds like this is your own language, what you mean by stroma. Q. What is your understanding of stroma? MR. BONEZZI: Objection. Go ahead. A. Stroma is everywhere in our bodies. It's the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. What do you meant by that? A. The endometriosis, I believe, was on the surface of the ovary, Q. Are you aware that Dr. Kennedy told the Hustons that there was cancer found in review of the ovarian endometriosis from April of 1999? A. I was not aware that he had that conversation, but I would just assume that he told them that, because 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it. Q. In what way do you disagree? A. I guess I want to have clarification from you, since it sounds like this is your own language, what you mean by stroma. Q. What is your understanding of stroma? MR. BONEZZI: Objection. Go ahead. A. Stroma is everywhere in our bodies. It's the connective tissue that holds us together, in a simplistic
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 opportunity to read it and make corrections? A. In all of these deposition transcripts, including Dr. Kennedy's, I have found many such situations where there clearly was tortured syntax probably from a deposition transcription error that was simply either overlooked or was felt to be so unimportant as to not be worth trying to change the transcript. Q. Are you aware that Dr. Kennedy made any corrections to his transcript in that section, pages 38 and 39? A. I am not aware of any changes to his transcript. Q. Now, you started to say earlier, if you change it to "on" the ovary, then you would agree with the statement. What do you meant by that? A. The endometriosis, I believe, was on the surface of the ovary, Q. Are you aware that Dr. Kennedy told the Hustons that there was cancer found in review of the ovarian endometriosis from April of 1999? A. I was not aware that he had that conversation, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 frankly malignant tumors are characterized partly by dissection into stromal planes? MR. BONEZZI: Would you read that back for me, please, or you can read it. MS. NISSENBERG: I can read it. It's not a quote, but it's probably confusing. Q. With epithelial tumors, isn't it true that frankly malignant tumors are characterized partly by dissections into stromal planes? MS. NISSENBERG: It's not a quote. MR. BONEZZI: It's not a quote. MR. BONEZZI: It's not a quote, but it's a quote from your document. If you had it there, you could read it as opposed to her. A. I don't like the quote, so I won't agree with it. Q. In what way do you disagree? A. I guess I want to have clarification from you, since it sounds like this is your own language, what you mean by stroma. Q. What is your understanding of stroma? MR. BONEZZI: Objection. Go ahead. A. Stroma is everywhere in our bodies. It's the

9 (Pages 33 to 36)

Howard Muntz, M.D.

,

۲

	Page 37	1	Page 39
1	O. Let's start with the stromal invasion that Dr.	1	ovarian carcinoma or carcinoma of an endometriosis
2	Tench identified on the B6 slide.	2	implant within or on the ovary.
3	If there were such stromal invasion on all	3	How important is dense adhesions in the pelvis
4	we have, of course, is the first recut, but if there were	4	when that ovary is adhesed as a clinical pathologic
5	stromal invasion, would that have any significance to you	5	factor?
6 7	as either a GYN oncologist or a GYN oncologist who likes to read his on slides?	67	A. If all you think the patient has is benign endometriosis, then you would fully expect there to be
8	MR. BONEZZI: Let me just object to that.	8	extraordinarily dense adhesions. In fact, sometimes the
9	A. Meanwhile, let me take a look again at his	9	worst adhesions we encounter in gynecologic surgery are
10	revised opinion.	10	in women with severe endometriosis.
11	Q. That's fine. I'm just going to represent to	11	Q. My question is, in a patient such as that where
12	you that this is not part of his letter, but Mr. Bonezzi	12	the benignity has been disproven and carcinoma is proven,
13	at Dr. Tench's deposition asked him to draw what he sees	13	the fact of dense adhesions, does it have any clinical
14 15	under the microscope, looking at the first recut of B6, and to identify the area that's ovarian and to identify	14 15	pathologic significance to you as a clinician? MR. BONEZZI: Objection.
16	the area that is endometrial and where is any invasion,	16	A. The second part would be now you have a patient
17	or Dr. Tench showed him where the invasion was across the	17	in whom you know she has ovarian cancer. Then dense
18	stroma.	18	adhesions in my own clinical experience, as well as in
19	So it doesn't appear there, but it was at his	19	several retrospective research studies, have been shown
20	deposition. And those transcripts will be available	20	to have a significant impact in a bad way, a bad impact
21 22	Monday. I'm sure Mr. Bonezzi will be furnishing you with	21	on the patient's survival.
22	a copy. But getting back to my question then, do you	22 23	Q. If you were suspicious of malignancy or it was part of the differential at the time of surgery and you
23	disagree with the statement that with epithelial tumors,	23	wanted to rule it out, would you do a sampling, a frozen
25	frankly malignant tumors are characterized partly by	25	section sampling from the densely adherent side during
	Page 38		Page 40
1	Page 38	1	Page 40
1	dissection into stromal planes?	1	that surgery?
2	dissection into stromal planes? MR. BONEZZI: Objection. You may answer.	2	that surgery? A. That's where I thought you were going. I
2 3	dissection into stromal planes?MR. BONEZZI: Objection. You may answer.A. This is very helpful, because I understand that	2 3	that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we
2	dissection into stromal planes? MR. BONEZZI: Objection. You may answer.	2	that surgery? A. That's where I thought you were going. I
2 3 4	dissection into stromal planes?MR. BONEZZI: Objection. You may answer.A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your	2 3 4 5 6	that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety
2 3 4 5 6 7	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth 	2 3 4 5 6 7	that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room.
2 3 4 5 6 7 8	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection 	2 3 4 5 6 7 8	that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent
2 3 4 5 6 7 8 9	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian 	2 3 4 5 6 7 8 9	that surgery?A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room.Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary
2 3 4 5 6 7 8 9 10	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. 	2 3 4 5 6 7 8 9 10	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman
2 3 4 5 6 7 8 9	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one 	2 3 4 5 6 7 8 9	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II.
2 3 4 5 6 7 8 9 10 11	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. 	2 3 4 5 6 7 8 9 10 11	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman
2 3 4 5 6 7 8 9 10 11 12 13 14	dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma.	2 3 4 5 6 7 8 9 10 11 12 13 14	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent
2 3 4 5 6 7 8 9 10 11 12 13 14 15	dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with the back to me again.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with back to me again.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present of patients who present with epithelial tumors involving the ovary present with Stage I or II disease?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer patients?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with stage I or II disease? A. My problem with that particular question is that it's not relevant to this case, but, in general, I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer patients? MR. BONEZZI: Objection to the term	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with stage I or II disease? A. My problem with that particular question is that it's not relevant to this case, but, in general, I would agree that that's an appropriate quote that I could
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer patients?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with epithelial tumors involving the other service of patients who present with stage I or II disease? A. My problem with that particular question is that it's not relevant to this case, but, in general, I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer patients? MR. BONEZZI: Objection to the term "significant." Go ahead and answer. A. Again, 1 would ask you to clarify in what context you're asking that question. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. My problem with that particular question is that it's not relevant to this case, but, in general, I would agree that that's an appropriate quote that I could put into any textbook. Q. And one of the purposes for having a classification system by stage for different cancers is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer patients? MR. BONEZZI: Objection to the term "significant." Go ahead and answer. A. Again, 1 would ask you to clarify in what context you're asking that question. Q. In what context? What specifics do you want? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. My problem with that particular question is that it's not relevant to this case, but, in general, I would agree that that's an appropriate quote that I could put into any textbook. Q. And one of the purposes for having a classification system by stage for different cancers is that there's some uniformity within stages with respect
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer patients? MR. BONEZZI: Objection to the term "significant." Go ahead and answer. A. Again, 1 would ask you to clarify in what context you're asking that question. Q. In what context? What specifics do you want? You have a patient with an ovarian mass. It's 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. My problem with that particular question is that it's not relevant to this case, but, in general, I would agree that that's an appropriate quote that I could put into any textbook. Q. And one of the purposes for having a classification system by stage for different cancers is that there's some uniformity within stages with respect to treatment modalities, prognoses, etc., correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 dissection into stromal planes? MR. BONEZZI: Objection. You may answer. A. This is very helpful, because I understand that we're talking about ovarian stroma. The difficulty when you're interpreting an ovary that is riddled with endometriosis is that your stromal planes are oftentimes fractured either by growth of the endometriosis or by the surgical dissection required to remove the adherent endometriotic ovarian mass from the pelvis. With those qualifiers, I would agree that one way we make the diagnosis of malignancy is to demonstrate under the microscope that there are areas of invasion of that malignant epithelium into the stroma. Q. Would you agree that dense adhesions in the pelvis of the ovary is a significant clinical pathologic factor to be analyzed when you're staging ovarian cancer patients? MR. BONEZZI: Objection to the term "significant." Go ahead and answer. A. Again, 1 would ask you to clarify in what context you're asking that question. Q. In what context? What specifics do you want? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 that surgery? A. That's where I thought you were going. I would, again, be very clear that if what we thought we were facing in the operating room was garden-variety endometriosis, then indeed we would not be doing any of those additional sampling procedures in the operating room. Q. Would you agree that approximately 30 percent of patients with epithelial tumors involving the ovary present with Stage I or II disease? And that's Roman numeral I and II. MR. BONEZZI: Objection. A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. Read that back to me again. Q. Would you agree that approximately 30 percent of patients who present with epithelial tumors involving the ovary present with Stage I or II disease? A. My problem with that particular question is that it's not relevant to this case, but, in general, I would agree that that's an appropriate quote that I could put into any textbook. Q. And one of the purposes for having a classification system by stage for different cancers is that there's some uniformity within stages with respect

0.0

1958

1	Page 41		Page 43
1	~	1	information that we could use for this discussion.
$\begin{vmatrix} 1\\2 \end{vmatrix}$	Q. So you could, for example, pick up the phone and speak to a GYN oncologist in Florida and be	2	O. Do they ascribe any percentage figures for
3	discussing a IC patient and he could be discussing a IC	3	five-year survival for Stage IC under the FIGO system?
4	patient and you're basically talking about the same kind	4	A. When you say FIGO, you're implying that you are
5	of patient in those terms, correct?	5	looking at the survival curves that the International
6	A. This case, though, would not be applicable	6	Cancer Committee submits in aggregate, are you not?
78	MR. BONEZZI: Excuse me. As I understand it, what she's asking though, however, is basically a	7 8	Q. I'm just wanting to know what your understanding is of the general survival figures for
9	hypothetical or in a general sense.	9	Stage IC. I know what Dr. Kennedy testified.
10	A. That's a good way for me to think about this.	10	Do you recall what he testified?
11	So I would say hypothetically I have a patient	11	A. No, I don't.
12	who has garden variety Stage IC ovarian cancer. There is	12	Q. I believe that he testified it was about 80
13	nothing special about her. There's no endometriosis.	13	percent. Does that sound right to you?
14	There's no dense adhesion. It's just a standard ovarian	14	A. No. Eighty percent is too high, if you're
15 16	cancer operation. And yes, indeed, I could easily pick up the	15 16	going to quote for all Stage ICs, in which you will include the really poorly differentiated subtypes, such
17	phone and talk to my friend down in Florida, maybe	17	as adenosquamous carcinoma or some of the cancers that
18	because she's going to go down there after my operation	18	can arise from endometriosis, which oftentimes have
19	and Imtransferring her care to my friend fill in the	19	poorer prognosis than other cancers.
20	blank Neil Thencorsi (phonetic) in Orlando.	20	Q. Such as clear cell, for example?
21 22	I'll pick up the phone and talk to Neil. She	21 22	À. Correct.
22 23	has Stage IC ovarian cancer. And yes, you are absolutely right. It would be very easy to have that conversation	22	Q. That's almost equivalent to small-cell carcinoma of the lung; it's very poor prognosis, correct?
23	about a very typical, run-of-the-mill Stage IC ovarian	$\frac{23}{24}$	A. I wouldn't go so far as to say that. The small
25	cancer case.	25	cell of the lung is a totally different entity compared
	Page 42		Page 44
1	Page 42	1	Page 44
1	Q. What percentage of patients, to your knowledge,	1	to clear cell.
2	Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years?	2	to clear cell. Q . I was just referring to prognoses. They're
	Q. What percentage of patients, to your knowledge,		to clear cell.
2 3 4 5	Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years?A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals.	2 3 4 5	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell
2 3 4 5 6	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, 	2 3 4 5 6	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable.
2 3 4 5 6 7	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a 	2 3 4 5 6 7	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell
2 3 4 5 6 7 8	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may 	2 3 4 5 6 7 8	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease,
2 3 4 5 6 7	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. 	2 3 4 5 6 7	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell
2 3 4 5 6 7 8 9 10 11	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate 	2 3 4 5 6 7 8 9 10 11	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. Q. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary.
2 3 4 5 6 7 8 9 10 11 12	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat 	2 3 4 5 6 7 8 9 10 11 12	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. Q. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. Q. Right, but clear cell of the ovary generally
2 3 4 5 6 7 8 9 10 11 12 13	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. 	2 3 4 5 6 7 8 9 10 11 12 13	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct?
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general 	2 3 4 5 6 7 8 9 10 11 12 13 14	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. <i>Q</i>. Are you aware of any or have you read any of
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general 	2 3 4 5 6 7 8 9 10 11 12 13 14	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? A. You would need to give me information about grade, histology, age of the patient, and a lot of other clinical factors before I would properly answer that 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. Q. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. Q. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. Q. Are you aware of any or have you read any of Dr. Robboy's pathology texts that he has written? A. Over the years I'm sure I have read if not the textbook excerpts from it or other papers that he has
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? A. You would need to give me information about grade, histology, age of the patient, and a lot of other clinical factors before I would properly answer that question. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. <i>Q</i>. Are you aware of any or have you read any of Dr. Robboy's pathology texts that he has written? A. Over the years I'm sure I have read if not the textbook excerpts from it or other papers that he has written.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? A. You would need to give me information about grade, histology, age of the patient, and a lot of other clinical factors before I would properly answer that question. Q. Are you familiar with the DeVita, Hellman and 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. <i>Q</i>. Are you aware of any or have you read any of Dr. Robboy's pathology texts that he has written? A. Over the years I'm sure I have read if not the textbook excerpts from it or other papers that he has written. <i>Q</i>. Do you recall he has a section in Chapter 19
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? A. You would need to give me information about grade, histology, age of the patient, and a lot of other clinical factors before I would properly answer that question. Q. Are you familiar with the DeVita, Hellman and Rosenberg text? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. <i>Q</i>. Are you aware of any or have you read any of Dr. Robboy's pathology texts that he has written? A. Over the years I'm sure I have read if not the textbook excerpts from it or other papers that he has written. <i>Q</i>. Do you recall he has a section in Chapter 19 where he's talking about the cancers involving the ovary
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? A. You would need to give me information about grade, histology, age of the patient, and a lot of other clinical factors before I would properly answer that question. Q. Are you familiar with the DeVita, Hellman and Rosenberg text? A. Yes. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. <i>Q</i>. Are you aware of any or have you read any of Dr. Robboy's pathology texts that he has written? A. Over the years I'm sure I have read if not the textbook excerpts from it or other papers that he has written. <i>Q</i>. Do you recall he has a section in Chapter 19 where he's talking about the cancers involving the ovary and he has one subsection on cancers or, excuse me,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? A. You would need to give me information about grade, histology, age of the patient, and a lot of other clinical factors before I would properly answer that question. Q. Are you familiar with the DeVita, Hellman and Rosenberg text? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. <i>Q</i>. Are you aware of any or have you read any of Dr. Robboy's pathology texts that he has written? A. Over the years I'm sure I have read if not the textbook excerpts from it or other papers that he has written. <i>Q</i>. Do you recall he has a section in Chapter 19 where he's talking about the cancers involving the ovary
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. What percentage of patients, to your knowledge, with Stage IC ovarian cancer survive five years? A. You can look almost at any textbook and get various survival figures for Stage IC ovarian cancer, but you will have a fairly broad range of survivals. You will also have different nomenclature, five-year survival, which may not be equivalent to a cure, versus long-term, disease-free survival, which may be equivalent to a cure. I would probably accept almost any reputable textbook that you quoted from as being an accurate representation of survival for Stage IC, with the caveat that it would not be applicable to this case. Q. With your knowledge, what is the general percentage? A. You would need to give me information about grade, histology, age of the patient, and a lot of other clinical factors before I would properly answer that question. Q. Are you familiar with the DeVita, Hellman and Rosenberg text? A. Yes. Q. I'm sure you consider that fairly authoritative 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 to clear cell. <i>Q</i>. I was just referring to prognoses. They're both not good? A. Small cell of the lung, though, is chemotherapy-sensitive. So in early stages, small cell of the lung is actually curable. <i>Q</i>. Actually, Stage I I mean Stage I, small-cell carcinoma of the lung is sometimes a surgical disease, believe it or not; isn't that true? A. That's true, but that's small cell of the lung. Again, it has nothing to do with clear cell to the ovary. <i>Q</i>. Right, but clear cell of the ovary generally has a poorer prognosis, correct? A. Oh, absolutely. I definitely agree with that. <i>Q</i>. Are you aware of any or have you read any of Dr. Robboy's pathology texts that he has written? A. Over the years I'm sure I have read if not the textbook excerpts from it or other papers that he has written. <i>Q</i>. Do you recall he has a section in Chapter 19 where he's talking about the cancers involving the ovary and he has one subsection on cancers or, excuse me, tumors of low-malignant potential, borderline tumors, and

11 (Pages 41 to 44)

× 1

	Page 45		Page 41
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Page 45 Do you recall reading this in his book, quote, patients diagnosed with early stage disease confined to the ovary or pelvis demonstrate a five-year survival rate of 80 percent? It's on page 532. MR. BONEZZI: I will object to the question. The second thing is, is this his newest text? MS. NISSENBERG: Yes. MR. BONEZZI: I know I've read it. This is the newest text that just came out? MS. NISSENBERG: I don't know if it's the last month's. MR. BONEZZI: His newest text has been out for only a couple of months, and it's already out of print and they're reprinting it. First of all, she asked if you have even read that newest text. THE WITNESS: I have not read that particular textbook. And if I've read his pathology textbook, it would have been a few years ago, either looking at cases of interest for myself or studying for my own board examination. So I wouldn't testify that I have actually read the book, but I'm willing to discuss the content of what he has written, and, again, using my filter as a	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\end{array} $	 Page 41 Q. (Indicating.) A. I would disagree with that paragraph. Q. You would disagree with that? A. Yes. This is an oversimplification of a very complex clinical subject that is appropriate as a snapshot or as a brief synopsis for pathologists, but I would not send any of my OB-GYN residents, for instance, to this textbook to have any educational value about treatment, prognosis, so on and so forth. Q. Have you ever made a diagnosis of A. Can I go off the record? Q. Ofcourse. (Discussion off the record.) Q. I think I was asking you if you've ever diagnosed malignant transformation of endometriosis. A. Yes. Q. And you would agree that only about one percent of endometriosis undergoes malignant transformation? Is that the generally accepted percentage? A. We actually don't know what the percentage is, and our increasing concern as clinicians in dealing with women with endometriosis, as we have a large group of women naturally aging into the cancer-age range, is that this one percent figure may be lower than it is.
	the book, but I'm willing to discuss the content of what he has written, and, again, using my filter as a	1	
25	practicing clinician correctly interpret what he is	25	Let me rephrase that. The one percent figure
	Page 46		Page 48
1 2 3	saying as a pathologist as it relates to clinical medicine.Q. Mr. Bonezzi is suggesting that the newest text	1 2 3	may be an underestimation. It's at least one percent.It may be higher.Q. How many times have you made that diagnosis, by
4 5	doesn't contain that statement. Do you MR. BONEZZI: No, I did not say that.	45	A. A number of times. Often enough that I begin
6 7	MS. NISSENBERG: Just a second. You asked him if he's read the newest text.	6 7	to think that I should go back through my stack of index cards, because like most obsessive-compulsive gynecologic
8 9	MR. BONEZZI: That's where it comes from. MS. NISSENBERG: This comes from the newest	8 9	oncologists, I keep a stack of index cards of all of the patients I've treated, and I think if I went back through
10	text?	10	my ten years of clinical practice, I would have anywhere
11 12	MR. BONEZZI: Yes. That's what I'm trying to tell you. That's from the newest text.	11 12	from half a dozen as a conservative estimate to upwards of 20. That's the upper range.
13 14	MS. NISSENBERG: Great. Thank you. Q. Okay. Let's move on here.	13 14	If I also add together anecdotal cases I've heard about when I've been chatting about cases with my
		15	other colleagues in town, we may have a Seattle series
15 16	A. I thought we hadn't finished the question.	1	that is approaching 50 cases of endometricesis leading to
16 17	MR. BONEZZI: And you also know that Dr. Robboy had disagreements not with the comment. He gave you	16 17	that is approaching 50 cases of endometriosis leading to the development of cancer.
16 17 18	MR. BONEZZI: And you also know that Dr. Robboy had disagreements not with the comment. He gave you qualifiers with that.	16 17 18	the development of cancer. Q. Do you recall Dr. Kennedy's physical
16 17	MR. BONEZZI: And you also know that Dr. Robboy had disagreements not with the comment. He gave you	16 17 18 19 20	the development of cancer.
16 17 18 19 20 21	MR. BONEZZI: And you also know that Dr. Robboy had disagreements not with the comment. He gave you qualifiers with that. Q. I'm going to show you the page that I'm referring to. MR. BONEZZI: I will object to the question and	16 17 18 19 20 21	 the development of cancer. Q. Do you recall Dr. Kennedy's physical examination of Mrs. Huston prior to her surgery? A. Yes, I do. Q. And was there any evidence of any disease
16 17 18 19 20	MR. BONEZZI: And you also know that Dr. Robboy had disagreements not with the comment. He gave you qualifiers with that. Q. I'm going to show you the page that I'm referring to.	16 17 18 19 20	the development of cancer.Q. Do you recall Dr. Kennedy's physicalexamination of Mrs. Huston prior to her surgery?A. Yes, I do.
16 17 18 19 20 21 22 23 24	MR. BONEZZI: And you also know that Dr. Robboy had disagreements not with the comment. He gave you qualifiers with that. Q. I'm going to show you the page that I'm referring to. MR. BONEZZI: I will object to the question and the information that's contained in that because of how Dr. Robboy responded to the questions, but go ahead and answer.	16 17 18 19 20 21 22 23 24	 the development of cancer. Q. Do you recall Dr. Kennedy's physical examination of Mrs. Huston prior to her surgery? A. Yes, I do. Q. And was there any evidence of any disease outside of the pelvis during that exam? A. No, there was not. Q. Was there anything in the GYN tract that was
16 17 18 19 20 21 22 23	MR. BONEZZI: And you also know that Dr. Robboy had disagreements not with the comment. He gave you qualifiers with that. Q. I'm going to show you the page that I'm referring to. MR. BONEZZI: I will object to the question and the information that's contained in that because of how Dr. Robboy responded to the questions, but go ahead and	16 17 18 19 20 21 22 23	 the development of cancer. Q. Do you recall Dr. Kennedy's physical examination of Mrs. Huston prior to her surgery? A. Yes, I do. Q. And was there any evidence of any disease outside of the pelvis during that exam? A. No, there was not.

	Dece 40		Daga 51
	Page 49		Page 51
1	examination?	1	Q. And a IC ovarian cancer is cancer involving one
$\begin{vmatrix} 2 \\ 2 \end{vmatrix}$	A. Simply the large ovarian tumor mass, which we	2	or both areas with, I believe, the capsules intact?
3	know now ended up being the clinically unimportant large		A. No.
4	ovarian tumor involving either the left or right ovary.	4	Q. Or ruptured. And the pelvic washings positive? Is that true?
5	I lose track of which side is which, but I think that was	5	
6	the dominant physical exam finding, was the large ovarian	67	A. You've misquoted the FIGO staging rules.Q. Tell me what a IC is.
78	mass. O. As you sit here today, you don't know which	8	Q. Tell me what a IC is. A. A IC is cancer involving one ovary and the
9	Q. As you sit here today, you don't know which side was the larger mass?	9	capsule is either ruptured or you have positive
10	A. I could figure that out just by flipping to the	10	peritoneal cytology.
11	pathology report. The laterality of the lesions are not	11	O. And you're aware that the cyst ruptured in this
12	important to me clinically, so I don't have that off the	12	case during surgery, are you not? Do you recall that
13	top of my head.	13	from the operative report?
14	So the left ovary was the large benign tumor,	14	MR. BONEZZI: You may look at the op report.
15	and the right ovary was the endometriotic ovary that is	15	A. I might as well, because the phraseology, I
16	of concern now.	16	think, of your question is important.
17	O. Correct. By the way, did you consult any texts	17	Now that I have reviewed the op note, can you
18	or other authoritative sources in forming any of your	18	ask me the question?
19	opinions in this case?	19	Q. Did the cyst rupture during surgery on April
20	A. No. Although, as we discussed, I'm happy to	20	29, 1999, according to Dr. Kennedy?
21	have any one of the standard gynecologic oncology	21	A. Am I allowed to say yes and no?
22	textbooks used for reference material, as long as I	22	Q. Fine. In what way did they not rupture?
23	reserve the right as a board certified gynecologic	23	A. The important distinction I'm making is that
24	oncologist to quibble with any quotes from that, any	24	this op note reads like a perfect example of severe
25	specific textbook.	25	pelvic peritoneal endometriosis, including the presence
	Page 50		Page 52
	Page 50	1	Page 52
1	Q. So the answer is no, you didn't rely on any	1	of a right-sided ovarian endometrioma.
2	Q. So the answer is no, you didn't rely on any texts, though?	2	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of
2 3	Q. So the answer is no, you didn't rely on any texts, though?A. No.	2 3	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian
2 3 4	Q. So the answer is no, you didn't rely on any texts, though?A. No.Q. Would you agree that overall the survival for	2 3 4	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous
2 3 4 5	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are 	2 3 4 5	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue.
2 3 4 5 6	Q. So the answer is no, you didn't rely on any texts, though?A. No.Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages?	2 3 4	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually
2 3 4 5 6 7	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say 	2 3 4 5 6 7	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that
2 3 4 5 6 7 8	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. 	2 3 4 5	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas
2 3 4 5 6 7 8 9	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say 	2 3 4 5 6 7 8	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that
2 3 4 5 6 7 8	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. 	2 3 4 5 6 7 8 9	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her
2 3 4 5 6 7 8 9 10	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. 	2 3 4 5 6 7 8 9 10	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure.
2 3 4 5 6 7 8 9 10 11	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. 	2 3 4 5 6 7 8 9 10 11	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth.
2 3 4 5 6 7 8 9 10 11 12	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could 	2 3 4 5 6 7 8 9 10 11 12 13 14	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) 	2 3 4 5 6 7 8 9 10 11 12 13	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the
$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ \end{array} $	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're making, I would emphasize that the problem with ovarian 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery? A. Yes, he does state that.
$ \begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ \end{array} $	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're making, I would emphasize that the problem with ovarian cancer is that when it has gone beyond Stage I, it has by 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery? A. Yes, he does state that. Q. Could you read that section into the record?
$ \begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ \end{array} $	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're making, I would emphasize that the problem with ovarian cancer is that when it has gone beyond Stage I, it has by definition gained access to the entire peritoneal cavity, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery? A. Yes, he does state that. Q. Could you read that section into the record? A. Actually, it's only a one-page op note, once
$ \begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ \end{array} $	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're making, I would emphasize that the problem with ovarian cancer is that when it has gone beyond Stage I, it has by definition gained access to the entire peritoneal cavity, so that it becomes very difficult to eradicate cancer, 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery? A. Yes, he does state that. Q. Could you read that section into the record? A. Actually, it's only a one-page op note, once you drop off the top and bottom of pages 1 and 2.
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ \end{array}$	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're making, I would emphasize that the problem with ovarian cancer is that when it has gone beyond Stage I, it has by definition gained access to the entire peritoneal cavity, so that it becomes very difficult to eradicate cancer, because as soon as it goes beyond Stage I, it has jumped 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery? A. Yes, he does state that. Q. Could you read that section into the record? A. Actually, it's only a one-page op note, once you drop off the top and bottom of pages 1 and 2. Q. Just read the portion regarding the rupture of
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ \end{array}$	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're making, I would emphasize that the problem with ovarian cancer is that when it has gone beyond Stage I, it has by definition gained access to the entire peritoneal cavity, so that it becomes very difficult to eradicate cancer, because as soon as it goes beyond Stage I, it has jumped all the way up to a regional disease process with at-risk 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery? A. Yes, he does state that. Q. Could you read that section into the record? A. Actually, it's only a one-page op note, once you drop off the top and bottom of pages 1 and 2. Q. Just read the portion regarding the rupture of the cyst, please.
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ \end{array}$	 Q. So the answer is no, you didn't rely on any texts, though? A. No. Q. Would you agree that overall the survival for ovarian cancer tends to be low because most women are diagnosed in later stages? MR. BONEZZI: Excuse me. Did you say "overall"? I didn't hear the beginning. MS. NISSENBERG: I don't remember. Did I say "overall"? Yes. MR. BONEZZI: Thank you. A. Actually, that's a very good question. Could you say it again? MS. NISSENBERG: Could you read it back? (Record read.) A. I think as a general statement that is true. And as a further refinement to the point you're making, I would emphasize that the problem with ovarian cancer is that when it has gone beyond Stage I, it has by definition gained access to the entire peritoneal cavity, so that it becomes very difficult to eradicate cancer, because as soon as it goes beyond Stage I, it has jumped 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	of a right-sided ovarian endometrioma. By that I mean there is a large aggregate of chocolate fluid that has dissected into the ovarian tissue and then become encapsulated by a rind of fibrous tissue. With this degree of endometriosis, you actually can make a very straightforward clinical assumption that she has been rupturing those ovarian endometriomas repetitively in the months to possibly years prior to her surgical procedure. We make that determination based upon reading the operative note and its description of extensive endometriosis, very dense adhesions, so on and so forth. So, indeed, the ovarian tissue had ruptured before she was ever operated on, Q. My question is, does Dr. Kennedy state that the cyst ruptured during surgery? A. Yes, he does state that. Q. Could you read that section into the record? A. Actually, it's only a one-page op note, once you drop off the top and bottom of pages 1 and 2. Q. Just read the portion regarding the rupture of

	Page 53		Page 55
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Page 53 things like that. Under postoperative diagnosis, he has the phrase, quote, evidence of endometriosis, end quote. Under operative findings, he says, quote, evidence of chocolate cyst within both ovaries, suggestive of endometrioma and endometriosis, period, end quote. Continuing on, quote, dense adherence of the right ovary to the pelvic sidewall and endometrial implants along the anterior vesicouterine peritoneum vesicouterine is V-E-S-I-C-0-U-T-E-R-I-N-E, and the next word is peritoneum period, end quote. Q. I was asking you to read, Doctor, just where it mentions that the cyst ruptured, not all of Dr. Kennedy's findings. A. I'm catching all of the findings that talk about endometriosis and endometriomas. Q. That wasn't my question. My question was, could you read into the record, please, the specific reference to the cyst rupturing during surgery? A. I'm getting to that. I'm <i>sorry</i>. I was just going through the op note in sequence and catching the things that I thought were relevant to Q. Since I'm paying by the page, I don't need you to read the entire operative report into the record. 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	Page 55 surgery and my friend at the pathology department calls me up and says, "Howard, I'm so <i>sorry</i> to tell you this, but the cytology from the pelvic washings of the patient you just operated on are obviously cancer, there is no doubt in my mind that we're seeing malignancy in her pelvic wash"? That's the scenario that you're wanting me to address? Q. The scenario is that the pelvic washings contain evidence of malignancy. Is that consistent with the presence of cancer in the patient? MR. BONEZZI: Objection. Go ahead and answer. A. I'm wondering why Bill is objecting. Q. He objects all the time. A. No, I'm happy that saying yes, that's evidence that there is malignancy present. Now as a clinician, I then have to start thinking what does this mean, and that gets more complicated. Q. And we're going to get to that. Don't let me forget. A. I'm sure it's probably about three or four lines down on your list of questions. Q. Now, hypothetically, if the surgical specimens from April 29, 1999, contain tumor cells that are
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Page 54 A. Sorry. Here's the part that you're interested in. Under operative procedure, it says, quote, the right pelvic mass was densely adherent, period. Some sharp and blunt dissection was done to free up these masses, period. Chocolate cyst ruptured during the procedure, period. Q. Thankyou. A. And then it goes on and talks about irrigation, and I think J've caught the part that you were interested in. Q. Yes. Thankyou. Now, if hypothetically the pelvic wash slides were, in fact, evidence of or contained evidence of malignancy, the pelvic wash slides obtained April 29, 1999, would that be consistent with the presence of cancer in this patient? MR. BONEZZI: Objection. A. So we're not going to call the pelvic wash atypical? We're going to actually make the diagnosis of malignancy? Q. Correct. A. So it's a hypothetical discussion. Q. Yes. 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Page 56 morphologically similar to those present in the vaginal biopsy of 2000 and the small bowel excision of August 2000, would you agree with Dr. Gramlich of the Cleveland Clinic that suggested that the cancer shares the same origin? MR. BONEZZI: Objection. A. I like the word "etiology" better than "origin." Q. Would you agree with him or disagree with him? A. I think by stating, quote, origin, end quote, I would be forced to disagree with him, because I think using that word creates potential for confusion in terms of the actual meaning of what he was trying to communicate. Q. Have you spoken with Dr. Gramlich? A. No, I have not. Q. So you don't know exactly what he was trying to communicate, do you, other than what appears in the word? A. Well, let me clarify. I would say that if he means what he said, I would disagree with him. If he says he meant something different from what was transcribed, then I would agree with him, because agreement is like kind of an ephemeral issue. But in terms of how he is quoted in his

		Т	
	Page 57		Page 59
1	deposition, I think that is not a completely accurate way	1	A. I'm still, actually, back at your original
2	to phrase the pathology situation.	2	question. I haven't moved on yet.
3	Q. And, again, if there are cell clusters in the	3	Q. But I've asked another question and I'd like an
4	April '99 pelvic wash slides that are virtually identical	4	answer, please. Do you want her to repeat the question
5	to cell clusters in the small bowel excision of August	5	to you?
6	2000, does that suggest to you that the cancer shares the	6	A. Yes, please.
7	same origin?	7	(Record read.)
8	A. I would again say etiology can I explain why	8	A. Yes, that's very true.
9	I don't like the word "origin"? Would that be helpful	9	Q. And in April of '99 or early May, before she
10	for the deposition?	10	was discharged, there was no evidence of any pelvic
11	Q. I just want to know if you agree with that or	11	extension of tumor? Isn't that true? I'm taking your
12	disagree with that.	12	attention back to April of 1999. Correct?
13	A. No, then I would say I disagree with that	13	A. Again, that's the whole problem with the
14	because of the use of the word "origin."	14	retrospective nature of this case review.
15	Q. There was no evidence on April 29, '99, or even	15	Q. The question is, in 1999, when Mrs. Huston was
16	shortly thereafter, before Mrs. Huston was discharged	16	a patient at Cleveland Clinic, before her discharge in
17	after the '99 surgery that there was any extension of	17	the first couple of days of May, was there any evidence
18	tumor to the uterus or tubes, correct?	18	that you see in the records that there was pelvic
19	A. I'm sorry. Could you read that I believe	19	extension of tumor in the patient? Yes or no. If
20	that's a correct statement. Could you read it back more	20	there's evidence, please point it out to me.
21	slowly?	21	A. Oh, but there's plenty of evidence that there
22	O. There was no evidence on April 29, 1999, or	22	was pelvic extension of her tumor in '99 based upon our
23	even shortly thereafter, before she was discharged after	23	subsequent knowledge that her pelvic wash and her ovarian
24	her '99 surgery that there was any extension of tumor to	24	tissue contained at least atypical cells, or I should
25	the uterus or tubes; is that correct?	25	say, more precisely, there was evidence that there was at
	,		
	Page 58		Page 60
1	A. Actually, that's a good way to phrase the	1	least a premalignant transformation of her endometriosis
2	A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous.	1 2	least a premalignant transformation of her endometriosis underway.
	A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future	1 2 3	least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was
2	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the 	3 4	least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind
2 3	A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal	3	least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was
2 3 4	A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they	3 4 5 6	least a premalignant transformation of her endometriosis underway.It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question.Q. The question is not what you're looking at now,
2 3 4 5	A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99?	3 4 5	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston.
2 3 4 5 6	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected 	3 4 5 6 7 8	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm
2 3 4 5 6 7 8 9	A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99?	3 4 5 6 7 8 9	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston.
2 3 4 5 6 7 8 9 10	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? 	3 4 5 6 7 8 9 10	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me
2 3 4 5 6 7 8 9 10 11	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. 	3 4 5 6 7 8 9 10 11	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic
2 3 4 5 6 7 8 9 10 11 12	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. 	3 4 5 6 7 8 9 10 11 12	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient?
2 3 4 5 6 7 8 9 10 11 12 13	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence 	3 4 5 6 7 8 9 10 11 12 13	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole
2 3 4 5 6 7 8 9 10 11 12 13 14	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had 	3 4 5 6 7 8 9 10 11 12	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going
2 3 4 5 6 7 8 9 10 11 12 13	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence 	3 4 5 6 7 8 9 10 11 12 13	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. 	3 4 5 6 7 8 9 10 11 12 13 14	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic peritoneal tissues. 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue. Q. Tim trying to ask the question more clearly.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue. Q. I'm trying to ask the question more clearly. I'm <i>sorry</i> if I'm being obfuscating in my questions.
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ \end{array}$	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic peritoneal tissues. Q. That's right. And Dr. Kennedy testified that had he known that there was this focus of high-grade 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue. Q. I'm trying to ask the question more clearly. I'm <i>sorry</i> if I'm being obfuscating in my questions. Is there anything in Mrs. Huston's medical
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic peritoneal tissues. Q. That's right. And Dr. Kennedy testified that had he known that there was this focus of high-grade cancer in B6, that he would have considered what 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue. Q. I'm trying to ask the question more clearly. I'm <i>sorry</i> if I'm being obfuscating in my questions. Is there anything in Mrs. Huston's medical records that are dated April or May of 1999 that reveals
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ \end{array}$	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic peritoneal tissues. Q. That's right. And Dr. Kennedy testified that had he known that there was this focus of high-grade 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue. Q. I'm trying to ask the question more clearly. I'm <i>sorry</i> if I'm being obfuscating in my questions. Is there anything in Mrs. Huston's medical records that are dated April or May of 1999 that reveals that there is pelvic extension of tumor? If there is,
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ \end{array}$	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic peritoneal tissues. Q. That's right. And Dr. Kennedy testified that had he known that there was this focus of high-grade cancer in B6, that he would have considered what treatment to render to the patient next? Isn't that true? 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue. Q. Tm trying to ask the question more clearly. I'm <i>sorry</i> if I'm being obfuscating in my questions. Is there anything in Mrs. Huston's medical records that are dated April or May of 1999 that reveals that there is pelvic extension of tumor? If there is, point it out to me.
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ \end{array}$	 A. Actually, that's a good way to phrase the question, because it makes the situation ambiguous. Are we talking about based upon future knowledge that she was going to develop cancer at the vaginal cuff probably from the deep pelvic peritoneal tissues or are we talking about what people thought they knew in '99? Q. If you go back to '99, no one even suspected or, rather, no one had diagnosed cancer in Mrs. Huston, correct? A. Correct. In 1999, no one had diagnosed cancer. Q. That's right. A. And so she was sent home without any evidence in the minds of her managing clinician that she had cancer anywhere else in her pelvis. Q. That's right. A. In fact, the only thing they thought she had was endometriosis extensively involving her pelvic peritoneal tissues. Q. That's right. And Dr. Kennedy testified that had he known that there was this focus of high-grade cancer in B6, that he would have considered what treatment to render to the patient next? Isn't that 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 least a premalignant transformation of her endometriosis underway. It may not have been cancer yet, but it was heading in that direction. That's where I'm getting kind of confused by how I should approach this question. Q. The question is not what you're looking at now, knowing what happened to Mrs. Huston. A. Excuse me. I'm <i>sorry</i>. I interrupted. I'm <i>sorry</i>. Go ahead and finish. Q. In the medical records, can you point out to me where anything exists to show that there was pelvic extension of tumor in the patient? A. I guess I'm still confused, because the whole retrospective nature of this lawsuit is that we're going backwards in time. So now we're interpreting, or I should say you're interpreting the endometriosis in her pelvis as representing malignancy, despite the original thought that it represented benign tissue. Q. I'm trying to ask the question more clearly. I'm <i>sorry</i> if I'm being obfuscating in my questions. Is there anything in Mrs. Huston's medical records that are dated April or May of 1999 that reveals that there is pelvic extension of tumor? If there is,

ŧ

*

	Page 61		Page 63
1 2 3 4 5 6 7 8 9 9 10 11 12 13 14 15 16 177 18 19 20 21 22 32 4 25	 least extensive endometriosis that was atypical in nature and potentially premalignant. Q. Now, Dr. Kennedy testified that he found no evidence of tumor at that time outside her ovary. Do you recall that testimony? I can show you the testimony. A. I do recall that. And that's, I think, a reasonable thing for him to state, although he's specifically referencing no evidence of like why don't we read that together. MR. BONEZZI: What page? MS. NISSENBERG: Page 40. 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Page 63 this patient? A. No. Q. And there was no evidence of any lymphadenopathy or positive retroperitoneal or inguinal nodes for the patient, correct? A. There was no evidence of that. On the other hand, they were not evaluated because of the presumption of a benign diagnosis. <i>Q</i>. And had Dr. Kennedy known about the true pathology, they would have undertaken other diagnostic tests or other tests to ascertain the extent of disease, correct? A. That's correct. Q. They may have even done a second-look surgery, correct? A. Correct. Q. And, in fact, they may have gotten or obtained a CA-125, correct? A. Correct. Q. Do you have any information as you sit here why one wasn't obtained for this patient until August of 2000? A. Because they did not think she had pelvic peritoneal cancer or a similar malignancy at that time.
24 25	MS. NISSENBERG: Page 40. Q. Beginning with page 39, where he says:	24 25	peritoneal cancer or a similar malignancy at that time. Q. Until August of 2000?
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	 Page 62 Certainly, if I, if I had been given information that there had been cancer present, depending on the grade of the clinical findings at the time of surgery, I would have needed to make recommendations as to whether additional treatment was advisable or not. And when I asked him to stage either clinically or surgically what she would have been at the time, he says: She would have been Stage I based on what I found. And he says he didn't have the pathologic findings. And then he says, lines 11 through 13: But I found no evidence for any tumor at that time outside of her ovary. My question is just do you remember reading this in Dr. Kennedy's deposition prior to me showing it to you now? Do you remember reading that or you don't remember reading it? A. I'm sure I read it, but I actually don't remember reading it. Q. Okay. There was also no evidence at the time of peritoneal implants outside of the pelvis anywhere, correct? A. He also did not look for them. Q. Do you see anything in the medical records dated the end of April, early May '99 that states that there are peritoneal implants outside of the pelvis in 	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	 Page 64 A. By the time she presents with a vaginal mass in June of 2000, you have a cancer diagnosis, and at that point in time you don't need a CA-125 level to help you render a diagnosis. Q. Why was one obtained in August of 2000? A. That was obtained so that you could ascertain where her baseline level was as you're giving her chemotherapy to monitor for her response to therapy. Q. Actually, that's after she had already had chemotherapy? Isn't that true? A. She had already started some chemotherapy treatments, but remember she had measurable disease in the summertime of 2000 in the form of the vaginal mass that was easily detected clinically. Q. By the way, since your opinion that the slides were not negligently misread is based on, quote, the difficulties faced by even the most expert pathologists when evaluating biopsy material and peritoneal washings in the setting of extensive endometriosis, end quote, would that be your opinion if in fact the vaginal biopsy of June of 2000, which you have not seen, was read out as normal? MR. BONEZZI: Objection. A. That's a confusing question. Q. Can you read it over to me?

anger an

		Τ	
	Page 65		Page 67
1	MS. NISSENBERG: Do you want to read it?	1	The best way to explain that is, because I do
2	THE WITNESS: You can skip the part where she's	2	review my own slides for my patients and I sit down
3	quoting.	3	frequently with our pathologists and look at slides
4	(Record read.)	4	together and review all these cases at least at Virginia
5	MR. BONEZZI: Let me object.	5	Mason for our own gynecologic cancer conferences, I have
6	A. But the vaginal biopsy in June of 2000 was read	6	a very deep understanding of when it's a difficult
7	out as cancer.	7	diagnosis, and even the most expert pathologists can
8	Q. Correct. But your opinion that the 1999	89	render an opinion that in retrospect based upon subsequent clinical behavior is found to be in error
9 10	slides, both surgical specimens and pelvic washings, that they were not negligently misread because you're aware of	10	versus the situation where it was a really negligent
11	the difficulty for even the most expert pathologists in	11	mistake where even I having looked at the slides would
12	interpreting biopsies and peritoneal washings in the	12	say yes, that's obviously cancer and this pathologist,
13	presence of extensive endometriosis, I mean that opinion	13	this hypothetical pathologist who called it benign indeed
14	is formed without even seeing the slides, correct?	14	made a mistake.
15	A. Correct.	15	In other words, I'm going back to my notion
16	O. And you're prepared to say that it's such a	16	that because I am a clinician dealing with cancer on a
17	difficult thing, that if somebody misses cancer, it can	17	daily basis, I almost can propose myself as a one-person
18	happen because there's extensive endometriosis in these	18	jury to mediate these disagreements between pathologists
19	patients and even the best pathologists can miss it,	19	and say, you know, this really was a hard case and it's
20	correct?	20	unfair for Dr. Tench, for instance, to accuse the
21	A. Correct.	21	Cleveland Clinic pathologist of malpractice, because I
22	Q. Would your opinion be the same if the vaginal f_{1}	22 23	can bet you more than a quarter that if the roles had been reversed, Dr. Tench could easily have made the same
23 24	biopsy of June of 2000 was read out as normal? MR. BONEZZI: Objection.	$23 \\ 24$	diagnosis back in '99 had he been on staff and I had
24	A. So you're saying the vaginal tissue in this	24	presented him with a similar pathology quandary.
25	A. 50 you're saying the vaginar tissue in this	20	presented min whith a similar pathology quantary.
h			
	Page 66		Page 68
1	Page 66 hypothetical situation is cancerous, obviously cancer?	1	Q. So your opinion is that Dr. Tench would not
2	hypothetical situation is cancerous, obviously cancer? Q. Yes.	1 2	Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these
2 3	hypothetical situation is cancerous, obviously cancer?Q. Yes.A. And a pathologist does a biopsy and incorrectly	3	Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides?
2 3 4	hypothetical situation is cancerous, obviously cancer?Q. Yes.A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're	3 4	Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides?A. I will say that more probably than not, if Dr.
2 3 4 5	hypothetical situation is cancerous, obviously cancer?Q. Yes.A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying?	3 4 5	Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides?A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had
2 3 4 5 6	hypothetical situation is cancerous, obviously cancer?Q. Yes.A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying?Q. You haven't seen the original slides, but	3 4 5 6	Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides?A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out
2 3 4 5 6 7	hypothetical situation is cancerous, obviously cancer?Q. Yes.A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying?Q. You haven't seen the original slides, but you're prepared to come into court and say that they were	3 4 5 6 7	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have
2 3 4 5 6 7 8	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get 	3 4 5 6 7 8	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic
2 3 4 5 6 7 8 9	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive 	3 4 5 6 7	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have
2 3 4 5 6 7 8	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get 	3 4 5 6 7 8 9	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did
2 3 4 5 6 7 8 9 10	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your 	3 4 5 6 7 8 9 10 11 12	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently?
2 3 4 5 6 7 8 9 10 11 12 13	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her 	3 4 5 6 7 8 9 10 11 12 13	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it.
2 3 4 5 6 7 8 9 10 11 12 13 14	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or 	3 4 5 6 7 8 9 10 11 12 13 14	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been 	3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they 	3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your opinion be the same, that they're not negligently misread 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed at Dr. Kennedy's request in 2000 and on which he
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your opinion be the same, that they're not negligently misread because it's very difficult for even the most expert 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed at Dr. Kennedy's request in 2000 and on which he identified a small focus of high-grade cancer? Is it
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your opinion be the same, that they're not negligently misread because it's very difficult for even the most expert pathologists to correctly interpret biopsies with a 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed at Dr. Kennedy's request in 2000 and on which he identified a small focus of high-grade cancer? Is it your opinion that Dr. Tench would have missed that, also,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your opinion be the same, that they're not negligently misread because it's very difficult for even the most expert pathologists to correctly interpret biopsies with a patient who has extensive endometriosis? 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed at Dr. Kennedy's request in 2000 and on which he identified a small focus of high-grade cancer? Is it your opinion that Dr. Tench would have missed that, also, if he had been sitting at the Cleveland Clinic?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your opinion be the same, that they're not negligently misread because it's very difficult for even the most expert pathologists to correctly interpret biopsies with a 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed at Dr. Kennedy's request in 2000 and on which he identified a small focus of high-grade cancer? Is it your opinion that Dr. Tench would have missed that, also, if he had been sitting at the Cleveland Clinic? A. I thinkso.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your opinion be the same, that they're not negligently misread because it's very difficult for even the most expert pathologists to correctly interpret biopsies with a patient who has extensive endometriosis? 	$\begin{array}{c} 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ \end{array}$	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed at Dr. Kennedy's request in 2000 and on which he identified a small focus of high-grade cancer? Is it your opinion that Dr. Tench would have missed that, also, if he had been sitting at the Cleveland Clinic?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 hypothetical situation is cancerous, obviously cancer? Q. Yes. A. And a pathologist does a biopsy and incorrectly labels that specimen as benign? Is that what you're saying? Q. You haven't seen the original slides, but you're prepared to come into court and say that they were not negligently misread because it's just hard to get these things right when a patient has got extensive endometriosis? Isn't that true? Isn't that what your opinion says? A. That's true. Q. In June of 2000, when Mrs. Huston had her vaginal biopsy, another slide that you haven't seen or set of slides that you haven't seen, if those had been read out as normal and the plaintiff claimed that they were negligently misread, quote, unquote, would your opinion be the same, that they're not negligently misread because it's very difficult for even the most expert pathologists to correctly interpret biopsies with a patient who has extensive endometriosis? 	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. So your opinion is that Dr. Tench would not have picked up what he picked up when he looked at these pelvic washing slides? A. I will say that more probably than not, if Dr. Tench through some violation of space-time continuum had been sitting at the Cleveland Clinic in '99 reading out Connie Huston's slides that he probably would have rendered the same written report as the Cleveland Clinic pathologist, looking at both cytology and histology, did in '99. Q. So he would have misread them, but not negligently? A. I think that's a very proper way to phrase it. It goes down to an issue of negligence. I don't think there was anything negligent done by the pathologist in this case. Q. What about the B6 slide Dr. Biscotti analyzed at Dr. Kennedy's request in 2000 and on which he identified a small focus of high-grade cancer? Is it your opinion that Dr. Tench would have missed that, also, if he had been sitting at the Cleveland Clinic? A. Ithinkso. MR. BONEZZI: Objection to the manner in which

17 (Pages 65 to 68)

	Page 69		Page 71	V.CODID
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	 after he made the comparison with the vaginal biopsy. MS. NISSENBERG: That has nothing to do with the question. MR. BONEZZI: It certainly does. The way in which you have phrased it is absolutely misleading. Q. Mr. Bonezzi is referring to the fact that Dr. Biscotti had the vaginal biopsy slide at the same time that he looked at B6. Nevertheless, Dr. Kennedy testified that Dr. Biscotti identified for him a small focus of high-grade cancer. So is your answer the same, that in your opinion Dr. Tench would also have read this out as normal tissue, normal endometriotic tissue, had he been at the Cleveland Clinic reading the surgical specimens in April of '99? MR. BONEZZI: Objection. A. I would actually go one step further and I would say that every single one of the expert pathologists retained by both plaintiff and defense in this case, if they had, again, through some violation of space-time continuum become the staff pathologist in 1999, I predict that all of them would have read this out as benign. 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 cancer and surface epithelial ovarian cancer behave biologically the same way, with dissemination directly into the peritoneal cavity. <i>Q</i>. Wave you ever treated patients when you're doing surgery where the cyst ruptures and seed the remaining GYN tissue that is left after the surgery? A. Can you ask that question again? Q. Sure. I might have said that in a confusing manner. Have you ever operated on patients where the ovarian cyst contained cancer cells, the cyst ruptures during surgery and seed tissue that is remaining after the surgery? A. It's a hypothetical concern with any ovarian cancer in which the epithelial cancer has become encapsulated and, therefore, is not in direct contact with the peritoneal cavity. Q. I don't think that answered my question. Do you want me to repeat the question? A. I guess I did answer it, because it's a hypothetical concern. We never actually know what happens, though, for those patients with a true encapsulated ovarian cancer that ruptures during surgery. <i>Q</i>. So you're not aware as you sit here of any patients on whom you have performed surgery in which the 	
$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Page 70 think could have been rendered based upon my understanding of the clinical nature of this case would have been endometriosis with some areas of atypia. Q. In fact, as we mentioned before, both the surgical specimen report for Section B, including B6, as well as the final report on the cytopathology specimen, the pelvic washing, omitted any reference to atypia. Isn't that true? A. That is true. Q. So Dr. Kennedy didn't even have the benefit of knowing that atypia existed in both B6 as well as in the pelvic washings in his decision on how to treat this patient. Isn't that true? A. That is true. Q. Is it a true statement that the most common form of dissemination of epithelial tumors throughout the peritoneal cavity is by exfoliation of malignant cells through the surface of the ovarian capsule? A. If you're talking about an epithelial ovarian cancer, then that's a true statement. I would go one step further and say that it is also a true statement if you're dealing with the very similar malignancy that arises from the surface of the adjacent pelvic peritoneum. In other words, the primary pelvic peritoneal 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	Page 72 cyst ruptured, leaving cancer cells to seed remaining tissue and when I say remaining tissue, tissue left after the surgery you're not aware of any patients on whom you have operated that that has occurred? A. I suspect that it has happened, based upon the patient's clinical course, but I guess I'm kind of struggling with the scientific precision of do we ever really know what happens to an individual cancer cell that drops onto the pelvic peritoneal surface when you're removing a ruptured cystic ovarian cancer. But I would agree with you. The hypothetical concern is that ovarian cancer is implantable, which is why we try whenever possible when we're dealing with a cystic encapsulated tumor mass to remove it intact. Q. That's why, in fact, when assigning a patient to either the IC or IIC category, the FIGO staging system asks the clinician to consider whether the cyst had ruptured spontaneously or during surgery. Isn't that true? A. That is true, in particular because if you've operated on somebody in whom the ovarian cyst ruptured before you got into the abdomen, that's a much more serious situation, perhaps more analogous to Connie Huston's case, because you have had that tissue contaminated in the pelvic peritoneum for an unknown	

	Dage 72		Dece 75
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	Page 73 period of time, possibly days, weeks, months, before you even operated on her in the First place. Q. So in those patients for whom the cysts have ruptured spontaneously, when you're assigning them to the category, they would be the IIC versus the patients where the cysts have ruptured during surgery and not before and they would be a IC, correct, according to the FIGO staging system? MR. BONEZZI: Would you read that back, please. (Record read.) MR. BONEZZI: Thank you. A. We're getting into an area of technicality, which is always better explained as a structured statement rather than a question-and-answer, because we're getting ourselves tripped up here. For instance, if I'm operating on somebody who has ovarian cancer again, I'm talking hypothetically, but a standard ovarian cancer, which is a true primary ovarian cancer in which the mass has become densely adherent to the pelvis, probably the point of adherence indeed represents malignancy. So when I reach my hands down in the pelvis and gingerly begin to mobilize that ovarian tumor mass up and into my operative field, it inevitably breaks at the precise point where there is cancer penetrating through	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 Page 75 Q. Getting back to my original question about IC versus IIC, as to whether or not the cyst had ruptured spontaneously, i.e., not before I mean on their own before surgery versus during surgery and not before, it's important to know if the patient is a IC or a IIC because that has a difference in the impact on survival, correct? A. Clinically, there is a great deal of overlap in the prognosis between Stage IC and Stage IIC. So I would hesitate to make a general statement about survival without knowing all of the other information that I have mentioned before, such as grade, histology, exactly what the adhesions were. In other words, were they benign endometriosis or were they actually malignant adhesions. And then you would also factor in subtleties such as the extent of her surgical staging, do we really know what her pelvic-peri workup, the status is, do we know what the status of her diaphragms are, so on and so forth. Q. And the FIGO system suggests that the flinician, No. 1, ascertain whether the rupture of the cyst was spontaneous or caused by surgery, as well as ascertaining whether the malignant cells in the pelvic washings are from the peritoneum or from the or obtained in the ascites. Isn't that true? A. Yes.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	 Page 74 the capsule into the pelvic peritoneal sidewall. Now, if 1 am surgeon who does not understand the spread patterns and clinical behavior of ovarian cancer, I might misclassify that patient as Stage IC, using the exact FIGO criteria that you're quoting. However, if I look more carefully and do some biopsies from that pelvic peritoneum and prove under the microscope that there actually is cancerous cells deep in the pelvic peritoneal tissue, then she officially qualifies as Stage IIC, because I have a written pathology report documenting spread to peritoneal tissues. Q. And you just reminded me of something that I had forgotten to write down, and I'm glad you did. Isn't it true that microscopic sections should be obtained at the area of dense adhesion to ascertain whether or not that represents malignancy versus a chemical reaction causing the adherence? A. You would not do those additional microscopic sections if you thought you were only dealing with only benign endometriosis, but it certainly is my clinical practice when I'm operating on a woman with documented ovarian cancer or a similar cancer of the pelvic peritoneum to do all those additional biopsies and submit them separately for histology evaluation. 	9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Page 76 Q. And it's because of the impact on prognosis of the different criteria for allotting cases to either IC or IIC? Isn't that true, in general? A. I think that you're blending two uses of the FIGO staging system. The first use of the FIGO staging system is simply for reporting results to not just national databases but also the international database that tracks ovarian cancer. In that situation, one of the rules is that when in doubt about the true stages of a woman's malignancy, that you report for data management purposes the lower of the stages. For example, if you had a patient that you weren't sure whether she was going to be categorized as a IC or IIC, you would report her out as a IC for the purposes of tumor registration. We have this discussion all the time when we're doing our cancer conferences, because we're part of the SER that's S-E-R the SER database here in the King County area, Seattle. And then, of course, we have requirements for American College of Surgeons Tumor Registry to report this information through our own registry process. But, I'm sorry, I'm rambling here.

19 (Pages 73 to 76)

Page 77	Page 79
 Q. I'm going to charge you for part of this transcript. A. Perfect. You know that the clinician, when they're making decisions about does she need chemotherapy, yes or no, so on and so forth, will take this discussion up to a more fine level of discussion so that we can render treatment decisions. Q. So if Mrs. Huston had been a IC on April 29, 1999, you couldn't tell me exactly the range of five-year survival? You thought 80 percent sounded high, but you couldn't give me an actual range. A. That's correct, because specifically if we're to accept the hypothesis that she had high-grade carcinoma, again quoting from your interpretation of one of the pathology reports, that she had high-grade, say Grade III, IC disease, at least IC disease and I would also remind you, again, that that is a IC identification for purposes of reporting it to the Tumor Registry. As a clinician, I'm thinking she has at least IIC disease. And we, actually, do not have any information about her upper abdominal disease status. She could easily be of the equivalent of a Stage IIIA or worse, had further surgical staging procedures been done. Q. Well, that's all speculation. 	 as a Stage IC in early May or end of April, April 30, 1999, for example, what would have been her percent chances for five-year survival? I know you said that 80 percent seemed high to you. So I'm asking you what range of percentages you can give me for Stage IC. A. IC what, question mark? Q. Ovarian or endometriosis, cancer of an endometriosis implant within or on the ovary. A. Those are two totally different scenarios. Q. Is it your testimony that the staging system for ovarian carcinoma is not utilized for patients with cancer in an endometriosis implant within the ovary? Is that your testimony? MR. BONEZZI: Objection to that question. A. My testimony is that she has primary pelvic peritoneal carcinoma arising from endometriosis, and that the ovary had only a focus of this endometrial malignancy on the surface of the ovary. So I'm objecting to using any staging or survival statistics based upon ovarian cancer literature. It is not applicable to this case. Q. Is it your testimony that a patient with cancer in an endometriosis implant within or on the ovary is not
Page 78 1 Q. In fact 2 MR. BONEZZI: Objection. 3 Q. In fact, she wasn't even staged to IC at the 4 time, correct?	Page 80 1 ovarian carcinoma that we have been talking about in this 2 deposition? 3 A. I would have to check back with my own 4 reference books, because I'm trying to remember now if
 A. Because she didn't have cancer. She wasn't staged as cancer at all. Q. You don't think she had cancer in '99? A. I actually do not think she had cancer in '99, but, more importantly, the clinicians managing her in '99 	 4 reference books, because I'm trying to remember now if 5 FIGO has agreed on a staging system for primary 6 peritoneal cancer, and I don't think they have. 7 Q. Let's go back to my other question. 8 What is the generally accepted five-year 9 survival for patients with Stage IC ovarian carcinoma
 10 did not think that she had cancer. So she was not 11 staged. 12 Q. You're digressing from my question, which was, 13 if she were staged to IC in April or early May of '99, 14 can you give me a range? I know you think 80 percent is 15 high but a range of figures of percentages for five year 	 10 using the FIGO system for IC? 11 A. So we're back to a hypothetical situation. 12 Q. If you want to call it a hypothetical, that's 13 fine. Just give me the percentages. You think <i>S0</i> 14 percent is too high?
 15 high, but a range of figures of percentages for five-year 16 survival that are generally ascribed to Stage IC patients 17 such as that? 18 MR. BONEZZI: Objection. 19 A. Your line of questioning has drifted from the 20 hypothetical, which is what we were talking about before 21 when you were asking me about ovarian cancer IC, what are 22 the overall survival statistics, and now we've drifted 23 into, quote, she, end quote. So now I think we're 	 A. Eighty percent would be the upper range. Q. What would be the lower range? A. The lower range would be in the range of 30 to 40 percent, possibly lower if you are looking at, you know, poorly differentiated carcinomas, adenosquamous carcinomas, clear-cell carcinomas, those rare but fatal types, of which Mrs. Huston had the adenosquamous carcinoma ovarian. Q. So adenosquamous carcinoma even in a IC is
 talking about Mrs. Huston again, are we not? Q. The question is, had Mrs. Huston been diagnosed 	fatal? Is that your opinion? That's the word that youjust used.

ŝ

Hust	on vs. Cleveland Clinic Foundation		Howard Muntz, M.I
	Page 81		Page 83
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	 A. It is very difficult to cure, and so the fatality rate is very high. Q. So your testimony is that for IC, that the low range of five-year survival is 30 to 40 percent or possibly lower? A. I think that's a fair statement. Q. What about IIC? A. IIC blends in really with the survival statistics for Stage IIIA, because a lot of us feel that there is really no clinical entity of IIC disease, because as soon as you have disease involving the pelvic peritoneum, you also by definition have at least microscopic disease of the abdominal peritoneum, which pulls your stage assignment up to IIIA. That, for instance, is why we have this disconnect between the data that we report to FIGO using their staging nomenclature and our clinical decisions and, indeed, our prognostic discussions with patients. For instance, we would in no way tell a patient with IIC ovarian cancer that she had a good prognosis. 	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	 A. Correct, because I would say I'm worried that you might actually have clinically occult Stage IIIA disease, that you have poorly differentiated carcinoma, and the FIGO aggregate data includes lots of women with well-differentiated cancers that would clinically behave better than my patient with adenosquamous carcinoma of the ovary, so on and so forth. That's why you need to always include all these qualifiers when you're discussing this. Q. So your opinion is that Mrs. Huston did not have cancer in 1999, in April of '99; is that correct? A. I think that more probably than not, she had premalignant atypical endometriosis. Q. And would that still be your opinion if the pelvic washings are proven to contain malignant cells that you said earlier would be consistent with cancer in the patient? A. You can have a pelvic wash that contain individual cells that look malignant, but they can be shed from an area of premalignant tissue.
21 22 23 24 25	We would be emphasizing to her that she has a very serious malignancy and would need aggressive treatment and we would hope that we could cure her. Q. To reask my question, what is the percentage of five-year survival for IIC ovarian carcinoma, using the Page 82	21 22 23 24 25	Q. No, I think I asked you earlier if the pelvic washings were proven to contain malignant cells, would that be consistent with the diagnosis of cancer in the patient, and I believe you said yes. Did I misquote you? Page 84
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	 FIGO system? A. Quoting from the FIGO annual reports? Q. Whatever you utilize in order for you to know what the range of survival is, five-year survival for patients who are staged as a IIC. What's the range? A. I will answer the question two ways. No. 1, if you want the FIGO survival, then we should just look that up in the FIGO annual report, because they will have a five-year survival for women that the FIGO system has assigned to Stage IIC. Q. Are you aware of what that is as you sit here? A. No. I would have to look it up. I'm assuming it's going to be in the range of 50 to 60 percent. MS. NISSENBERG: Off the record. (Discussion off the record.) A. I never answered part 2 of the question. Q. I didn't realize there was a two-part. A. Part 2 of the answer. Clinically, I would put that patient in a lower survival rate, particularly if she had Grade III malignancy. Q. But my question was only the percentage of five-year survival for a stage IIC. So by that patient, you're talking about a IIC patient? You would tell them this is what FIGO says your five-year survival is, but it's really worse than that? 	$ \begin{array}{c} 1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\23\\24\\25\end{array} $	 A. You're quoting me correctly, but I'm embellishing the answer to make it more clear. Q. So if, in fact, Mrs. Huston's pelvic washings indeed contain malignant cells on April 29, 1999, if it's proven that they indeed contain malignant cells, not an isolated cell here and there, would your opinion still be the same, that she did not have cancer on April 29, 1999? A. Her cytology material did not contain enough cellular material to make that diagnosis of an outright malignancy. So your question doesn't at all match up with what we know about her either clinically or based upon the pathology review. Q. You as you sit here don't even believe that she had malignancy in the pelvic washings in April of '99, correct? A, I believe that more probably than not they were atypical endometriosis cells that based upon her subsequent clinical history can be viewed as premalignant. Q. Now, my hypothetical is that the pelvic washings contain true malignant cells and not the isolated here and there, true malignant cells. That's my hypothetical, not what you believe actually was in the pelvic wash slides, even though you may disagree with some of the other people who have testified in this case,

21 (Pages 81 to 84)

	Page 85		Page 87
1	including Cleveland Clinic pathologists and/or defense	1	premalignant phase and then they develop frank, invasive
2	experts.	2	malignancy.
3	MR. BONEZZI: Objection. Misstates the	3	Q. And you can't tell me as you sit here today
4	testimony.	4	when you think this frank malignancy was first present in
5	Q. Hypothetically then, can you state that the patient did not have cancer, given that scenario?	5	Mrs. Huston, correct? A. That's correct.
6 7	A. So you're giving me a scenario now. We have	7	O. What is your opinion as to when Mrs. Huston was
8	pelvic washings that have large aggregated clusters of	8	first diagnosable with cancer?
9	malignant cells. So there's no ambiguity.	9	MR. BONEZZI: Objection.
10	Again, like I said, my pathology colleague	10	A. I cannot even begin to speculate about that.
11	calls me up and says, "Howard, there is no ambiguity.	11	Q. I would iike you to presume that you were
12	These cells are detached from a true invasive cancer	12	Mrs. Huston's treating GYN oncologist in April of '99.
13	somewhere in that patient's abdominal cavity."	13	Hypothetically, if you were told that both
14	That's the hypothetical we're talking about	14	pelvic washings and B6 contained malignancy, how would
15 16	now, and I'd say yes, that indicates that she has cancer someplace.	15 16	you have gone about treating the patient? A. I would have reviewed the microscope slides
17	Q. So you don't believe she had cancer, because	17	myself, because that would be an important part of my
18	you don't believe that malignant cells existed in the	18	decision-making process, to see for myself just how
19	pelvic washings; you just think that there was atypia and	19	malignant-appearing these cells were, because I'm
20	possibly some premalignant endometriosis cells, correct?	20	facing
21	A. That's a fair statement.	21	MR. BONEZZI: Wait. What she wants to know is
22	Q. And is that the basis of your opinion that she	22	what treatment plan would you initiate hypothetically.
23	did not have cancer in 1999?	23	Q. What diagnostic tests as well. What would you
24 25	A. More probably than not, she did not have cancer	24 25	have done after you looked at the slides, assuming you
23	in 1999.	23	were satisfied that your pathology department had read
	Page 86		Page 88
1	Q. And that's the basis? Is that the basis? I'm	1	them correctly?
2	asking.	2	MR. BONEZZI: Objection. Ask your question
3	A. The basis for what?	3	without throwing those caveats in. All right?
4 5	Q. What is the basis or what are the bases that Mrs. Huston did not have cancer on April 29, 1999?	45	A. That's okay, although it's helpful, because this particular case, it's so ambiguous that we would
		5	
		6	
5 6 7	A. That the cytology and histology material even	6 7	automatically be getting pathology second or third
6	A. That the cytology and histology material even with a very aggressive interpretation by your expert	6 7 8	automatically be getting pathology second or third opinions before we committed a healthy woman to
6 7 8 9	A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99.	7 8 9	automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i> . So the first thing you would do is you would
6 7 8 9 10	A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent,	7 8 9 10	automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i> . So the first thing you would do is you would look at the slides yourself and maybe even have them
6 7 8 9 10 11	A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to	7 8 9 10 11	automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i> . So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility.
6 7 8 9 10 11 12	A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom.	7 8 9 10 11 12	automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i> . So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you
6 7 8 9 10 11 12 13	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed 	7 8 9 10 11 12 13	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient?
6 7 8 9 10 11 12 13 14	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? 	7 8 9 10 11 12 13 14	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly,
6 7 8 9 10 11 12 13 14 15	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I 	7 8 9 10 11 12 13 14 15	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule.
6 7 8 9 10 11 12 13 14	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? 	7 8 9 10 11 12 13 14	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly,
6 7 8 9 10 11 12 13 14 15 16	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a 	7 8 9 10 11 12 13 14 15 16 17 18	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we
6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a frankly malignant process sometime between the spring of '99 and the summer of 2000. Q. We know that she had cancer diagnosed at the 	7 8 9 10 11 12 13 14 15 16 17 18 19	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we would do a colonoscopy, an upper endoscopy study, so on
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a frankly malignant process sometime between the spring of '99 and the summer of 2000. Q. We know that she had cancer diagnosed at the Cleveland Clinic in June of 2000. 	7 8 9 10 11 12 13 14 15 16 17 18 19 20	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we would do a colonoscopy, an upper endoscopy study, so on and so forth.
$\begin{array}{c} 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \end{array}$	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a frankly malignant process sometime between the spring of '99 and the summer of 2000. Q. We know that she had cancer diagnosed at the Cleveland Clinic in June of 2000. A. Correct. She obviously had cancer in June of 	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we would do a colonoscopy, an upper endoscopy study, so on and so forth. Q. You would try to determine the extent of
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a frankly malignant process sometime between the spring of '99 and the summer of 2000. Q. We know that she had cancer diagnosed at the Cleveland Clinic in June of 2000. A. Correct. She obviously had cancer in June of 2000. You asked me when did it become cancer, 	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we would do a colonoscopy, an upper endoscopy study, so on and so forth. Q. You would try to determine the extent of disease, correct?
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a frankly malignant process sometime between the spring of '99 and the summer of 2000. Q. We know that she had cancer diagnosed at the Cleveland Clinic in June of 2000. A. Correct. She obviously had cancer in June of 2000. You asked me when did it become cancer, Q. And you can't say? 	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we would do a colonoscopy, an upper endoscopy study, so on and so forth. Q. You would try to determine the extent of disease, correct? A. Correct. Just the usual diagnostic workup that
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a frankly malignant process sometime between the spring of '99 and the summer of 2000. Q. We know that she had cancer diagnosed at the Cleveland Clinic in June of 2000. A. Correct. She obviously had cancer in June of 2000. You asked me when did it become cancer, Q. And you can't say? A. It's just - you know, it's a continuum. You 	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we would do a colonoscopy, an upper endoscopy study, so on and so forth. Q. You would try to determine the extent of disease, correct? A. Correct. Just the usual diagnostic workup that any oncologist would do.
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. That the cytology and histology material even with a very aggressive interpretation by your expert witnesses did not meet my threshold for really proving that she had a frank malignancy in '99. So I think it fails to meet the 51 percent, more-probable-than-not criteria that attorneys require to bring this into a courtroom. Q. When do you think Mrs. Huston first developed cancer? A. There's no way to really know that for sure. I would speculate that it probably, you know, became a frankly malignant process sometime between the spring of '99 and the summer of 2000. Q. We know that she had cancer diagnosed at the Cleveland Clinic in June of 2000. A. Correct. She obviously had cancer in June of 2000. You asked me when did it become cancer, Q. And you can't say? 	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 automatically be getting pathology second or third opinions before we committed a healthy woman to potentially toxic chemotherapy. <i>Q</i>. So the first thing you would do is you would look at the slides yourself and maybe even have them relooked at by someone else or another facility. What diagnostic tests or levels would you obtain for the patient? A. I'll try to run through this very quickly, because I know we are running behind schedule. CA-125 blood test. We would do the usual chest X-ray, abdominopelvic CAT scan. If there is any ambiguity about this being a gastrointestinal primary, we would do a colonoscopy, an upper endoscopy study, so on and so forth. Q. You would try to determine the extent of disease, correct? A. Correct. Just the usual diagnostic workup that

.....

	Page 89		Page 91
1	either cancer or endometriosis implant within or on the	1	moving target. I think we all would be in agreement that
2	ovary or primary ovarian, what treatment would you	2	right now, including in 1999, that we would treat her
34	recommend for her?	3	Note: White the second
5	A. I might have to take her back to the operating room if I felt that I had either I personally, if I	4 5	Q. And that would be whether or not she had primary ovarian Stage IC or carcinoma arising into
6	had done her surgery, had not done an adequate job of	6	endometriosis implant within or on the ovary?
7	evaluating her upper abdomen, again because I didn't	7	A. Correct.
8	think she had cancer.	8	Q. Do you recall from reading Dr. Biscotti's
9	So I would have taken a quick look, but I would	9	testimony that when he looked at both the vaginal biopsy
10	have not done any omental biopsies, certainly not have	10	and the original B6 that both show adenosquamous
11	exposed her to the surgical risk of a lymph node	11	carcinoma?
12	dissection for this kind of clinical story, but I might	12	A. I think you're misinterpreting what he either
13	say, you know, I need to go back to the operating room to	13	said or was trying to say.
14	thoroughly evaluate whether or not she actually has Stage	14	Q. You don't recall that testimony?
15 16	III disease, because it's quite possible that she has retroperitoneal lymph node involvement or lymph node	15 16	A. The Biscotti deposition went around in circles on this issue. So you can choose your quotes. I'm sure
17	disease, diaphragmatic implants that I did not appreciate	17	Dr. Biscotti would be quoted differently by Mr. Bonezzi.
18	at the time of my initial exploratory surgery.	18	Q. I'll look for the exact quote. I didn't
19	Or I might decide that she has Grade III	19	testify. Dr. Bonezzi did. I mean Dr. Biscotti. Sorry.
20	disease, it's at least Stage IIC based upon what I have	20	I'm getting tired.
21	learned from my pathology interpretation, and I would	21	I'm going to read to you from page 37, and I
22	move straight to either chemotherapy if I felt she had a	22	asked Dr. Biscotti
23	disseminated process that placed her entire pelvic	23	MR. BONEZZI: Which line?
24	peritoneal cavity at risk for malignancy or I would	24	MS. NISSENBERG: Beginning with line 8.
25	consider pelvic radiation therapy if I felt that her	25	Q. Okay. And at that point, did you then decide
	Page 90	-	Page 92
1	disease was limited to the pelvis.	1	that the typical cells it should be "atypical,"
2	disease was limited to the pelvis.Q. So you would do a second-look surgery in that	2	that the typical cells it should be "atypical," speaking of
2 3	disease was limited to the pelvis. Q. So you would do a second-look surgery in that case?	2 3	that the typical cells it should be "atypical,"speaking ofA. It's a typographical error.
2 3 4	disease was limited to the pelvis.Q. So you would do a second-look surgery in that case?A. No. I would have to decide whether or not a	2 3 4	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of
2 3 4 5	disease was limited to the pelvis.Q. So you would do a second-look surgery in that case?A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical	2 3 4 5	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma?
2 3 4	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the 	2 3 4	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of
2 3 4 5 6	disease was limited to the pelvis.Q. So you would do a second-look surgery in that case?A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical	2 3 4 5 6	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens
2 3 4 5 6 7	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? 	2 3 4 5 6 7	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas.
2 3 4 5 6 7 8 9 10	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this 	2 3 4 5 6 7 8 9 10	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were?
2 3 4 5 6 7 8 9 10 11	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? 	2 3 4 5 6 7 8 9 10 11	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were.
2 3 4 5 6 7 8 9 10 11 12	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. 	2 3 4 5 6 7 8 9 10 11 12	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't
2 3 4 5 6 7 8 9 10 11 12 13	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had 	2 3 4 5 6 7 8 9 10 11 12 13	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his
2 3 4 5 6 7 8 9 10 11 12 13 14	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was 	2 3 4 5 6 7 8 9 10 11 12 13 14	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire
2 3 4 5 6 7 8 9 10 11 12 13 14	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was 	2 3 4 5 6 7 8 9 10 11 12 13 14	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about IC, ruptured versus not. Although I'm sorry. Let's back up for a second, because your hypothetical includes that she has 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire context in which your conversation with Dr. Biscotti was taking place. It goes back to the ability, looking in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about IC, ruptured versus not. Although I'm sorry. Let's back up for a second, because your hypothetical includes that she has positive peritoneal cytology that's unambiguously 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire context in which your conversation with Dr. Biscotti was taking place. It goes back to the ability, looking in retrospect, knowing what the slides look like in 2000,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about IC, ruptured versus not. Although I'm sorry. Let's back up for a second, because your hypothetical includes that she has positive peritoneal cytology that's unambiguously positive. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire context in which your conversation with Dr. Biscotti was taking place. It goes back to the ability, looking in retrospect, knowing what the slides look like in 2000, that you can more easily pick out a cell here or a cell
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about IC, ruptured versus not. Although I'm sorry. Let's back up for a second, because your hypothetical includes that she has positive peritoneal cytology that's unambiguously positive. So I would treat that patient with chemotherapy 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire context in which your conversation with Dr. Biscotti was taking place. It goes back to the ability, looking in retrospect, knowing what the slides look like in 2000, that you can more easily pick out a cell here or a cell over there either in the cytology or histology material
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about IC, ruptured versus not. Although I'm sorry. Let's back up for a second, because your hypothetical includes that she has positive peritoneal cytology that's unambiguously positive. So I would treat that patient with chemotherapy even if she had Grade I disease. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire context in which your conversation with Dr. Biscotti was taking place. It goes back to the ability, looking in retrospect, knowing what the slides look like in 2000, that you can more easily pick out a cell here or a cell over there either in the cytology or histology material of '99 that bears a resemblance to the 2000 material.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about IC, ruptured versus not. Although Tm sorry. Let's back up for a second, because your hypothetical includes that she has positive peritoneal cytology that's unambiguously positive. So I would treat that patient with chemotherapy even if she had Grade I disease. Q. Are you aware of the gold standard for the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire context in which your conversation with Dr. Biscotti was taking place. It goes back to the ability, looking in retrospect, knowing what the slides look like in 2000, that you can more easily pick out a cell here or a cell over there either in the cytology or histology material of '99 that bears a resemblance to the 2000 material. Q. I'm not asking you whether or not Dr. Biscotti
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 disease was limited to the pelvis. Q. So you would do a second-look surgery in that case? A. No. I would have to decide whether or not a second-look surgery was necessary for my clinical Q. Okay. And if you were convinced that the patient after doing this workup was a IC, would you recommend her for any type of chemotherapy with a medical oncologist? A. She has a Grade III disease for this hypothetical discussion? Q. The hypothetical is that she's IC. A. No, it's very important, because if she had only Grade I, I might wonder whether chemotherapy was required. It would get back to this whole debate about IC, ruptured versus not. Although I'm sorry. Let's back up for a second, because your hypothetical includes that she has positive peritoneal cytology that's unambiguously positive. So I would treat that patient with chemotherapy even if she had Grade I disease. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 that the typical cells it should be "atypical," speaking of A. It's a typographical error. Q that you saw were actually a focus of high-grade carcinoma? Answer: Yes. When I had taken both specimens in aggregate, I decided that well, let me take that back. I decided that they were carcinomas, that they were adenosquamous carcinomas. Question: Both were? Answer: Both were. Do you recall reading this testimony? I didn't make this up. This is Dr. Biscotti's testimony, his language. A. Yes, but on the prior page is the entire context in which your conversation with Dr. Biscotti was taking place. It goes back to the ability, looking in retrospect, knowing what the slides look like in 2000, that you can more easily pick out a cell here or a cell over there either in the cytology or histology material of '99 that bears a resemblance to the 2000 material.

23 (Pages 89 to 92)

	Page 03		Page 05
1 2 3 4 5 6 7 8 9 10 11 12 13	 Page 93 that when he compared both the vaginal biopsy and the original B6, and he saw the original B6, that both contained adenosquamous carcinoma? Do you recall that now? A. Oh, I agree with you that this is what it says in the deposition, and I guess I should simply let Dr. Biscotti try and clarify what he meant. Q. And does that suggest to you that the cancer shared the same origin or etiology, as you would like to say? A. I think I would agree with that, especially now that you're allowing me to use the word "etiology." Q. Would you also answer in the affirmative if I 	1 2 3 4 5 6 7 8 9 10 11 12 13	Page 95 Q. Would you agree that a cytopathologist reading pelvic wash slides needs to be able to recognize cells suspicious for malignancy? A. Yes. Q. And is the cytopathologist's experience and training part of the ability, would you say, to recognize such cells? A. Yes. Q. Are you aware of the level of experience and training that Dr. Brainerd had at the time she read the cytology specimens in this case? A. I can't remember now exactly what her level of experience was, but I'm sure it's referenced in her
14 15 16	used the word "origin" or only with the word "etiology"? A. Only with the word "etiology." Q. Do you recall Dr. Biscotti referring to the	13 14 15 16	deposition in detail. Q. So you don't recollect that she had not actually completed her formal cytopathology training at
17 18 19 20	original B6 as a "key slide"?A. Oh, yes. I think it is a key slide.Q. Would you agree that it's not good medical practice for a key slide to be missing from an	17 18 19 20	 the time she read these slides, correct? MR. BONEZZI: Objection. A. I don't recollect that. O. Are you familiar with the term first-order
21 22 23	institution?MR. BONEZZI: Objection.A. Actually, I would go one step further and just	21 22 23	tumor kinetics? A. Yes. Q. What does that mean to you?
24 25	state that it is very common for a slide like this to be missing. It is so common that it almost becomes standard	24 25	A. It just describes the growth pattern or algorithmic growth rate of the cancer cell when it's
	Page 94		Page 96
1	of care that you can't lay your hands on a really	1	growing with first-order kinetics.
2 3	interesting slide. Because it has been passed around so many	23	Q. And that theory is used partly to support the, I believe, generally accepted belief that it is easier to
4	times, it gets simply lost because it gets distributed	4	treat a cancer when the tumor burden is small and has not
5	around the department. It's probably in the bottom of	5	disseminated? Isn't that true?
6 7 8	somebody's briefcase and they don't even know it's there. Q. Do you recollect in the discharge summaries from August of 2000 references to review of slides reveal	6 7 8	A. It's easier to treat the cancer when the tumor burden is smaller. And dissemination is simply kind of part of that whole process, is it not?
9	questionable malignancy or cancer, post-status, further	9	Q. So, in fact, you would want to tseat the tumor,
10 11	review of pathology? Do you recall language to that effect?	10 11	most solid tumors I'm not talking about the rare exceptions, but you would want to treat most solid tumors
12	A. Oh, yes. I think that's also a very honest	11	when the tumor burden is smaller before the cancer has
13	assessment of the case.	13	spread, correct? Would you agree with that as a general
14	Q. What is your understanding of what those	14	principle?
15	references mean?	15	A. I hate to slow us down, but you're blending two
16 I7	A. It goes back to the whole issue that Alexander Kennedy as a very reputable and caring clinician wanted	16 17	concepts together in one question again. O. The question is, would you prefer
18	to know €or his own sake why Mrs. Huston developed this	18	A. When you're talking about the size of the tumor
19	fatal malignancy and he did the appropriate retrospective	19	burden, you're talking about the individual measurements
20	review of all the material that had been removed from her	:20	of, say, a tumor mass, whether it's one millimeter or one
21	hysterectomy specimen back in '99.	(21 (22)	centimeter. Dissemination refers to spread pattern
22 23	Q. Would you agree that a pathologist reading surgical specimens needs to be able to recognize cells	:22 23	throughout the body.
23 24	suspicious for malignancy?	23 24	So you could have disseminated cancer that's like tiny, microscopic, one or two millimeters, or you
25	A. Yes.	25	can have a local tumor that's ten centimeters in size.

wy

	Page 97		Page 95
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	So you're blending two concepts together.	$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	actually made the same mistake that we're both making as
23	In general, though, of course you want to treat cancer as early as you can find it. I don't quibble with	$\begin{vmatrix} 2\\ 3 \end{vmatrix}$	we talk back and forth. I'm taking into account the notion that she has a really poorly differentiated
4	that.	4	aggressive malignancy and I'm giving her a higher stage
5	Q. Now, you seem to think that Dr. Weiss ignored	5	assignment than IC or even IIC.
6	the existence of positive pelvic washings. You state	6	$Q_{.}$ But if Dr. Weiss is correct in ascribing a IC
7	that Dr. Weiss has ignored the presumptive presence of	7	to her, do you still disagree with his figures for
8	malignancy in adjacent pelvic peritoneal tissues.	8	five-year chance of survival?
9 10	Is that your opinion?	9 10	A. Yes, I do, because there's plenty of literature from the ovarian cancer studies that if you have a
10	A. And then I go on to say in parenthesis, if the plaintiffs theory in this case is accepted, close	11	typical ovarian cancer, setting aside all discussion
12	parenthesis, end quote.	12	about peritoneal cancer, endometriosis, so on and so
13	O. So is it your opinion that Dr. Weiss has	13	forth, just a normal Stage I ovarian cancer, that factors
14	somehow ignored the positive pelvic washings?	14	like dense adherence, so on and forth, positive
15	A. What I'm referring to is that he has assigned	15	peritoneal fluid, all of them will pull that survival
16	her to Stage IC, as I gather you have also from your line	16	number down.
17 18	of questioning. That's why you keep on asking about	17	Remember again that the FIGO literature is
18	survival statistics for Stage IC disease. That's where he gets his, I believe, 80 percent	18 19	quoting survival in aggregate, so that you have an average which is made up of lows and highs.
20	five-year survival quotation. He actually quotes her at	20	I'm saying that she is on the wrong side of the
21	60, dash, 80 percent, I believe, in his original letter	21	survival curve here and the wrong side sorry, the
22	to you.	22	wrong side of the bell curve, so I cannot mix my syntax.
23	Q. That's correct. If the tumor is appropriately	23	She's at the bottom end of any bell curve that
24	treated, end quote.	24	we would draw around any Stage IC, IIC group of patients.
25	A. Yes. So this paragraph in my original	25	Q. I think your answer sort of begs the difference
	Dama 00		D 100
	Page 98		Page 100
1	statement is challenging that overly optimistic	1	between a IC and IIC, because the reason Dr. Weiss is
2	estimation of her survival, had her diagnosis been truly	2	ascribing a IC category to her is because of the presence
3 4	cancer and had her diagnosis been made in 1999. So those are two very important qualifications.	3 4	of the positive peritoneal washings. So by your answer, you seem to imply that if
5	I feel that		
		5	she had all this and then she also had these positive
6	Q. What was the first?	5 6	she had all this and then she also had these positive washings, it would move her or upstage her to a worse
7	A. If her cancer - can you read it back? I like		she had all this and then she also had these positive washings, it would move her or upstage her to a worse category?
7 8	A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it?	6 7 8	washings, it would move her or upstage her to a worse category?A. No. Let me clarify.
7 8 9	A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.)	6 7 8 9	washings, it would move her or upstage her to a worse category?A. No. Let me clarify.Q. Okay, good.
7 8 9 10	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. 	6 7 8 9 10	washings, it would move her or upstage her to a worse category?A. No. Let me clarify.Q. Okay, good.A. That's a very good point. The IC category
7 8 9 10 11	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 	6 7 8 9 10 11	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category
7 8 9 10 11 12	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? 	6 7 8 9 10 11 12	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery.
7 8 9 10 11	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 	6 7 8 9 10 11	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category
7 8 9 10 11 12 13	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent 	6 7 8 9 10 11 12 13	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this
7 8 9 10 11 12 13 14 15 16	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. 	6 7 8 9 10 11 12 13 14 15 16	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon
7 8 9 10 11 12 13 14 15 16 17	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? 	6 7 8 9 10 11 12 13 14 15 16 17	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the
7 8 9 10 11 12 13 14 15 16 17 18	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? A. I think it might have been as low as 20 	6 7 8 9 10 11 12 13 14 15 16 17 18	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the abdominal cavity, before the cyst ruptured.
7 8 9 10 11 12 13 14 15 16 17 18 19	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? A. I think it might have been as low as 20 percent. 	6 7 8 9 10 11 12 13 14 15 16 17 18 19	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the abdominal cavity, before the cyst ruptured. So we're not saying that the cyst ruptured and
7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? A. I think it might have been as low as 20 percent. Q. Based on what? 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the abdominal cavity, before the cyst ruptured. So we're not saying that the cyst ruptured and caused a positive pelvic washing? You don't think that's
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? A. I think it might have been as low as 20 percent. Q. Based on what? A. I think that she probably had unrecognized 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the abdominal cavity, before the cyst ruptured. So we're not saying that the cyst ruptured and
7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? A. I think it might have been as low as 20 percent. Q. Based on what? 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the abdominal cavity, before the cyst ruptured. So we're not saying that the cyst ruptured and caused a positive pelvic washing? You don't think that's what we're saying; is that correct? It wouldn't make
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? A. I think it might have been as low as 20 percent. Q. Based on what? A. I think that she probably had unrecognized Stage III disease, if your theory is accepted that she had cancer, true invasive cancer of this histology type in 1999. 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the abdominal cavity, before the cyst ruptured. So we're not saying that the cyst ruptured and caused a positive pelvic washing? You don't think that's what we're saying; is that correct? It wouldn't make sense. A. I'm in total agreement, and you're not understanding my point.
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. If her cancer - can you read it back? I like the way I said it the first time. How did I say it? (Record read.) A. Correct. Q. So if she had been diagnosed with cancer in 1999? A. No. If she had cancer at all and if that cancer had been diagnosed in 1999, I think her survival would have been much lower than the 60 to 80 percent quoted by your expert witness. Q. And what do you think it would have been? A. I think it might have been as low as 20 percent. Q. Based on what? A. I think that she probably had unrecognized Stage III disease, if your theory is accepted that she had cancer, true invasive cancer of this histology type 	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 washings, it would move her or upstage her to a worse category? A. No. Let me clarify. Q. Okay, good. A. That's a very good point. The IC category includes patients who are assigned to that category because their ovarian capsule ruptures during surgery. They would be classified as Stage IC even if their peritoneal washings were benign. Q. But in the patient in other words, in this patient, obviously the pelvic washings are obtained upon immediate entry into the peritoneal cavity, to the abdominal cavity, before the cyst ruptured. So we're not saying that the cyst ruptured and caused a positive pelvic washing? You don't think that's what we're saying; is that correct? It wouldn't make sense. A. I'm in total agreement, and you're not

Buell Realtime Reporting (206) 287-9066

25 (Pages 97 to 100)

Howard Muntz, M.D.

	Page 101		Page 103
1	A. Dr. Weiss is quoting aggregate survival data	1	prophylactic hysterectomy and bilateral oophorectomy
2	for Stage IC.	2	because of a strong family history for breast or ovarian
3	Q. Right.	3	cancer, and perhaps she's even one of our patients who
4	A. And one way he gets to a higher survival number	4	has a documented mutation in one of the cancer-causing
5	than I'm willing to accept is that he's not throwing out	5	genes.
6 7	the patients who have IC only because the cyst ruptured, despite having benign cytology in the pelvic washings.	67	We routinely do extensive peritoneal washings, looking for any evidence of pelvic peritoneal malignancy
8	He's not throwing out the patients with the really bad	8	in the patient at the time we do their prophylactic
9	histology like adenosquamous.	9	surgery.
10	And, furthermore, he's keeping her stuck at IC,	10	In that situation, the one case I'm
11	when I think we have all agreed that she's at least IIC,	11	remembering, we did not find any evidence of cancer,
12	and I'm saying clinically she's probably worse than that.	12	despite very close sectioning of her ovaries, fallopian
13	O. Well, I disagree that we've all said she's a	13	tubes and her endometrium.
14	IIC. Obviously, that's not what we think, nor do our	14	We did have positive peritoneal cytology. My
15	experts think that. That may be your opinion, but that's	15	colleague re-explored her afterwards and did additional
16	certainly not the opinion of all of us in this case.	16	samplings of the omentum and found small deposits of
17	IC contains patients with, as we know, positive	17	cancer in the omentum.
18	peritoneal washings and cancer involving one, or left or	18	Presumedly, this patient had clinically and
19	right ovary, correct?	19	indeed pathologically occult carcinoma of the pelvic
20	A. (No audibile response.)	20	peritoneum that was unrecognizable even in the hands of a
21 22	Q. So if you put her in the category of IC, I mean	21	skilled gynecologic oncologist working with expert
22	the fact that she's got positive washings, well, you say it's a grouping and it includes patients that have benign	22	pathologists.
23 24	washings, but it also includes patients that have	23 24	Q. So there are situations that you know of even anecdotally in which a patient has positive pelvic
25	positive peritoneal washings, correct?	24	washings, no known primary, but treatment is rendered to
25	positive peritonear washings, concer.	23	washings, no known primary, but treatment is rendered to
			D 444
	Page 102		Page 104
1	A. That's correct.	1	the patient presumptively for malignancy, correct?
2	A. That's correct.Q. So now what percentage? Do you think she was	2	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is
2 3	A. That's correct.Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you	2 3	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to
2 3 4	A. That's correct.Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99?	2 3 4	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that.
2 3 4 5	A. That's correct.Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99?A. I think her chances of survival could have been	2 3 4 5	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have
2 3 4 5 6	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given 	2 3 4 5 6	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly
2 3 4 5 6 7	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. 	2 3 4 5 6 7	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and
2 3 4 5 6 7 8	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? 	2 3 4 5 6 7 8	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're
2 3 4 5 6 7 8 9	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 	2 3 4 5 6 7 8 9	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease.
2 3 4 5 6 7 8	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. 	2 3 4 5 6 7 8	the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're
2 3 4 5 6 7 8 9 10	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 	2 3 4 5 6 7 8 9 10	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is
2 3 4 5 6 7 8 9 10 11	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat 	2 3 4 5 6 7 8 9 10 11 12 13	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing?
2 3 4 5 6 7 8 9 10 11 12 13 14	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? 	2 3 4 5 6 7 8 9 10 11 12 13 14	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. Q. How have they treated the patients, if you 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that, because I was anecdotally talking about women with family
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. Q. How have they treated the patients, if you know? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that, because I was anecdotally talking about women with family histories of breast and ovarian cancer.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. Q. How have they treated the patients, if you know? A. It's variable, depending upon the clinical 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that, because I was anecdotally talking about women with family histories of breast and ovarian cancer. Those would be the two most important things
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. Q. How have they treated the patients, if you know? A. It's variable, depending upon the clinical circumstances. The stories I'm recollecting, a cancer 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that, because I was anecdotally talking about women with family histories of breast and ovarian cancer. Those would be the two most important things that I would want to know about.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. Q. How have they treated the patients, if you know? A. It's variable, depending upon the clinical circumstances. The stories I'm recollecting, a cancer was discovered with subsequent diagnostic evaluations. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that, because I was anecdotally talking about women with family histories of breast and ovarian cancer. Those would be the two most important things that I would want to know about. (Brief recess.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. Q. How have they treated the patients, if you know? A. It's variable, depending upon the clinical circumstances. The stories I'm recollecting, a cancer was discovered with subsequent diagnostic evaluations. The one anecdote, I think, that is probably 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that, because I was anecdotally talking about women with family histories of breast and ovarian cancer. Those would be the two most important things that I would want to know about. (Brief recess.) Q. I think we were just going over Mrs. Huston's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. That's correct. Q. So now what percentage? Do you think she was 20 percent, did I hear you say, or what percentage do you think she had of survival as of April of '99? A. I think her chances of survival could have been as low as 20 percent, even if diagnosed in 1999 and given chemotherapy at that point in time. Q. And as high as what? A. I would probably not quote her more than 50 percent. Q. Have you ever treated patients who have positive pelvic washings, you were unable to really ascertain the site for the primary cancer, but you treat them presumptively for GYN malignancy? A. I can't think of a situation in my personal practice where that's happened, but I have anecdotally shared stories with my colleagues where they have had actually that scenario. Q. How have they treated the patients, if you know? A. It's variable, depending upon the clinical circumstances. The stories I'm recollecting, a cancer was discovered with subsequent diagnostic evaluations. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 the patient presumptively for malignancy, correct? A. Correct, because what we're dealing with is probably a cancer of unknown primary, is the best way to view that. It is recognized biologically that you can have a primary cancer site that disseminates, particularly since we're dealing with pelvic peritoneal tumors, and you are never able to recognize the primary site. You're simply treating the metastatic disease. Q. And are you aware of what type of treatment is rendered to these patients that we've been discussing? A. They would all get carboplatin taxol chemotherapy. Q. Thank you. That's what I was looking for. By the way, did she have any risk factors for ovarian carcinoma? A. Age of 52. I don't as I sit here now recollect what her family history was. I just thought of that, because I was anecdotally talking about women with family histories of breast and ovarian cancer. Those would be the two most important things that I would want to know about. (Brief recess.)

	Daga 105		Page 107
	Page 105		
1	you stated if she was age 52 and family history, if she		periods around or in conjunction with.
2	had a family history	2	A. No. What I mpointing out is it sounds like at
3	A. As it just so happened, I flipped open to this	3	age 52 she was not postmenopausal, but was still
4	page in the record, which is a handwritten history note	4	perimenopausal.
5	from around the time that she was admitted to the	5	And the subtlety I'm pointing out is that the
6	hospital for her first operation.	6	hormonal fluctuations, highs and lows of estrogen levels,
7	There is mention here that she had surgery in	7	which are typical of perimenopause, may be associated as
8	1976 for endometriosis, and endometriosis itself is now	8	a triggering event for cancers associated with
9 10	recognized as a risk factor for ovarian cancer.	9 10	endometriosis.
	She had birth control pills for a year only.	10	These are estrogen-stimulated malignancies, and
11	It is recognized that long-term use of birth control	11 12	so the high-estrogen levels of the perimenopause may be
12 13	pills is protective against ovarian cancer or similar	12	one of the etiological factors behind what happened to her.
13	cancers of the pelvic peritoneum, but this brief exposure to oral contraceptives would not be protective.	13	
14	The next entry here, there is a mention that	14	Q. So at the time she first presented to the Cleveland Clinic, she was of an age group that is
16	she has no biological children of her own, and not having	15	considered to be a risk factor? You listed her age.
17	children is a risk factor for developing ovarian	10	A. Correct.
18	carcinoma.	18	
19	The next entry here is that she started having	19	Q. That's the first. She had history of endometriosis. That's considered a risk factor for
20	her natural menstrual cycles at about age 11.	20	ovarian cancer.
$20 \\ 21$	That's relatively young for her generation, and	20	She was nulli parous, N-U-L-L-I P-A-R-0-U-S, no
$\begin{vmatrix} 21\\22 \end{vmatrix}$	so we can presume that she had a longer period of time	21	children biologically.
$\begin{vmatrix} 22\\23 \end{vmatrix}$	during which she had normal ovulatory function, and that	23	She had started her periods at a relatively
24	itself becomes a risk factor for cancer of the ovary and	24	young age with longer exposure to ovulatory function,
25	similar pelvic peritoneal malignancies.	25	which is also a risk factor, and the hormonal fluctuation
1			
	Page 106		Page 108
1	She still was having some episodic menstrual	1	in conjunction with these episodic periods during her
2	cycles around the time that she presented for her surgery	2	perimenopausal period would also be a risk factor,
3	in 1999, and it is felt that in some women, especially	3	correct?
4	the women who have endometriosis associated with	4	A. Specifically for the endometriosis-associated
5	malignancies, that the erratic hormonal function around	5	cancers.
6	the time of the perimenopause might be one of the	6	O. Is that the total list of her risk factors for
7	triggers for development of these types of malignancy.	7	ovarian as you sit here?
8	And the one thing I don't see here is family	8	A. Did you catch family history, which is a blank
9	history, which is very important in discussing inherent	9	in terms of my knowledge, but would be an important
10	risk factors for developing these malignancies.	10	influence in discussing this?
11	I would assume that it's buried somewhere here	11	Q. But even if we don't know her family history,
12	in the chart. Her husband may not know her family	12	the other items I have mentioned, those are all risk
13	history. Unfortunately, she, of course, is no longer	13	factors for ovarian carcinoma, correct?
14	around for us to ask that.	14	A. Correct, as well as similar cancers of the
15	Q. But Dr. Kennedy would have ascertained that	15	pelvic peritoneum.
16	when he saw the patient, correct?	16	Q. In your report, you state on the second page:
17	A. Possibly. As I said, if it's in the record,	17	Because Mrs. Huston's malignancy was aggressive and
18	it's buried deep in the file and I cannot locate it right	18	demonstrated no response to chemotherapy, it would be
19	now.	19	incurable whether it was diagnosed in April 1999 or June
20	Q. That last reference that you made, continuing	20	2000.
21	to have periods erratically and	21	Does that suggest that her chances for survival
22	MR. BONEZZI: Episodically.	:22	in April of 1999 were zero, in your opinion?
23 24	Q. Did you use the word "erratic"?	:23 '24	A. Oh, I think my attempt at prognostic
: 74		14	Dercentages that we discussed earlier was hretty

- Q. Did you use the word "erratic"?A. I think I said "episodic."
- 25 Q. I thought you said the risk factor was erratic

27 (Pages 105 to 108)

24 percentages that we discussed earlier was pretty

25 accurate, about 20 percent.

	n 100		D 111
1	Page 109 The trouble is, when we're talking about one	1	Page 11I
1	individual person, the survival percentages are difficult	$\begin{vmatrix} 1\\2 \end{vmatrix}$	A best treated with chemotherapy.
2 3	to wrap our hands around, but the emphasis I'm making is	$\begin{vmatrix} 2\\ 3 \end{vmatrix}$	Q. But, in your opinion, it wasn't treatable?A. We would not know that in June of 2000.
4	that it's very, very low. If not zero, it was certainly	4	In other words, we would have a patient with a
5	very low, even in 1999.	5	pelvic malignancy, which is treatable with chemotherapy,
6	O. Would this be the 20 to 50 percent high, 20	6	and at that time, we hope she will be one of the patients
7	percent low to 50 percent high you told me?	7	who has a response to that treatment and, therefore,
8	A. Correct.	8	could become one of the 20 percent who do live after
9	O. So instead of the word "incurable," would you	9	there's cancer.
10	amend your opinion then to state that her disease, if	10	O. One of the, I'm sorry?
11	appreciated and diagnosed in April of 1999, only carried	11	A. She could become one of those 20 percent who
12	a survival rate of a low of 20 percent to a high of 50	12	survives after this malignancy.
13	percent?	13	Unfortunately, her subsequent clinical course
14	A. No, because we know from her personal history	14	demonstrated that she did not have a cancer that was
15	that her unique malignancy was unresponsive to	15	responsible excuse me, did not have a cancer that was
16	chemotherapy and, therefore, her own cancer was	16	responsive to chemotherapy and, therefore, we can say
17	incurable.	17	retrospectively her cancer was incurable.
18	So I am sticking by the "incurable" statement	18	Q. But she was not treated until her cancer was
19 20	as it refers to her personally, even though I am saying in aggregate women like her might have about a 20 percent	19 20	fairly widespread; isn't that true? A. That is true.
20	chance of cure.	20	· · · · · · · · · · · · · · · · · · ·
$\frac{21}{22}$	Q. We don't know if her cancer would have been	$\frac{21}{22}$	Q. So she wasn't given an opportunity to see whether or not she would be responsive to chemotherapy
23	incurable had she received chemotherapy in April 1999, do	22	when her tumor burden was much smaller, i.e.,
24	we?	24	microscopic? Isn't that true? Was she given that
25	A. I disagree with that statement. More probably	25	opportunity or not?
			11 2
	Page 110		Page 112
Ι	than not, based upon the complete lack of response to	1	A. Your question has two aspects to it that I'll
2	chemotherapy in the year 2000, it is presumed that her	2	break apart.
3	cancer would be unresponsive to chemotherapy in 1999.	$\frac{2}{3}$	I will agree that she did not get chemotherapy
4	Q. Would you agree that her disease and her tumor	4	in 1999, when her cancer was probably only microscopic or
5	burden were far more extensive in June of 2000 than they	5	perhaps was only premalignant, depending on which premise
6	were in April of 1999, when at the most there was only	6	you follow in terms of the etiology of her subsequent
7	microscopic evidence of disease, if you accept the	_	
		7	malignancy.
8	plaintiff's pathology reports?	8	
9	plaintiff's pathology reports? A. That is a correct statement.	8 9	malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what
9 10	plaintiff's pathology reports?A. That is a correct statement.Q. So by your earlier testimony, we know that in	8 9 10	malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no
9 10 11	plaintiff's pathology reports?A. That is a correct statement.Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden	8 9 10 11	malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy.
9 10 11 12	plaintiff's pathology reports?A. That is a correct statement.Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct?	8 9 10 11 12	malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer
9 10 11 12 13	plaintiff's pathology reports?A. That is a correct statement.Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct?A. That is correct.	8 9 10 11 12 13	malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all.
9 10 11 12 13 14	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable 	8 9 10 11 12 13 14	malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of
9 10 11 12 13 14 15	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 	8 9 10 11 12 13 14 15	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only
9 10 11 12 13 14 15 16	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what 	8 9 10 11 12 13 14 15 16	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which
9 10 11 12 13 14 15 16 17	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what you're saying? 	8 9 10 11 12 13 14 15 16 17	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or
9 10 11 12 13 14 15 16 17 18	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what 	8 9 10 11 12 13 14 15 16	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or diagnostic procedures were undertaken for the patient at
9 10 11 12 13 14 15 16 17	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what you're saying? MR. BONEZZI: Objection. A. That is correct. 	8 9 10 11 12 13 14 15 16 17 18	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or diagnostic procedures were undertaken for the patient at that time? Isn't that true? Yes or no.
9 10 11 12 13 14 15 16 17 18 19	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what you're saying? MR. BONEZZI: Objection. A. That is correct. 	8 9 10 11 12 13 14 15 16 17 18 19	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or diagnostic procedures were undertaken for the patient at
9 10 11 12 13 14 15 16 17 18 19 20	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what you're saying? MR. BONEZZI: Objection. A. That is correct. Q. Why is it that Mrs. Huston was sent by Dr. 	8 9 10 11 12 13 14 15 16 17 18 19 20	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or diagnostic procedures were undertaken for the patient at that time? Isn't that true? Yes or no. A. You're lumping a very rapid sequence of
9 10 11 12 13 14 15 16 17 18 19 20 21	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what you're saying? MR. BONEZZI: Objection. A. That is correct. Q. Why is it that Mrs. Huston was sent by Dr. Kennedy to Dr. Markman for chemotherapy in July of 2000? A. Because this type of malignancy, if she has any hope of cure at all, is going to be I lost my strain 	8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or diagnostic procedures were undertaken for the patient at that time? Isn't that true? Yes or no. A. You're lumping a very rapid sequence of clinical events together.
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what you're saying? MR. BONEZZI: Objection. A. That is correct. Q. Why is it that Mrs. Huston was sent by Dr. Kennedy to Dr. Markman for chemotherapy in July of 2000? A. Because this type of malignancy, if she has any hope of cure at all, is going to be I lost my strain of thought there. 	8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or diagnostic procedures were undertaken for the patient at that time? Isn't that true? Yes or no. A. You're lumping a very rapid sequence of clinical events together. Q. I'll break it down. In June of 2000, Mrs. Huston had a vaginal biopsy.
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 plaintiff's pathology reports? A. That is a correct statement. Q. So by your earlier testimony, we know that in general it's easier to treat cancer when the tumor burden is smaller, correct? A. That is correct. Q. Yet you are telling us that she was incurable and had zero percent chance of survival back in April 1999, had the correct diagnosis been made? Is that what you're saying? MR. BONEZZI: Objection. A. That is correct. Q. Why is it that Mrs. Huston was sent by Dr. Kennedy to Dr. Markman for chemotherapy in July of 2000? A. Because this type of malignancy, if she has any hope of cure at all, is going to be I lost my strain 	8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 malignancy. The second issue, though, is that she did receive chemotherapy in 2000, at a time when she had what we call measurable disease, and we saw absolutely no response to that chemotherapy. So the inherent biological nature of her cancer is that it did not have any response at all. Q. In fact, we don't even know the true extent of disease when she started chemotherapy, because the only thing that had been done was the vaginal biopsy, which led to a diagnosis of cancer, and no other tests or diagnostic procedures were undertaken for the patient at that time? Isn't that true? Yes or no. A. You're lumping a very rapid sequence of clinical events together. Q. I'll break it down. In June of 2000, Mrs. Huston had a vaginal

Huston vs. Cleveland Clinic Foundation

\$

.

	Page 113		Page 115
1	started referring in the records to a diagnosis of	1	Q. I'm making correct representations.
2	ovarian cancer and she was sent to Dr. Markman at the	2	Would you agree that if the pelvic washings
3	Cleveland Clinic for chemotherapy, no other diagnostic	3	contained cells suspicious for malignancy, that
4	procedures were undertaken for her to determine the	4	appropriate follow-up for this patient would have been
5	extent of disease? Isn't that true?	5	less than one year?
6	A. When did she have her exploratory surgery,	6	A. I think that's a very accurate statement.
7	again, for the bowel obstruction?	7	O. And were you aware that that is the time period
8	Q. August of 2000, at the time the CA-125 was	8	that Mrs. Huston was told to wait before coming back to
9	obtained.	9	the Cleveland Clinic?
10	A. Refresh my memory. At what point does she	10	A. Yes, that was the time period that she was
11	actually get her first dose of chemotherapy during that	11	instructed, because she was presumed to have benign
12	very rapid sequence of events around June, July and	12	disease and was placed on the standard one-year rotation
13	August?	13	to come back for routine GYN examinations.
14	Q. In July of 2000, prior to the time that any	14	However, she did have symptoms preceding her
15	diagnostic tests were undertaken to determine the extent	15	arrival for that routine appointment, and some of the
16	of disease. Do you recall that?	16	delay in diagnosis may have been related to ignoring
17	A. Diagnostic tests were undertaken. We had the	17	vaginal bleeding and abnormal symptoms of discomfort,
18	diagnostic biopsy. We had a physical exam. We had a	18	back pain, so on and so forth. It is unfortunate she
19	very good sense of her disease burden at that time.	19	waited until June to come in for her biopsy.
20	Q. No CA-125 was obtained, correct?	20	Q. There's no evidence, Doctor, in the records
21	A. That is my understanding.	21	that Mrs. Huston had any vaginal bleeding prior to July
22	Q. That's correct. They were not obtained, or the	22	8th, is there?
23	levels were not obtained until August of 2000.	23	A. I disagree. I believe that there's clear
24	At the time that she began chemotherapy, the	24	mention that she had some vaginal bleeding.
25	only thing that the Cleveland Clinic knew was that there	25	Q. Feel free to look through the records.
		1	
1	Page 114	-	Page 116
	Page 114 was a diagnosis of adenosquamous from the vaginal biopsy.	1	Page 116 A. (Witness reviews documents.)
1	was a diagnosis of adenosquamous from the vaginal biopsy,	1 2	A. (Witness reviews documents.)
1	was a diagnosis of adenosquamous from the vaginal biopsy, correct?	2	
1 2 3	was a diagnosis of adenosquamous from the vaginal biopsy, correct?A. I think that's correct.	1	A. (Witness reviews documents.) I don't really think that's actually important to the case.
1 2 3 4	was a diagnosis of adenosquamous from the vaginal biopsy, correct?A. I think that's correct.Q. And what Dr. Kennedy was able to ascertain by	2 3 4	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she
1 2 3 4 5	was a diagnosis of adenosquamous from the vaginal biopsy, correct?A. I think that's correct.Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct?	2 3 4 5	A. (Witness reviews documents.) I don't really think that's actually important to the case.Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and
1 2 3 4	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're 	2 3 4	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is
1 記 金 3 4 5 6	was a diagnosis of adenosquamous from the vaginal biopsy, correct?A. I think that's correct.Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct?	2 3 4 5 6	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had
1 2 3 4 5 6 7	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, 	2 3 4 5 6 7	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is
1 2 3 4 5 6 7 8	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of 	2 3 4 5 6 7 8	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the
1 2 3 4 5 6 7 8 9	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. 	2 3 4 5 6 7 8 9	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy
1 2 3 4 5 6 7 8 9 10	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of 	2 3 4 5 6 7 8 9 10	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of
1 2 3 4 5 6 7 8 9 10 11	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before 	2 3 4 5 6 7 8 9 10 11	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.)
1 2 3 4 5 6 7 8 9 10 11 12	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, 	2 3 4 5 6 7 8 9 10 11 12	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in 	2 3 4 5 6 7 8 9 10 11 12 13	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, I'll make a representation, but you're welcome to spend as much time as you need going through the record.
1 2 3 4 5 6 7 8 9 10 11 12 13 14	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? 	2 3 4 5 6 7 8 9 10 11 12 13 14	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, I'll make a representation, but you're welcome to spend as much time
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, 111 make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, I'll make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. There was a cancer diagnosis, chemotherapy, and then the rest becomes clinically apparent whether or not she 	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, 1'll make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands Community Hospital, and was then sent to the Cleveland
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. There was a cancer diagnosis, chemotherapy, and then the rest becomes clinically apparent whether or not she responds to treatment. 	$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ \end{array} $	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, I'll make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands Community Hospital, and was then sent to the Cleveland Clinic, which was a date subsequent to the vaginal
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. There was a cancer diagnosis, chemotherapy, and then the responds to treatment. Q. And she, in fact, for example, had no urinary 	$ \begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ \end{array} $	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, 111 make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands Community Hospital, and was then sent to the Cleveland Clinic, which was a date subsequent to the vaginal biopsy.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. There was a cancer diagnosis, chemotherapy, and then the rest becomes clinically apparent whether or not she responds to treatment. Q. And she, in fact, for example, had no urinary symptomatology at the time the vaginal biopsy came back? 	$\begin{array}{c c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ \end{array}$	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, 111 make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands Community Hospital, and was then sent to the Cleveland Clinic, which was a date subsequent to the vaginal biopsy. So getting back to your original statement that
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. There was a cancer diagnosis, chemotherapy, and then the rest becomes clinically apparent whether or not she responds to treatment. Q. And she, in fact, for example, had no urinary symptomatology at the time the vaginal biopsy came back? Isn't that true? 	$\begin{array}{c ccccc} 2 & 3 \\ 4 & 5 \\ 6 & 7 \\ 8 & 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \end{array}$	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, 111 make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands Community Hospital, and was then sent to the Cleveland Clinic, which was a date subsequent to the vaginal biopsy. So getting back to your original statement that unfortunately the patient ignored vaginal bleeding, you
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. There was a cancer diagnosis, chemotherapy, and then the rest becomes clinically apparent whether or not she responds to treatment. Q. And she, in fact, for example, had no urinary symptomatology at the time the vaginal biopsy came back? Isn't that true? A. I don't know that one way or the other. I 	$\begin{array}{c c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ \end{array}$	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, 111 make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands Community Hospital, and was then sent to the Cleveland Clinic, which was a date subsequent to the vaginal biopsy. So getting back to your original statement that unfortunately the patient ignored vaginal bleeding, you also mentioned back pain.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 was a diagnosis of adenosquamous from the vaginal biopsy, correct? A. I think that's correct. Q. And what Dr. Kennedy was able to ascertain by having Dr. Biscotti look back at the slides, correct? A. That's a separate issue, because what we're talking about now is her clinical course in June, July, August, during which she had a relentless progression of the disease, despite having received one dose of chemotherapy. Q. At the time of the vaginal biopsy and before she started her chemotherapy, other than the biopsy, nothing was done to determine the extent of disease in the patient? Isn't that true? A. I would have to review the record again to make sure. I'm not at all bothered by what you're stating. There was a cancer diagnosis, chemotherapy, and then the rest becomes clinically apparent whether or not she responds to treatment. Q. And she, in fact, for example, had no urinary symptomatology at the time the vaginal biopsy came back? Isn't that true? 	$\begin{array}{c ccccc} 2 & 3 \\ 4 & 5 \\ 6 & 7 \\ 8 & 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \end{array}$	 A. (Witness reviews documents.) I don't really think that's actually important to the case. Q. You just stated that it's unfortunate that she ignored symptoms of bleeding and other symptoms and waited, as though somehow it's Mrs. Huston's fault, is the implication, but, in fact, if the patient had not had any vaginal bleeding until a date subsequent to the vaginal biopsy Do I stand corrected? Is there an episode of bleeding prior to the vaginal biopsy, prior to July 8th? A. (Witness reviews documents.) Q. In order to save time, 111 make a representation, but you're welcome to spend as much time as you need going through the record. I don't believe that there was any episode of vaginal bleeding until July 8th, when Mrs. Huston presented to the emergency room, I think it's Firelands Community Hospital, and was then sent to the Cleveland Clinic, which was a date subsequent to the vaginal biopsy. So getting back to your original statement that unfortunately the patient ignored vaginal bleeding, you

29 (Pages 113 to 116)

	Page 117		Page 119
1	this patient, I believe in July of 2000, that was		present.
$\begin{vmatrix} 2\\ 3 \end{vmatrix}$	negative for cancer? Are you aware of that? A. Yes, I'm aware of that, although the typical	23	A. Oh, I think I did.Q. You said sometime between spring of '99
4	back pain of a deep-seated pelvic malignancy is not	4	MR. BONEZZI: Right.
5	related to bone metastases. It's just more of kind of a	5	A. And that's
6	crampy back pain that is analogous to women in labor who	6	Q. But now you're saying several months before,
7	sometimes have back pain.	7	you just said.
8	Q. Mrs. Huston would have no reason to suspect	8	A. That puts us well into that time frame.
9	that she had a pelvic malignancy if she started having	9	Q. And by several months, you think it was present
10	some back pain? Isn't that true?	10	by January 2000?
11	A. She would have no reason to have any inkling of	11	A. That's where I would think it would be
12	why she was having back pain, other than perhaps	12	completely inappropriate for me to try and place a
13	recognizing that if she was having any new abnormal	13	specific date, because that would quickly veer into what
14 15	symptom, that presentation to her physician earlier than the scheduled one-year visit would be appropriate.	14	I would call junk science. I would be upset if any expert witness in this
16	O. Dr. Kennedy was telling her to come back in one	16	case tried to place any precise dates on that kind of
17	year because he was relying on the pathology that had	17	line of questioning.
18	been read out from the April '99 surgery, correct?	18	Q. And, again, you can't say whether her cancer
19	A. Absolutely.	19	was diagnosable, correct, other than June of 2000?
20	Q. And he had a right to rely on that, correct?	20	A. We do know that it was a sizable malignancy at
21	À. Yes.	21	the vaginal apex, easily detected with a routine clinical
22	Q. And Mrs. Huston in turn was relying on Dr.	22	examination.
23	Kennedy's advice to come back in one year because she	23	That's why I'm saying, just that's common
24	trusted him and he told her that the pathology was	24	sense, a few months earlier, it probably also was
25	normal, correct?	25	diagnosable by routine pelvic exam.
	Page 118		Page 120
1	Page 118 MR RONEZZI: Objection Go shead and answer	1	Page 120
$\frac{1}{2}$	MR. BONEZZI: Objection. Go ahead and answer.	1	Q. In fact, Dr. Kennedy thought it was
2	MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal	2	Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he?
	MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the	2 3	Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he?A. I'm not sure exactly what he thought it was.
2 3 4	MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine.	2	Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he?A. I'm not sure exactly what he thought it was.Q. You don't recall that from his testimony?
2 3	MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the	2 3 4	Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he?A. I'm not sure exactly what he thought it was.
2 3 4 5 6 7	MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history?	2 3 4 5 6 7	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know.
2 3 4 5 6 7 8	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. 	2 3 4 5 6 7 8	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember.
2 3 4 5 6 7 8 9	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in 	2 3 4 5 6 7 8 9	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're
2 3 4 5 6 7 8 9 10	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to 	2 3 4 5 6 7 8 9 10	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you
2 3 4 5 6 7 8 9 10 11	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? 	2 3 4 5 6 7 8 9 10 11	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew
2 3 4 5 6 7 8 9 10 11 12	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for 	2 3 4 5 6 7 8 9 10 11 12	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it.
2 3 4 5 6 7 8 9 10 11 12 13	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. 	2 3 4 5 6 7 8 9 10 11 12 13	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said,
2 3 4 5 6 7 8 9 10 11 12 13 14	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was 	2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule
2 3 4 5 6 7 8 9 10 11 12 13	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. 	2 3 4 5 6 7 8 9 10 11 12 13	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a little bit earlier and have her vaginal tumor mass 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path. Q. And, also, Doctor, rule out endometriosis, correct? A. Correct, because he's thinking his differential
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a little bit earlier and have her vaginal tumor mass diagnosed when it was smaller. I was merely commenting on the notion that the large progression of her disease or, more accurately, the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path. Q. And, also, Doctor, rule out endometriosis, correct? A. Correct, because he's thinking his differentia1 diagnosis is maybe it's endometriosis, because we know
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a little bit earlier and have her vaginal tumor mass diagnosed when it was smaller. I was merely commenting on the notion that the large progression of her disease or, more accurately, the local growth of her tumor was taking place for several 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path. Q. And, also, Doctor, rule out endometriosis, correct? A. Correct, because he's thinking his differentia1 diagnosis is maybe it's endometriosis, because we know this can happen where you have endometriosis grow into
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a little bit earlier and have her vaginal tumor mass diagnosed when it was smaller. I was merely commenting on the notion that the large progression of her disease or, more accurately, the local growth of her tumor was taking place for several months before she came in for that June visit. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path. Q. And, also, Doctor, rule out endometriosis, correct? A. Correct, because he's thinking his differentia1 diagnosis is maybe it's endometriosis, because we know this can happen where you have endometriosis grow into the vaginal cuff after a hysterectomy, but he's also
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a little bit earlier and have her vaginal tumor mass diagnosed when it was smaller. I was merely commenting on the notion that the large progression of her disease or, more accurately, the local growth of her tumor was taking place for several months before she came in for that June visit. Q. Can you give me a time now? Before you weren't 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path. Q. And, also, Doctor, rule out endometriosis, correct? A. Correct, because he's thinking his differential diagnosis is maybe it's endometriosis, because we know this can happen where you have endometriosis grow into the vaginal cuff after a hysterectomy, but he's also saying, as a gynecologic cancer doctor, "I wonder if this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a little bit earlier and have her vaginal tumor mass diagnosed when it was smaller. I was merely commenting on the notion that the large progression of her disease or, more accurately, the local growth of her tumor was taking place for several months before she came in for that June visit. Q. Can you give me a time now? Before you weren't able to say when you thought that the cancer 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path. Q. And, also, Doctor, rule out endometriosis, correct? A. Correct, because he's thinking his differential diagnosis is maybe it's endometriosis, because we know this can happen where you have endometriosis grow into the vaginal cuff after a hysterectomy, but he's also saying, as a gynecologic cancer doctor, "I wonder if this is cancer, we need to do the biopsy to rule out path,"
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 MR. BONEZZI: Objection. Go ahead and answer. A. A patient who is not having any abnormal symptoms would, of course, simply come back in the one-year scheduled visit as a matter of routine. Q. In fact, I believe Mrs. Huston went to a chiropractor for her back pain and it resolved. Do you recall that from the medical history? A. Oh, I don't recall that it resolved. Q. So you don't think Mrs. Huston was wrong in relying on Dr. Kennedy telling her to wait one year to come back, do you? A. No, I think she was appropriately scheduled for her one-year visit with Dr. Kennedy. I certainly don't want to imply that it was like her fault if she missed an opportunity to come in a little bit earlier and have her vaginal tumor mass diagnosed when it was smaller. I was merely commenting on the notion that the large progression of her disease or, more accurately, the local growth of her tumor was taking place for several months before she came in for that June visit. Q. Can you give me a time now? Before you weren't 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. In fact, Dr. Kennedy thought it was endometriosis when he saw it, didn't he? A. I'm not sure exactly what he thought it was. Q. You don't recall that from his testimony? MR. BONEZZI: Don't guess, if you don't know. A. I don't recall actually what he said, but I would also postulate that he may not even himself truly remember. I'm placing myself in his shoes. You're examining the patient. You are a cancer doctor, so you have seen these types of malignancies before, and he knew he had to biopsy it. In fact, it was on his requisition, he said, quote, R, slash, O, space, P-A-T-H, end quote, or rule out path. Q. And, also, Doctor, rule out endometriosis, correct? A. Correct, because he's thinking his differential diagnosis is maybe it's endometriosis, because we know this can happen where you have endometriosis grow into the vaginal cuff after a hysterectomy, but he's also saying, as a gynecologic cancer doctor, "I wonder if this

an ,

18 18 19

	Page 121	Page 12
 speculum examination, is that requisition, and the phrase is "rule out path." Q. Correct. And, in fact, he was surprised to the diagnosis came back and it was not endometry ou recall that? MR. BONEZZI: If you don't know, tell hat A. I don't know exactly how he phrased his deposition testimony, but, again, I think that Dr. Kennedy and I are similar in our clinical approal patients. I suspect that he was dismayed, would have a better phrase to use, for how he probably felt wigot the phone call from the pathologist. It sound she was a very nice woman, and he would have immediately what this meant for her. Q. By the way, have you read Mr. Huston's deposition testimony in this case? A. No, I have not. I don't think I have that either. Q. Are you aware as you sit here today what Huston testified what Dr. Kennedy told Mr. and Huston when the correct diagnosis was made in 2000? A. No, I don't know what he said. MS. NISSENBERG: I'mdone. 	e first nat riosis. Do er. ch to our e been then he s like cnown Mr. Mrs.	CERTIFICATE STATE OF WASHINGTON)) ss COUNTY OF SNOHOMISH) I, JOLENE C. HANECA, a Certified Shorthand Reporter and Notary Public in and for the State of Washington, do hereby certify that the foregoing transcript of the deposition of HOWARD MUNTZ, M.D., having been duly sworn, on JUNE 22, 2002, is true and accurate to the best of my knowledge, skill and ability. IN WITNESS WHEREOF, I have hereunto set my hand and seal this 24th day of June, 2002. JOLENE C. HANECA, RPR, CCR My commission expires: March 28.2006
(Deposition concluded at 11:55 a.m.) A F F I D A V I T STATE OF WASHINGTON)) ss COUNTYOFKING)	Page 122	
I have read my within deposition, and the same is true and accurate, save and except for and/or corrections, if any, as indicated by me o "CORRECTIONS" flyleaf page hereof.		
HOWARD MUNTZ, M.D. SUBSCRIBED AND SWORN TO be	fore me this	
day of ,2002. NOTARY PUBLIC in and for the		
State of Washington, residing at		

31 (Pages 121 to 123)

م پن

Page 1

F				rag
A	54:20 58:1 59:1 62:17	aggregated 85:8	answer 6:21 7:1 9:19	105:5 106:2,5,14
abdomen 72:22 89:7	64:9 69:18 71:21 74:8	aggressive 81:22 86:7	21:4,5,19 22:13 29:3	105.5 100.2,5,14
abdominal 77:21 81:13	75:13 77:20 78:8 83:2		29:12 32:7 38:2,20	arrival 115:15
85:13 100:18	84:23 89:14 92:4	aging 47:23	42:18 46:24 50:1	arrived 14:25 68:25
abdominopelvic 88:17	93:23 95:16 97:20	ago 15:20 26:19 45:19	55:12 59:4 66:24	ascertain 63:11 64:6
ability 92:18 95:6	99:1 102:18 113:11	agree 24:2,10,15,21	69:12 71:20 82:6,18	74:1675:20 102:13
123:11	116:2 120:6,24	31:15 34:14 35:9,22	84:2 92:6,11 93:13	114:4
able 94:23 95:2 104:8	add 48:13	36:14 38:11,15 40:8	99:25 100:4 118:I	ascertained 106:15
114:4 118:23	additional 16:2 40:6	40:14,19 44:14 47:17	answered 71:18 82:16	
abnormal 61:4 115:17	62:574:19,24 103:15	50:4 56:3,9,23 57:11	answers 9:9,17	ascertaining 75:22
117:13 118:2	address 55:7	72:11 93:5,11,19	anterior 53:10	ascites 75:24
abnormality 30:24	adenosquamous 43: 17	94:22 95:1 96:13	anyone 8:16	ascribe 43:2
about 7:13 9:3 10:1,23	80:19,21,23 83:6	110:4 112:3 115:2	anything 12:3,6 13:10	ascribed 78:16
13:24 15:21 17:24	91:1092:9,24 93:3	agreed 80:5 101:11	14:21 16:4 22:8,10,14	ascribing 99:6 100:2
18:3,13,23,25 19:9,12	101:9 114:1	agreement 56:24 91:1	29:24 30:12 48:24	aside 99:11
	adequacy 27:12	100:23		asked 7:2,11 9:10,14,21
19:16,17,20,25 20:17	adequate 30:20 89:6	ahead 10:14 21:4,14,19	60:11,21 62:23 68:15	10:1 12:1 26:19 27:2
20:21,22 22:10 23:9	adherence 53:8 61:3,6	22:1329:230:336:21	anywhere 12:13 48:10	37:13 45:15 46:6 59:3
23:12 26:1,19 27:18	73:20 74:18 99:14	38:20 46:23 55:12	58:1562:20	62:6 68:24 83:21
28:7 30:12 36:25 38:4	adherent 38:9,25 39:25	60:9 66:24 118:I	apart 112:2	86:22 91:22
41:4,10,13,24 42:16	54:4 73:20	ah-hah 61:2	apex 119:21	asking 38:22 41:8 47:14
43:12 44:21 47:8,17	adhesed 39:4	al 1:9	apparent 114:19	53:13 78:21 79:5 86:2
48:14,14 52:25 53:17	adhesion 41:14 61:8	albeit 21:10	appear 6:6 15:4 37:19	92:23,25 97:17
54:9 55:22 58:3,6	74:16	Alexander 94:16	appears 56:18	asks 72:17
63:9 68:17 70:19 75:1	idhesions 38:15 39:3,8	algorithmic 95:25	applicable 41:6 42:13	aspect 11:19 12:11 22:4
75:9 76:11 77:4,21	39:9,13,18 52:13 61:9		79:22	27:8
78:20,21,24 80:1 81:7	61:9 75:12,13	allegation 26:12 allege 26:7	appointment 115:15	aspects 112:1
82:23 84:11 85:14	adjacent 70:24 97:8	allotting 76:2	appreciate 89:17	assessment 94:13
87:10,15 88:18 90:15	idministration 5:6	allowed 5 1:21	appreciated 109:11	assigned 82:10 97:15
96:10,18,19 97:17	admission 14:15	allowing 93:12	approach 60:5 121:9	100:11
99:12 104:19,22	idmitted 105:5	ilmost 27:17 42:3,10	approaching 48:16	assigning 72: 1573:4
105:20 108:25 109:1	idmonitions 6:18	43:22 67:17 93:25	ippropriate 34:24	assignment 81:14 99:5
109:20 114:7	advice 117:23	along 53:10	40:1947:594:19	associated 25:9 106:4
ibsolutely 41:22 44:14	advisable 62:5	already 9:17,18 16:8	115:4 117:15	107:7,8
69:5 112:10 117:19	affirmative 93:13	17:24 18:1 27:9 45:13	ippropriately 23:13	issume 7:1 13:17 14:13
iccept 42:10,25 77:13	a fter 14:2 16:20,21	64:9,11	97:23 118:12	18:14 34:23 106:11
101:5 110:7	18:2,9,11 41:18 54:25	although 14:24 15:19	ipproximately 4:25	114:25
iccepted 47:1980:8	57:17,23 64:9 69:1	49:20 61:20 88:4	16:18 40:8,14	assuming 82:1287:24
96:3 97:1198:22	71:6,12 72:3 87:24		April 14:15 24:25 26:9	88:25
access 50:20	90:7 111:8,12 120:21	90:17 117:3	31:9,23 32:6 34:21	issumption 52:7
according 6:11 51:20	afterwards 103:15	always 73:13 83:8	51:19 54:15 55:25	attempt 108:23
73:7 79:25	again 24: 14 27: 16 29:4	<i>e</i> mbiguity 85:9,11	57:4,15,22 59:9,12	ittention 59:12
aiccount 10: 1299:2	30:5,25 32:3 37:9	88:18	60:22 62:24 69:15	attorney 26:7
accuracy 24:24	38:21 40:3,13 44:11	ambiguous 58:2 88:5	77:8 78:13 79:1,1	attorneys 86:11
ccurate 22:25 42:11	- 1	smend 109:10	83:11 84:4,7,14 86:5	itypia 24:4,12,17 28:18
57:1 108:25 115:6	45:24 50:13 57:3,8 59:13 69:21 71:7	American 76:23	87:12 102:4 108:19	28:24 29:17 30:11
122:8 123:10	73:17 77:14,17 78:24	amount 7:16 30:10,18	108:22 109:11,23	70:3,7,11 85:19
ccurately 118:19	-	analogous 72:23 117:6	110:6,15 117:18	atypial 28:7
accuse 67:20	85:10 89:7 96:16	nalyze 22:20	2rea 8:5 9:23 28:10	atypical 25:7 28:18,23
cknowledging 31:6	99:17 113:7 114:15	analyzed 38:17 68:17	30:24 37:15,16 61:7	28:23 54:20 59:24
across 37:17	119:18 121:8	and/or 85:1 122:9	73:12 74:16 76:21	61:13 83:13 84:17
	against 13:1 105:12	anecdotal 48:13	83:20	92:1
	age 42:17 104:17 105:1	anecdotally 102:16	areas 38:13 51:2 70:3	<i>t</i>-risk 50:23
ctual 10:3 56:13 77:11	105:20 107:3,15,16	103:24 104:19	arise 43: 18	2udibile 101:20
actually 7:24 8:6 10:5	107:24	inecdote 102:24	arises 70:23	August 14:16 56:2 57:5
11:4 17:20 19:11 25:8	aggregate 43:6 52:2	annual 82:2,8	arising 79: 17 9 1:5	63:21,25 64:5 94:8
1	83:4 92:7 99:18 101:1	another 59:3 66:14	around 18:1620:20	112.0 12 22 114.0
29:23 44:6,7 45:22	1			113:8,13,23 114:8
29:23 44:6,7 45:22 47:20 50:1252:6,20	109:20	88:11	91:15 94:3,5 99:24	authoritative 42:23

49:18	18:10 42:18 52:15	93:1 112:16,24	25:17 27:9,10 44:3	69:11 70:20 71:1,1,11
1		113:18 114:1,11,12	51:2 53:5 65:9 68:9	71:15,15,23 72:1,8,10
automatically 14:8	57:16,23 59:9,16 70:4		1	
88:6	72:22 73:1,6 75:3,4,4	114:22 115:19 116:9	69:20 70:4,11 87:13	72:12 73:17,18,19,25
available 12:9 14:2	75:11 78:20 88:7	116:11,21 120:12,23	91:9,10 92:6,10,11	74:4,23,23 76:9,19
16:5 37:20	96:12 100:18 114:11	birth 105:10,11	93:1,2 99:1	78:5,6,7,8,10,21 79:8
Avenue 1:17 2:9	115:8 118:21,22	Biscotti 15:7,10 27:23	bothered 114:17	79:13,21,23 80:6
average 99:19	119:6 120:11 122:18	28:9,16 31:4 68:17,25	bottom 52:2194:5	81:20 83:11,16,23
avoided 30:8	began 113:24	69:7,10 91:15,17,19	99:23	84:7 85:6,12,15,17,23
aware 17:4 23:3,21	begin 48:5 73:23 87:10	91:22 92:16,23 93:7	bowel 6:156:257:5	85:24 86:5,14,19,21
27:22 28:13,16,21,25	beginning 32:8 50:8	93:16 114:5	113:7	86:22 87:8 89:1,8
29:10,13,15,19 31:8	61:25 91:24	Biscotti's 29:25 91:8	Brainerd 14:19 15:17	93:8 94:9 95:25 96:4
33:24 34:8,11,19,22	begs 99:25	92:13	95:10	96:6,12,23 97:3 98:3
44:15 51:11 65:10	behalf 5:20,22 8:11	bit 66:25 118:16	Brainerd's 29:15	98:7,11,13,14,23,23
71:24 72:3 82:11	11:12		break 112:2,22	99:10,11,12,13
	1	blank 8:2,9 12:4 41:20	,	
90:23 95:9 104:10	behave 71:1 83:5	108:8	breaks 73:24	101:18 102:13,22
115:7116:25 117:2,3	behavior 67:9 74:3	bleeding 115:17,21,24	breast 103:2 104:20	103:3,11,17 104:3,6
121:20	behind 88:15 107:12	116:5,8,11,17,23	brief 14:2 47:6 104:23	104:20 105:9,12,24
awfully 24:7	being 10:22,23 12:25	blending 76:4 96:15	105:13	107:20 109:16,22
a.m 121:25	32:5 42:11 49:3 60:20	97:198:25	briefcase 94:6	110:3,11 111:9,14,15
	88:18	blends 81:8	briefly 21:10,15	111:17,18 112:4,12
<u> </u>	belief 96:3	block 30:17	bring 86:12	112:17 113:2 114:18
B 70:5	believe 31:22 32:5	blood 88:16	brings 17:22	117:2 118:23,25
back 11:25 14:12 24:6	34:17 43:12 44:9 51:2	blunt 54:5	broad 6:1042:5	119:18 120:10,22,23
26:18 32:2,13 36:3	57:19 83:24 84:13,16	board 45:20 49:23	brought 11:22	cancerous 35:3 66:1
37:23 40:13 48:6,9	84:23 85:17,18 96:3	bodies 36:22	burden 35:11 96:4,7,12	74:8
50:14 57:20 58:8 59:1	97:19,21 104:25	body 96:22	96:19 110:5,11	cancers 40:22 43:17,19
59:1261:267:15,24	115:23 116:16 117:1	bone 116:25 117:5	111:23 113:19	44:21,22 83:5 105:13
73:975:180:3,7,11	118:5	bonezzi 2:7,8 8:16,21	buried 106:11,18	107:8 108:5,14
89:4,13 90:15,17 92:E3	believes 3 1:9	8:23 9:1,9,13,16	B6 27:24 28:10,13,17	cancer-age 47:23
92:18,24 94:16,21	bell 99:22,23	10:14 11:25 13:22,23	28:19 30:1 31:1,4	cancer-causing 103:4
98:7 99:2 110:15	benefit 30:25 70:10	14:12 15:6,8,25 17:7	37:2,14 58:22 68:17	capsule 51:9 70:18 74:1
114:5,22 115:8,13,18	benign 20:7 24:5,13,18	17:12,20,23 18:12	69:8 70:5,11 87:14	100:12
116:22,24 117:4,6,7	39:6 49:14 60:18 63:8	19:7,11,15 20:9,11,16	91:10 93:2,2,17	capsules 51:2
117:10,12,16,23	66:4 67:1369:24	21:3,10,13,16,18 22:5		carboplatin 91:3
118:3,6,11 121:4	74:21 75:12 100:14	22:6,11,13 24:6 27:10	<u> </u>	104:12
backwards 19:11 35:20	101:7,23 115:11	29:2 30:3,22 31:2,16	C 1:23 2:1 123:1,1,6,16	carcinoma 24:3,11,16
60:15	laenignity 39:12	31:20,25 32:19,23,25	California 2:4	30:7,13 39:1,1,12
bad 39:20,20 101:8	laest 5:7 7:5 65:19 67:1	36:3,11,21 37:8,12,21	call 54:19 80:12 112:10	43:17,23 44:8 77:14
based 25:152:1158:3	104:3 111:1 123:10	38:2,19 39:15 40:12	119:14 121:13	79:12,17 80:1,9,22,23
59:22 62:8 64:16 67:E3	lset 67:22	41:7 45:5,8,12 46:3,5	called 10:5 67:13	81:25 83:3,6 91:5,11
70:1 72:5 79:21 84:11	setter 35:1156:7 66:25	46:8,11,16,21 50:7,11	calls 55:1 85:11	92:5 93:3 103:19
84:17 89:20 98:20	73:13 83:6 121:12	51:14 54:18 55:12	came 45:9 114:22	104:16,25 105:18
110:1	between 17:14,17 67:18	56:6 58:25 61:23	118:21 121:4	104:10,25 105:10
baseline 64:7	75:8 81:16 86:17	64:23 65:5,24 66:22	cancer 5:11,16,19 6:2	carcinomas 80:19,20
bases 86:4	100:1 119:3	68:23 69:4,6,17 73:9	6:10 12:20 13:3,9	80:20 92:8,9
basically 25:23 41:4,8			24:20 27:24 28:6,11	cards 48:7,8
	lieyond 50:19,22	73:11 78:2,18 79:15		
basis 67:17 85:22 86:1	liilateral 103:1	85:3 87:9,21 88:2	30:20 31:10,19,23	care 27:7 41:19 94:1
86:1,3,4	Bill 32:24 55:13 118:24	91:17,19,23 93:22	32:6,9,15 33:15 34:20	carefully 74:6
bears 92:22	biological 105:16	95:18 106:22 110:18	35:10,16 38:17 39:17	careless 30:6
became 86:16	112:12	118:1 119:4 120:5	41:12,15,22,25 42:2,4	caring 35:2,15 94:17
become 52:4 69:22	biologically 71:2 104:5	121:6	42:24 43:6 48:17 50:5	carried 109:11
71:15 73:19 86:22	107:22	Bonezzi's11:14 13:21	50:19,21 51:1,1,8	case 4:19,21 5:4,7,14,17
111:8,11	biopsies 65:12 66:20	loook 45:1,23	54:17 55:4,10 56:4	5:18,20,24 8:7,8,11
becomes 16:5 50:21	74:7,24 89:10	books 80:4	57:6 58:4,9,11,15,22	8:13 9:2,4 10:2,7 11:9
93:25 105:24 114:19	biopsy 30:8,14,14 56:2	laorderline 44:23	60:3 61:12 62:2 63:24	11:10,12,19 12:1,11
before 4:23 6:217:23	64:18,20 65:6,23 66:3	Boston 5:5	64:2 65:7,17 66:1	12:12,19 13:12,14,24
8:17 11:9 13:19 16:20	66:14 69:1,7 91:9	both 5:10 20:14,15	67:5,12,16 68:19	14:3 15:18 16:11,24
			,	
L				L
The state of the state of the

	18:12,13 19:1 20:7	chances 79:3 102:5	85:186:20 107:15	compared 43:25 93:1	34:22 41:23 92:16
	23:10,23 25:13 26:4	108:21	113:3,25 115:9	comparison 69:1	conversations 18:14,16
	26:24 27:4,7,8 30:5	change 17:6,9 31:14	116:19	complete 13:1231:25	28:2
	40:18 41:6,25 42:13	34:7,13	clinic 1:911:17,20	110:1	convinced 90:6
	49:19 51:12 59:14	changes 25:7 34:11	12:16,24 13:8 14:15	completed 95:16	copies 14:23
	67:19 68:16 69:21	122:8	23:16,19 24:3,11,16	completely 31:15 57:1	copy 11:24 37:22
	70:2 72:24 77:25	Chapter 44:20	26:8 28:14 33:17 56:4	119:12	correct 6:15 10:24,25
	79:22 84:25 88:5 90:3	chapter-and-verse	59:16 67:21 68:6,8,21	complex 47:5	11:14 14:19,20 16:8,9
	94:13 95:11 97:11	10:12	69:15 85:186:20	complicated 55:19	20:12,13,15,16 21:11
	101:16 102:25 103:10	characterization 21:3	107:15 113:3,25	concepts 96:1697:1	21:12,17,20 22:1,22
	116:3 119:16 121:17	21:14	115:9 116:20	concern 47:21 49:16	22:23 23:1,2 24:22
	cases 5:9,13 7:15 9:7	characterized 36:1,8	clinical 7:14 14:14 20:5	71:14,21 72:12	25:14 27:20,21,25
	11:1,3 25:7 45:19	37:25	22:16 23:1,10 25:11	concerned 29:6	28:19,20 29:17,18
	48:13,14,16 67:4 76:2	charge 77:1	27:2,5 38: 1639:4,13	concise IO: 19	30:21 35:7,8,13 40:24
	CAT 88:17	chart 106:12	39:18 42:18 46:1 47:5	concluded 121:25	40:25 41:5 43:21,23
	catch 52:25 108:8	chatting 48:14	48:10 52:7 62:3 67:9	conclusion 68:25	44: 13 49: 17 54:22
	catching 53:16,22	check 80:3	70:2 72:6 74:3,21	conferences 67:5 76:19	57:18,20,25 58:10,11
	categories 6:10	chemical 74:18	81:10,17 84:18 89:12	confined 45:2	59:12 62:21 63:5,12
	categorized 76:15	chemotherapy 5:6 64:8	90:5 102:21 111:13	confirmed 18:18	63:13,15,16,18,19
	category 72:16 73:5	64:10,11 77:5 88:8	112:21 114:7 119:21	confused 10:20 60:5,13	65:8,14,15,20,21 73:7
	100:2,7,10,11 101:21	89:22 90:8,14,21,24	121:9	confusing 27:7 36:6	75:6 77:1278:4 83:1
	caught 54:10	102:7 104:13 108:18	clinically 49:3,12 62:6	64:24 71:8	83:11 84:15 85:20
	caused 75:21 100:20	102:7 104:13 108:18	64: 14 75:7 82: 18 83:2	confusion 56:12	86:21 87:5,6 88:22,23
	causing 74:18	111:1,5,16,22 112:3,9	83:5 84:11 101:12	conjunction 107:1	91:795:1796:13
	acaveat 42:12	112:11,15 113:3,11	103:18 114:19	108:1	97:23 98:10 99:6
	acaveat 42.12	112:11,15 115:3,11	clinician 27:17 33:22	connection 5:2	100:21 101:19,25
	cavity 50:20 70:17 71:3	chemotherapy-sensit	34:24 35:24 39:14	connective 36:23	100.21 101.19,25
	71:17 85:13 89:24	44:5	45:25 55:17 58:14	Connie 68:7 72:23	107:17 108:3,13,14
		chest 88 :16	67:1672:1775:20	conservative 48:11	109:8 110:9,12,13,16
	100:17,18			consider 42:23 72:17	110:19 113:20,22
	CA-125 63:18 64:3	children 105:16,17	77:3,19 94:17	89:25	114:2,3,5 115:1
	88:16 113:8,20	107:22	clinicians 47:21 78:9	1	
	CCR 1:23 123:16	chiropractor 118:6	close 97:11 103:12	considered 23:14 58:22	117:18,20,25 119:19
	cell 6:8,13 28:23 30:17	chocolate 52:3 53:5	clusters 28:23 57:3,5	107:16,19	120:17,18 121:3,22
	43:20,25 44:1,4,5,10	54:6	85:8 85:10 102:15	consist 13:11	corrected 116:10
	44:11,12 57:3,5 72:8	choose 91:16	colleague 85:10 103:15	consistent 54:16 55:10	corrections 33:25 34:1
	84:6 92:20,20 95:25	circles 91:15	colleagues 48:15	83:16,23	34:9 122:9,10
	cells 21:2 28:23,24	circumstances 102:22	102:17	consult 49:17	correctly 5:19 22:20
	29:20,21 55:25 59:24	city 8:3	collect 10:10	contact 14:6 71:16	45:25 66:20 84:1 88:1
	70:17 71:11 72:1 74:8	claim 12:19,25 13:2,5,7	(College 76:23	contacted 13:14,18,20	correctness 27:12
	75:22 83:15,19,22	13:11 23:14	colonoscopy 88:19	contacts 14:1	correspondence 18:19
	84:4,5,17,21,22 85:9	claimed 66:16	come 66:7 115:13,19	contain 28:22 46:4 55:9	cortex 17:15
	85:12,18,20 86:25	clarification 36:17	117:16,23 118:3,11	55:25 83:15,18,22	counsel 9:1 16:16
	87:19 92:1 94:23 95:2	clarified 20:17	118:15	84:4,5,8,21	county 1:276:21 122:5
	95:7 115:3	clarify 9:25 38:21	comes 46:8,9	contained 46:22 54:14	123:4
	cellular 30:10 84:9	56:20 93:7 100:8	coming 115:8	59:24 7 1:11 87:14	couple 45: 13 54:25
	centimeter 96:21	classification 40:22	comma 26:6,7 32:9	93:3115:3	59:17
	centimeters 96:25	classified 100:13	33:2,6,21	contains 101:17	course 19:4 27:1 35:23
	certain 14:5	clear 40:3 43:20 44:1	comment 46: 17	contaminated 72:25	37:4 47:12 72:6 76:22
	certainly 62:169:4	44:11,12 84:2 115:23	commenting 118:18	content 16:25 29:8	97:2 106:13 111:13
	74:21 89:10 101:16	clearly 34:4 60:19	commission 123:18	45:23	114:7 118:3
	109:4 118:14	clear-cell 80:20	committed 88:7	context 38:22,23 92:16	court 1:1 32:1466:7
	certified 49:23 123:6	Cleveland 1:9 2:10 8:4	Committee 43:6	continuing 53:8 106:20	courtesy 25:16
	certify 123:8	9:23 11:17,20 12:16	common 1:170:15	continuum 68:5 69:22	courtroom 86:12
	chair 120:25	12:24 13:8 14:15	93:24,25 119:23	86:24	covered 30:2
****	challenging 98:1	23:16 24:3,11,16 26:8	communicate 56:14,18	contraceptives 105:14	covers 13:12
	chance 19:6 21:8 99:8	28:14 56:3 59:16	Community 116:19	control 105:10,11	COYNE 1:7
	109:21 110:15	67:21 68:6,8,21 69:15	compare 17:15	conversation 16:23	crampy 117:6

			1	1
created 12:10	decision 70:12	despite 60:17 101:7	65:17 66:19 67:6 81:1	dissections 36:9
creates 56:12	decisions 23:177:4,7	103:12 114:9	109:2	disseminated 6:3 89:23
criteria 74:5 76:2 86:11	81:17	detached 85:12	difficulties 18:25 20:19	96:5,23
critical 22:24	decision-making 87:18	detail 95:14	64:17	disseminates 104:6
crossing 17:14	deep 58:5 67:6 74:8	details 19:24	difficulty 28:5 38:5	dissemination 70:16
cuff 58:5 61:7 120:21	106:18	detected 64:14 119:21	65:11	7 1:2 96:7,2 1
curable 44:6	deep-seated 117:4	determination 52:11	digressing 78:12	distinction 51:23
cure 42:8,9 81:1,23	DEFENDANT 2:7	determine 88:21 113:4	direct 33:5 71:16	distributed 94:4
109:21 110:23	Defendants 1:10	113:15 114:13	direction 60:4	doctor 4:16 26:18 33:5
Curriculum 3:15	defense 4:19 5:10,21	develop 25:7 31:1958:4	directly 71:2	53:13 115:20 120:10
curve 99:21,22,23	7:22 8:12,13 9:1,11	87:1	disagree 26:10 36:16	120:16,22
curves 43:5	11:2,10,13 14:4,22	developed 6:3 86:13	37:24 47:2,3 56:9,11	document 12:10 36:12
CWAHOGA 1:2	16:3,16 69:20 85:1	94:18	56:21 57:12,13 84:24	documented 74:22
cycles 105:20 106:2	definitely 44: 14	developing 31:1032:9	99:7 101:13 109:25	103:4
cyst 51:11,19 52:17,23	definition 50:20 81:12	32:15 33:15 105:17	115:23	documenting 74:11
53:5,14,20 54:6 71:5	degree 52:6	106:10	disagreed 25:24	documents 116:1,12
71:11,11 72:1,17,21	delay 115:16	development 48:17	disagreeing 26:12	doing 10:19 40:5 71:5
75:2,21 100:18,19	demonstrate 24:4,12,17	106:7	disagreements 46:17	76:19 90:7 120:25
101:6	38:12 45:3	DeVita 42:20	67:18	dominant 49:6
cystic 72:10,14	demonstrated 108:18	diagnosable 87:8	discarded 12:10	dome 5:9 15:1 54:5
	111:14	119:19,25	discharge 59: 1694:7	63:14 68:15 77:23
cysts 73:3,6	dense 38:15 39:3,8,13	diagnose 12:20 13:3		87:24 89:6,6,10
cytologic 24:4,12,17 cytology 20:19 25:18	39:17 41:14 52:13	35:10	discharged 57:16,23 59:10	112:16 114:13 116:25
26:10 30:17 51:10	53:8 61:3 74:16 99:14	diagnosed 6:12 35:15	discomfort 115:17	112:16 114:13 116:25
55:3 68:9 84:8 86:6		45:2 47:15 50:6 58:9	disconnect 81:16	dose 113:11 114:9
	densely 38:25 39:25 54:4 73:19	58:11 78:25 86:19	discovered 102:23	doubt 13:23 55:5 76:11
90:1992:21 95:11 101:7 103:14		1	discuss 20: 1021:9	down 24:8 41:17,18
	department 26:8 55:1 87:25 94:5	98:11,14 102:6 108:19 109:11 118:17	45:23	55:23 61:9 67:2 68:14
cytopathologist 15:17 26:3,22 95:1	depending 62:2 102:21	diagnosis 13:8 30:20	discussed 11:19 12:11	73:22 74:14 96:15
cytopathologist's 95:5	112:5	38:12 47:10 48:3 53:2	16:22,24 20:14 21:16	99:16 112:22
	deposed 5:6	54:20 63:8 64:2,4	49:20 108:24	dozen 7:6 48:11
cytopathology 70:6 95:16	deposition 1:13 3:1	67:7,24 69:25 83:23	discussing 30:8 41:3,3	Dr 14:16,17 15:9,9,10
95:16	4:20,23 6:16 8:6,8	-	83:9 104:11 106:9	15:17 17:1 18:22,24
D	9:15,22 10:3,23 15:16	84:9 98:2,3 110:16 112:17 113:1 114:1	108:10	19:2,4,7,10,12,16,17
D 2:7 122:1		114:18 115:16 120:19	discussion 10:15 20:17	19:22 20:10,14,14,20
daily 67:17	15:21 16:3 17:23	121:4,22	43:1 47:13 54:23	20:21 21:1,9,16,22
darn 68:24	18:15 19:4,8 20:23			
darh 08.24 dash 97:21	21:8 23:4 25:1,16	diagnostic 30:11 63:10	76:1877:6,682:15 90:1199:11	22:4,8,10 23:3,7,13 23:22,25 24:2,10,15
	27:20 28:12 29:5,13	87:23 88:12,23 102:23 112:18 113:3		
data 76:12 81:16 83:4 101:1	31:9,18 32:12 33:8		discussions 81:18	27:19,22,23 28:8,9,16 28:22 29:1,4,10,15,25
database 76:8,20	34:2,5 37:13,20 57:1	113:15,17,18 diaphragmatic 89:17	disease 6:4 40:10,16 44:8 45:2 48:21 50:23	31:4,8,17,24 32:4,14
databases 76:8,20	57:10 62:14 80:2			
	91:15 93:6 95:14	diaphragms 50:25	63:11 64:12 77:16,16	33:11,24,24 34:3,8,19 37:1,13,17 43:9 44:16
date 1:22 116:8,20 119:13	121:8,17,25 122:7 123:9	75:17 dictate 33:17	77:20,21 81:10,11,13 83:3 88:22 89:15,17	46:16,23 48:18 51:20
dated 25:22 60:22	(depositions 7:7 11:6			40:10,23 48:18 51:20 52:16 53:14 56:3,15
62:24	14:18,24 15:1,3,9,11	difference 17:14,17	89:20 90:1,10,22 97:18 98:22 104:9	52:16 53:14 56:3,15 58:20 61:15 62:14
	14:18,24 15:1,3,9,11 15:14,20 26:1,1,20,20	75:6 99:25 different 9:4 10:1 27:15	109:10 110:4,7	63:9 67:20,23 68:1,4
dates 119:16 day 122:19 123:13	28:15 33:14	40:22 42:6 43:25	112:10,15 113:5,16	68:17,18,20,24 69:6,9
days 54:25 59:17 73:1	deposits 103:16	40:22 42:0 43:23 56:22 76:2 79:10	112:10,15 115:5,16	69:9,13 70:10 91:8,17
deal 75:7	describe 5:8 15:24	differential 39:23	115:12 118:19	91:19,19,22 92:13,16
dealing25:647:21	described 21:25	120:18	disease-free 42:8	92:23 93:6,16 95:10
67:1670:22 72:13	describes 95:24	differentiated 35:18,21	dismayed 121:11	97:5,7,13 99:6 100:1
74:20 104:2,7	describing 24:20	35:21 43:16 80:19	disproven 39:12	101:1 106:15 110:20
debate 90:15	description 14:3 52:12	83:3 99:3	dispute 27:18	110:21112:25 113:2
decide 89:19 90:4 91:25	61:8	differently 91:17	dissected 52:3	114:4,5 117:16,22
decided 88:25 92:7,8	descriptions 25: 17	difficult 17:13 20:2	dissection 36:2 38:1,8	118:10,13 120:1
deciding 27:17	designated 4:18	21:22 25:6 50:21	54:5 61:10 89:12	121:8,21
		لا مشارك كارك شد مستعد ، بد مس	01100111000114	

 $G_{2}^{(n)}=\frac{1}{2}\left[\frac{1}{2}\left(\frac{1}{2}\right) -\frac{1}{2}\left(\frac{1}{2}\right) -\frac{1}{2}$

				I age
draft 12:8	79:197:12,24 99:23	107:10	except 122:8	69:6 70:4 72: 15 78: 1
dramatic 28: 18 29:7	120:14	et 1:9	exceptions 96:11	78:3 84:3 96:9 101:22
draw 37:1399:24	ended 49:3	etc 40:24	excerpts 44:18	112:14 114:21 116:7
drawing 8:2,9	endometrial 37:16 53:9	etiological 107:12	excision 56:2 57:5	118:5 120:1,13 121:3
drifted 78:19,22	79:18	etiology 56:7 57:8 93:9	excuse 9:9 32:19,24	factor 38:17 39:5 75:14
drop 31:1352:21	endometrioma 52:1	93:12,14,15 112:6	41:7 44:22 50:7 60:8	105:9,17,24 106:25
dropped 33:22	53:6	evaluate 20:2 89:14	111:15	107:16,19,25 108:2
drops 72:9	endometriomas 52:8	evaluated 63:7	Executor 1:6	factors 42:18 99:13
Drs 14:18 15:6 26:6	53:17	evaluating 64:1889:7	exfoliation 70:17	104:15,25 106:10
Duke 18:22 19:22	endometriosis 25:7,9	evaluation 22:21 74:25	exhibit 3:12 4:4	107:12 108:6,13
duly 4:7 123:9	31:10 32:10,15,17,20	evaluations 102:23	EXHIBITS 3:14	failed 13:8
during 7:11 16:22	32:23 33:3,6,16 34:17	even 15:2 25:24 45:15	existed 17:5 70:11	fails 86:10
33:13 39:25 48:22,25	34:21 35:6 38:6,8	57:15,23 58:8 63:14	85:18	failure 12:20 13:3
51:12,19 52:17 53:20	39:1,7,10 40:5 41:13	64:17 65:11,14,19	existence 97:6	failure-to-diagnose-t
54:6 71:12,23 72:18	43: 1847:15,18,22	66:19 67:7,11 70:10	exists 17:4 60:11	5:16
73:6 75:4 100:12	48:16 51:25 52:6,13	73:2 78:3 80:23 84:13	expect 28:25 39:7	fair 20:24 22:2 24:23
105:23 108:1 113:11	53:3,6,17 58:18 60:1	84:24 86:6 87:10	experience 25:6,11	81:6 85:21
114:8	60:16 61:3,13 64:19	88:10 90:22 94:6 99:5	39:18 95:5,9,13	fairly 30:4 42:5,23
	65:13,18 66:10,21	100:13 102:6 103:3	expert 5: 10 7:4 8:13,25	111:19
E	70:3 74:21 75:13 79:8	103:20,23 108:11	17:2 64:17 65:11	fallopian 103:12
E 2:1,1 4:11 123:1,1	79:9,13,17,24 83:13	109:5,19 112:14	66:1967:7 69:19 86:7	familiar 6:16,19 13:25
earlier 10:7 34:13	84:17 85:20 89:1 91:6	120:7	98:16 103:21 119:15	25:19 33:18 42:20
35:10 83:16,21	99:12 105:8,8 106:4	evening 17:21	experts 4: 1927:985:2	95:20
108:24 110:10 117:14	107:9,19 120:2,16,19	(:vent 107:8	101:15	family 103:2 104:18,19
118:16 119:24	120:20 121:4	cvents 112:21 113:12	expires 123:18	105:1,2106:8,12
early 6:1344:545:2	endometriosis-associ	ever 4:23 7:19,22 8:16	explain 57:8 67:1	108:8,11
59:9 62:24 78:13 79:1	108:4	11:12,19 12:11 15:16	Explained 73:13	far 43:24 110:5
97:3	endometriotic 38:9	16:13 17:1 47:10,14	explaining 36:24	fashion 30:6
easier 96:3,6 110:11	49:15 69:14	52:15 71:4,10 72:7	exploratory 89:18	fast 6:24 24:7
easily 41: 16 64:14	endometrium 103:13	102:11	113:6	fatal 80:20,24 94:19
67:23 77:22 92:20	endoscopy 88:19	every 69:19	exposed 89:11	fatality 81:2
119:21	enough 6:16 48:5 84:8	everywhere 32:17	exposure 105:13	Fault 116:6 118:15
easy 4 1:23	entire 50:20 53:25	36:22	107:24	February 32:5
educational 47:8	89:23 92:15	evidence 48:21 53:3,5	extending 50:24	feel 81:9 98:5 115:25
educed 20:15	entity 43:25 81:10	54:14,14 55:9,15	extension 57:17,24	feels 20:1
effect 20:7 23:4 94:11	entry 100:17 105:15,19	57:15,22 58:13 59:10	59:11,19,22 60:12,23	fellow 5:5
Eighty 43: 14 80:15	ephemeral 56:24	59:17,20,21,25 61:11	extensive 19:4 20:17	felt 34:6 89:5,22,25
either 10:8 24:9 25:7,13	tpisode 116:10,16	61:16,2162:1I,19	25:16 52:12 61:3,13	106:3 121:12
27:3 29:25 34:6 37:6	episodic 106:1,24 108:1	63:3,6 103:7,11 110:7	64:19 65:13,18 66:9	few 5:9 6:3 45:19
38:7 45:19 49:4 51:9	Episodically106:22	115:20	66:21 103:6 110:5	119:24
62:6 72:1676:2 84:11	epithelial 28:24 29:20	evolved 25:8	extensively 23:12 58:18	fibrous 52:4
89:1,5,22 91:12 92:21	29:21 35:25 36:7	exact 74:5 91:18	extent 63:11 75:15	field 42:24 73:24
121:19	37:24 40:9,15 70:16	exactly 56: 17 75: 11	88:21 112:14 113:5	Fifth 1:17
embellishing 84:2	70:19 71:1,15	77:9 95:12 120:3	113:15 114:13	FIGO 6:6,11 43:3,4
emergency 6: 1 116:18	epithelium 38:14	121:7	extra 33:21	51:672:1673:774:5
emphasis 109:3	equivalent 42:7,9 43:22	exam 48:22 49:6 113:18	extraordinarily 39:8	75:1976:5,679:25
emphasize 26:9 30:5	77:22	119:25	extremely 30:24	80:5,10 81:16 82:1,2
50:18	eradicate 50:21	examination 1:13 3:2,5	eyes 25:16	82:7,8,9,24 83:4
emphasizing 26:14	erratic 106:5,23,25	45:21 48:19 49:1	F	99:17
81:21	erratically 106:21	119:22 121:1		figure 47:24,25 49:10
employee 23:16,18	error 5:5 34:5 67:9	examinations 115:13	F 122:1,1 123:1	figured 28:15
encapsulated 52:4	92:3	examined 4:8	faced 64:17	figures 42:4 43:2,8
71:16,23 72:14	specially 93:11106:3	examining 120:10,25	facility 88:11	78:15 99:7
encounter 39:9	estimate 48: 11	example 41: 143:20	facing 40:4 87:20	file 11:22 12:3 106:18
end 16:25 24:13 26:11	estimation 98:2	51:24 76:14 79:2	fact 5:7 6: 13 24: 19	filed 9:5 12:25
30:1353:3,6,1256:10	estrogen 107:6	114:21	32:12 39:8,13 54:14	fill 41:19
62:24 64:19 78:23	estrogen-stimulated	excellent 42:25	58:17 63:17 64:20	filter 27:1645:24

	7	T	7	1
filtering 25:10	FOUNDATION 1:9	78:16 80:8 96:3	107:15	78:9 79:2 81:21,23
final 12:1070:6	four 5:1 7:8 14:17	generation 105:21	grouping 101:23	84:8,11,17 89:3,4,6,7
find 8:21 97:3 103:11	25:25 26:20,20 55:22	genes 103:5	grow 120:20	89:11,23,25 90:8 91:2
finding 49:6	fractured 38:7	germ 6:8,13	growing 96:1	94:20 95:12,13,16
findings 28:19 53:4,15	frame 119:8	gets 32:13 55:18 94:4,4	growth 38:7 95:24,25	97:16,20 98:2,2,3,7
53:16 62:3,9	frank 86:9 87:1,4	97:19 101:4	118:20	98:1499:4,7 100:2,6
fine 37:11 51:22 77:6	frankly 36:1,8 37:25	getting 17:14 18:15	guess 17:13 36:17 60:13	100:6 101:10,21
80:13	86:17	37:23 53:21 60:4	71:20 72:6 93:6 120:5	102:5,9 103:12,13,15
finish 6:21 60:9	free 54:5 115:25	73:12,15 75:1 88:6	GYN 11:16,20 12:12	104:18 105:6,16,20
finished 11:446:15	frequently 67:3	91:20 116:22	22:17,19 27:1 35:1,14	105:21 106:2,12,12
Firelands 116:18	friend 41:17,19 55:1	gingerly 73:23	37:6,6 41:2 48:24	107:13,16,23 108:1,6
firm 8:1,14,17 11:14	from 13:21 14:15,21	gist 5:23 22:2	71:6 87:12 102:14	108:11,21 109:10,14
14:22 16:3	16:3,25 17:9 20:8,9	give 8:6 10:6,11,16 12:6	115:13	109:15,16,19,20,22
firms 7:22,25 9:22	20:22 22:5,8,11 27:7	27:1242:1677:11	gynecologic 25:5 27:6	110:2,4,4 111:13,17
first 4:7 11:25 13:14	28:14 29:22,24 30:16	78:1479:6 80:13	39:9 48:7 49:21,23	111:18,23 112:4,6,12
14:6,11,16 17:9,15,18	30:17,19 34:5,21	118:22	67:5 103:21 120:22	113:4,6,11,19 114:7
28:17 37:4,14 45:15	36:12,17 38:10 39:25	given 7:7,19 9:7,11,14		114:12 115:14,19
59:17 73:2 76:6 86:13	42:11 43:18 44:18	9:21 19:4 62:1 85:6	a	117:14,16,24 118:6
87:4,8 88:9 98:6,8	46:8,9,12 48: 11 49:24	102:6 111:21,24	half 7:6 48:11	118:10,13,15,16,19
105:6 107:14,18	50:24 51:13 55:3.25	giving 64:7 85:7 99:4	hand 63:7 123:12	118:20 119:18 120:25
113:11 121:1	56:22 58:5 70:23 74:7	glad 74:14	hands 73:22 94:1	121:6,15
first-order 95:20 96:1	75:23,23 77:14 78:12	gleaned 22:5;11	103:20 109:3	hereof 122:10
five 5:17:8,9 42:2	78:19 79:17 82:2	go 6:17 8:8 10:8,14	handwritten 105:4	hereunto 123:12
five-year 42:7 43:3 45:3	83:20 85:12 89:21	21:4,14,19 22:13	HANECA 1:23 123:6	hesitate 75:9
77:9 78:15 79:3 80:8	91:8,21 93:20 94:8,20	23:11 29:2 30:3 36:21	123:16	hesitation 33:13
81:4,25 82:4,9,22,25	97:16 99:10 105:5	38:20 41:18 43:24	HANECAJC2741 1:23	high 43:14 77:10 78:15
97:20 99:8	109:14112:25 114:1	46:23 47:11 48:6	Hang 31:20	79:4 80:14 81:2 102:8
flipped 105:3	117:18 118:7 120:4	55:12 58:8 60:9 61:2	happen 65:18 120:20	109:6,7,12
flipping 49:10	121:13	66:24 69:18 70:21	happened 60:7 72:5	higher 48:2 99:4 101:4
floor 50:24	front 16:7	80:7 86:25 89:13	102:16 105:3 107:12	highly 5:15 35:21
Florida 41:2,17	frozen 39:24	93:23 97:10 118:1	happens 71:22 72:8	highs 99:19 107:6
fluctuation 107:25	full 26:5	goes 50:22 54:9 68:14	happy 23:24 28:3 49:20	high-estrogen 107:11
fluctuations 107:6	fully 39:7	92:18 94:16	55:15	high-grade 27:24 28:6
fluid 52:3 99:15	function 105:23 106:5	going 7:17 9:16 26:16	hard 66:8 67:19	28:11 30:7,13 35:16
flyleaf 122:10	107:24	26:17,18 27:11 28:4	hate 96:15	35:20 58:21 68:19
focus 27:24 28:11 58:2 1	funny 8:19	37:11 40:2 41:18	having 4:6 40:21 42:25	69:10 77:13,15 92:5
68:19 69:10 79:18	furnished 12:2	43:15 46:19 53:22	61:8 67:11 101:7	him 9:10 18:2,13,21
92:4	furnishing 37:21	54:19,20 55:20 58:4	105:16,19 106:1	21:11 27:23 28:9
follow 112:6	further 28:16 50:17	60:14 67:15 76:15	114:5,9 117:9,12,13	37:13,17 46:6 56:9,9
follows 4:9 26:5 33:14	69:18 70:21 77:23	77:1 82:13 91:21	118:2 123:9	56:11,21,23 61:20
follow-up 115:4	93:23 94:9	104:24 110:23 116:15	lhead 49:13	62:6 67:25 69:10
forced 56:11	furthermore 101:10	gold 90:23,25	lheading 60:4	117:24
foregoing 123:8	future 58:3	gone 50:19 87:15	lhealthy 88:7	himself 20:4 120:7
forget 55:21		g ood 25:20 33:19 41:10	lnear 50:8 102:3	histology 20:19 25:18
forgotten 74:14	<u> </u>	44:3 50:12 58:1 81:20	lieard 48:14	26:10 42:17 68:9
form 64:13 70:16	gained 50:20	93:19 100:9,10	IHellman 42:20	74:25 75:11 86:6
formal 95:16	garden 41:12	113:19	help 64:3	92:21 98:23 101:9
formed 4:21 65:14	garden-variety 40:4	gotten 63:17	helpful 38:3 57:9 88:4	histories 104:20
former23:16	gastrointestinal 88:18	grade 42:17 62:2 75:11	helping 14:4	liistory 20:6 84:18
forming 15:4 49:18	gather 97:16	77:16 82:20 89:19	lier 6:220:529:22	103:2 104:18 105:1,2
forth 47:9 52:13 75:18	gave 22:11 46:17	90:10,14,22	36:13 41:13,19 48:19	105:4 106:9,13
77:5 83:7 88:20 99:2	general 8:4 9:23 12:24	Gramlich 15:7,9 56:3	52:9 55:5 57:24 58:14	107:18 108:8,11
99:13,14 115:18	16:24 35:12,13,19,23	56:15	58:15,18 59:4,16,22	109:14 118:7
forthright 31:6	40:18 41:9 42:14 43:8	great 10:18 46:13 75:7	59:23,23 60:1,16	liolds 36:23
forward 10:2 28:5	50:16 75:9 76:3 96:13	GREY 2:3	61:16 62:12 64:7,7,8	home 6:2 58:13
1	0 0 0 1 1 0 1 1	10.0	66.10 70.0 75.15 16	E 21.204.10
found 34:3,20 61:15 62:8,11 67:9 103:16	97:2 110:11 generally 44: 1247: 19	gross 19:3 group 47:22 99:24	66:13 73:2 75:15,16 75:17 76:16 77:21	lionest 31:394:12 lionestly 15:5 19:19

111:6 II 4 hormonal 106:5 107:6 IIC	noring 115:16 40:10,11,16	Infinitesimal 7:16	J	119:16
hormonal 106:5 107:6 IIC	40:10.11.16			
1		influence 108:10	January 119:10	kinetics 95:21 96:1
107.25	C 72:16 73:5 74:10	information 10:16	job 89:6	king 76:20 122:5
	75:2,5,8 76:3,16	19:22 25:11 35:23	JOHN 1:6	knew 17:5 58:7 113:25
hospital 105:6 116:19 7	77:20 81:7,8,10,20,25	42:16 43:1 46:22 62:1	JOLENE , 1:23 123:6,16	120:11
howard 1:15 3:1 4:6,15 8	82:5,10,22,23 89:20	63:20 75:10 76:24	Jolla 2:4	know 11:16 12:15,24
55:2 85:11 122:14 9	99:5,24 100:1 101:11	77:21	JUDGE 1:7	17:1119:24,25 20:1
123:9 1	101:14	infrequent 10:4	Julie 15:21	20:22,25 22:9 28:4
husband 106:12 III	77:16 82:20 89:15	inguinal 63:4	July 110:21 113:12,14	35:16 39:17 43:7,9
huston 1:631:2232:6 8	89: 19 90: 10 98:22	inherent 106:9 112:12	114:7 115:21 116:11	45:8,10 46:16 47:20
48:19 57:16 58:9 III	A 77:22 81:9,14 83:2	initial 14:9 89:18	116:17 117:1	49:3,8 56:17 57:11
59:1560:766:1377:8 im	mature 5:146:8	initiate 87:22	jumped 50:22	67:19 68:24 71:21
	mediate 100:17	inkling 117:11	jumping 28:5	72:8 75:5,16,17 77:3
· · · · · · · · · · · · · · · · · · ·	mediately 13:24	ins 20: 18	june 1:22 4:1 64:2,21	78:1479:4 80:19 82:3
	21:15	instance 30:7 33:17	65:6,23 66:1386:20	84:11 86:15,16,19,24
	pact 39:20,20 75:6	47:7 67:20 73:16	86:21 108:19110:5	87:21 88:15 89:13
	76:1	81:15,19	111:3 112:23 113:12	94:6,18 101:17
	plant 35:6 39:2 79:9	instead 109:9		102:20 103:23 104:22
	79:13,24 89:1 91:6	institution 93:21	114:7 115:19 118:21	106:12 108:11 109:14
	plantable 72:12	instructed 115:11	119:19 121:22 123:10 123:13	109:22 110:10 111:3
	plants 53:10 62:20	intact 51:2 72:14		112:14 114:24 119:20
	52:25 89:17	intend 4:21	junk 119:14	120:5,19 121:6,7,24
	plication 116:7	interest 45:20	jury 27:17 67:18	knowing 20:5 60:7
	ply 100:4 118:14	interested 14:3 54:1,10	just 6:20,20,24 8:2 9:2	70:11 75:10 92:19
	plying 43:4	interesting 94:2	10:10 15:1 16:19	knowledge 7:5 42:1,14
	portance 22:1530:5	international 43:5 76:8	17:11 18:15,18 20:21	58:4 59:23 108:9
	portant 22:25 27:14	interpret 45:25 66:20	29:10 34:23 35:22	123:11
	5:1,4,14,24 39:3	interpretation 19:1	37:8,11 41:14 43:7	known 58:21 63:9
	9:12 51:16,23 75:5	24:24 26:3,23 27:13	44:2 45:9 46:6 49:10	103:25 121:14
	37:17 90:13 98: 4	77:1486:789:21	52:22 53:13,21 55:4	103.23 121.14
	04:21 106:9 108:9	interpretations 22:24	57:11 62:13 66:8	L
	16:2	interpreted 28:10	74:13 76:7 80:13,25	La 2:4
	portantly 20:3 78:9	interpreting 38:5 60:15	82:7 85:19 86:24	lab 22:20
	ccurate 33:9	60:16 65:12	87:18 88:23 93:23	labels 66:4
			95:24 99:13 104:18	
	ppropriate 119:12	iinterrupted 60:8 iinterruption 10:13	104:24 105:3 116:4	labor 117:6
T	lude 43:16 83:8		117:5 119:7,23	lack 110:1
	ludes 18:9 83:4	invasion 37:1,3,5,16,17	~~~	language 10:21 30:6
	0:18 100:11 101:23	38:13	K	36:18 92:14 94:10
	01:24	invasive 85:12 87:1	keep 48:8 97:17	large 47:22 49:2,3,6,14
	luding 20:18 32:18	98:23	lkeeping 101:10	52:2 85:8 118:19
	4:3 51:25 70:5 85:1	involve 5:11 11:14	Kennedy 14:18 23:3,7	larger 49:9
	1:2	involved 5:5	23:13,25 27:22 28:9	last 7:8 10:4 45:10
	orrectly 66:3	involvement 89:16	31:8,24 32:4,14 33:11	106:20
	reasing 47:21	involving 24:20 40:9,15	33:24,24 34:8,19 43:9	later 6:3 50:6
-	urable 108:19 109:9	44:21,24 49:4 51:1,8	51:20 52:16 58:20	laterality 49:11
	09:17,18,23 110:14	58:18 81:11 101:18	61:15 63:9 69:9 70:10	lawsuit 23:15,17,20
	11:17	irregular 28:23	94:17 106:15 110:21	24:160:14
	leed 40:5 41:16	irrelevant 23:25	112:25 114:4 117:16	lay 94:1
	2:14 67:13 73:21	irrigation 54:9	118:10,13 120:1	leading 48:16
	1:18 84:4,5 103:19	irritable 6:1	121:9,21	learn 20:8 35:3
	ex 3:2,12 48:6,8	isolated 84:6,22	JKennedy's 23:22 27:19	llearned 89:21
	licated 15:8 122:9	issue 26:3,23 56:24	31:18 34:3 48:18	least 48: 159:24 60: 1
	licates 85:15	68:14 91:16 94:16	53:14 62:14 68:18	61:13 67:4 77:16,19
	licating 47:1	112:8 114:6	117:23	81:12 89:20 101:11
	lividual 72:8 83:19	issues 18:17	key 93:17,18,20	leaving 72:1
8	6:19 109:2	items 108:12	ltind 41:4 56:24 60:4	led 112:17
116:23 ine	vitably 73:24	i.e 35:10,16 75:3 111:23	72:6 89:12 96:7 117:5	left 49:4,14 71:6 72:2

101:18	looking 28:17 31:16,17	38:14 44:24 47:15,18	medical 4: 16 5:9 7:12	mobilize 73:23
legal 10:21	37:14 43:5 45:19 60:6	70:17 75:13,22 83:15	7:20 16:7 25:2 60:10	modalities 40:24
length 18:25	68:9 80:18 92:18	83:19,22 84:4,5,21,22	60:21 62:23 90:8	moment 10:10
lesions 24:5,13,18 49:11			93:19 114:25 118:7	Monday 37:21
Iess 7:6 115:5			medicine 46:2	monitor 64:8
let 10:10 31:12 32:3	lost 15:5 94:4 110:23	malignant-appearing 87:19	meet 16:16 86:8,10	month 13:18
37:8,9 47:25 55:20	lot 25:6 42:17 81:9	malpractice 5:4,9,16	meeting 17:23,25 18:4	months 6:3 15:20 45:13
56:20 65:5 92:7 93:6	lots 83:4	67:21	18:5,7	52:9 73:1 118:21
100:8	low 50:5 81:3 98:18	management 76:12	member 14:1	119:6,9,24
letter 11:24 12:2 13:17	102:6 109:4,5,7,12	managing 35:24 58:14	memory 113:10	month's 45:11
14:12 15:4 16:8,20,21	lower 47:24 76:13	78:9	menstrual 105:20	more 9:24 13:3,4,11
16:25 23:12 26:5,21	80:16,17,18 81:5	manner 68:23 71:9	106:1	20:6,17 24:4,17 55:18
27:20 37:1297:21	82:19 98:15	many 4:25 7:4 9:21	mention 29:16,19 105:;/	57:20 59:25 60:19
Let's 37:146:1452:24	lows 99:19 107:6	16:18 25:17,17 34:3	105:15 115:24	67:22 68:4 72:22,23
80:7 90:17	low-grade 24:4,13,18	48:3 94:3	mentioned 70:4 75:11	74:6 77:6 78:9 83:12
level 64:3,7 77:6 95:9	35:17,21	March 11:25 13:17	108:12 116:24	84:2,16 85:24 92:20
95:12	low-malignant 44:23	16:25 25:23 123:18	mentions 53:14	102:9 109:25 110:5
levels 88:12 107:6,11	lumping 112:20	mark 79:7	merel 2:3 9:17	117:5 118:19
113:23	lung 43:23,25 44:4,6,8	marked 4:4	merely 118:18	more-probable-than
Levin 15:7,9	44:10	Markman 14:18 110:21	met 8:20,22,24 18:1,21	86:11
like 25:21 31:4 32:12	lymph 89:11,16,16	113:2	21:11,15	morphologically 56:1
36:14,18 48:7 51:24	lymphadenopathy 63:4	Mason 7:17 12:12 67:5	metastases 117:5	most 7:8 10:4 18:16
53:156:7,24 57:9		mass 35:2,3 38:10,24	metastatic 104:9	20:2 30:10 32:12 35:9
59:3 61:21 85:10	M	38:25 49:2,7,9 54:4	microscope 37:14 38:13	48:7 50:5 64:17 65:11
87:11 92:19 93:9,24	M 1:64:11	64:1,13 72:14 73:19	74:8 87:16	66:19 67:7 69:25,25
96:24 98:7 99:14	made 33:25 34:8 47:10	73:23 96:20 118:16	microscopic 74:15,19	70:15 96:10,11
101:9 107:2 109:20	48:3 67:14,23 69:1	masses 54:6	81:13 96:24 110:7	104:21 110:6 120:24
118:15 121:13	98:3 99:1,19 106:20	match 84:10	111:24 112:4	move 46:1489:22
likes 37:6	110:16 121:22	material 16:5 20:1,4	might 15:1 26:15 51:15	100:6
limit 25:4	make 12:5 13:8 27:6	26:10 30:9,10,12,17	71:8 74:4 83:2 89:4	moved 59:2
limited 90:1	30:20 34:1 38:12 52:7	49:22 64:18 84:8,9	89:12,19 90:14 98:18	moves 10:2
line 31:18 32:1,8 78:19	52:11 54:20 62:4	86:6 92:21,22 94:20	106:6 109:20	moving 91:1
91:23,24 97:16	66:22 75:9 84:2,9	materials 14:5,7,9	millimeter 96:20	much 13:12 18:20
119:17	92:13 100:21 114:15	matter 12:7 118:4	millimeters 96:24	23:18 72:22 98:15
lines 55:23 62:10	116:13	matters 7:129:25 33:20	mind 25:20 55:5	111:23 116:14
list 55:23 108:6	makes 33:23 58:2	may 11:22 28:6 38:2	minds 58:14	muntz 1:15 3:1 4:6,15
listed 14:11 107:16	making 22:25 50:18	42:7,8 47:24 48:1,2	minute 30:9	122:14 123:9
listen 9:9,17	51:23 77:4 99:1 109:3	48:15 51:14 59:9,17	minutes 26:19	Murphy 2:8
literature 79:21 99:9	115:1	60:3,22 62:24 63:14	misclassify 74:4	mutation 103:4
99:17	malignancies 105:25	63:17 78:13 79:1	misdiagnosed 6:1	myself 45:20 67:17
litiga6ion25:208:16	106:5,10 107:10	84:24 101:15 106:12	misinterpreting 91:12	87:17,1 8 120:9
_	120:11	107:7,11 115:16	misleading 69:5	M-U-N-T-Z 4:15
live 111:8	malignancy 6:8 25:9	120:7	misphrase 32:25	M.D 1:15 3:1 4:6
local 96:25 118:20	38:12 39:22 54:15,21	maybe 21:15 23:14	misquote 83:25	122:14 123:9
locate 106:18	55:5,9,16 60:17 63:24	41:17 88:10 120:19	misquoted 51:6	N
long 49:22	70:23 73:21 74:17	mean 36:1944:7 52:2	misquoting 28:1	
longer 12:9 105:22	76:12 79:18 81:22	55:18 65:13 75:3	misread 25:24 26:9,13	N 2:1 4:11,11
106:13 107:24	82:20 84:10,14 86:9	91:19 94:15 95:23	26:15 64:16 65:10	name 4:13 8:1,14
long-term 42:8 105:11	87:2,4,14 89:24 94:9	101:21	66:8,17,18 68:11	mamed 7:4
look 11:22 25:20 37:9	94:19,24 95:3 97:8	meaning 33:20 56:13	miss 65:19	mational 76:7
42:3 51:14 62:22 67:3	99:4 102:14 103:7	means 56:21	missed 68:20 118:15	natural 105:20
74:6 82:7,12 83:19	104:1 106:7 108:17	meant 34: 16 56:22 93:7	misses 65:17	naturally 47:23
88:10 89:9 91:18	109:15 110:22 111:5	121:15	missing 28:13,19 93:20	iature 12:18 18:22
92:19 114:5 115:25	111:12 112:7 115:3	measurable 64:12	93:25	59:14 60:14 61:13 70:2 112:12
looked 17:21 31:4	117:4,9 119:20	112:10	Misstates 85:3	70:2 112:12
67:1168:269:887:24 01:0	malignant 5:15 21:2 25:8 36:1,8 37:25	measurements 96:19	mistake 67:11,14 99:1	necessary 30:12 90:5 need 42: 16 53:24 64:3
91:9	23.0 30.1,0 37.23	mediate 67:18	mix 99:22	nccu 42. 10 <i>33.</i> 24 04.3
			1	

 $E_{\rm e}^{\rm e} E_{\rm e}^{\rm e} = E_{\rm e}^{\rm e}$

Page 9

				1 age
77:4 81:22 83:8 89:13	obfuscating 60:20	oncology 49:21	15:4 24:23 26:6 49:19	79:12,21 80:1,9,22
116:15 120:23	object 37:8 45:5 46:21	one 4:19 5:4,14 6:910:1	88:7	81:20,25 89:2 91:5
needed 62:4	65:5	11:2,6,9 15:19,23	opportunity 15:13	99:10,11,13 100:12
needs 94:23 95:2	objecting 55:13 79:20	17:4,5,7,12,24,25	16:15 34:1 111:21,25	103:2 104:16,20,25
negative 117:2	Objection 21:3,13,18	18:5,7 19:5 38:11	118:15	105:9,12,17 107:20
negligence 7:12,20	22:6,13 29:2 30:3,22	40:2144:22 47:17,24	opposed 19:12 36:13	108:7,13 113:2
68:14	31:2 36:21 38:2,19	47:25 48:1 49:21 51:1	optimistic 98:1	ovaries 53:5 103:12
negligent 67:10 68:15	39:15 40:12 54:18	51:8 58:8,9,11 63:21	oral 1:13 105:14	ovary 6:9,13 24:3,11,16
negligently 26:8,9,13	55:1256:658:25	64:5 69:18,19 70:21	order 82:3 116:13	31:11,13,14 32:10,16
26:14,16 64:16 65:10	64:23 65:24 66:22	76:10 77:1493:23	origin 56:5,8,10 57:7,9	32:18,20,21 33:1,3,7
66:8,17,18 68:12	68:23 69:17 78:2,18	96:16,20,20,24 101:4	57:14 93:9,14	33:16 34:14,18 35:6
Neil 41:20,21	79:15 85:3 87:9 88:2	101:18 102:24 103:3	original 18:19 20:4	38:6,16 39:2,4 40:9
never 16:4 25:3,13,15	93:22 95:18 110:18	103:4,10 106:6,8	25:22 27:3,14,24	40:1644:11,12,21,25
25:25 27:2 71:21	118:1	107:12 109:1 111:6,8	28:10,13,19 29:16	45:3 49:4,14,15,15
82:16 104:8	objects 55:14	111:10,11 114:9,24	30:131:1,4,7 59:1	51:8 53:9 61:4,16
Nevertheless 69:9	obsessive-compulsive	115:5 117:16,23	60:17 66:6 75:1 91:10	62:1279:9,13,18,19
new 117:13	48:7	118:10	93:2,2,17 97:21,25	79:24 83:7 89:2 91:6
newest 45:6,9,12,16	obstruction 113:7	one-man 27:17	116:22	101:19 105:24
46:3,7,9,12	obtain 88:13	one-page 52:20	Orlando 41:20	over 32:3 44: 1764:25
next 17:22 53:11 58:23	obtained 54:15 63:17	one-person 67:17	other 14:24 17:24 19:10	92:21 104:24
105:15,19	63:21 64:5,6 74:16	one-year 115:12 117:15	21:7 23:9 28:18,24	overall 50:4,8,10 78:22
nice 121:14	75:24 100:16 113:9	118:4,13	42:17 43:19 44:18	overlap 75:7
nissenberg 2:3 3:7 4:12	113:20,22,23	only 5:18 6:2 7:13	48:15 49:18 56:18	overlooked 34:6
9:12,14,20 19:14 24:8	obviously 16:4 55:4	14:17 23:11,18 29:19	63:6,10,11 67:15	overly 29:7 98:1
31:17,21 32:2,22,24	66:167:1286:21	45:13 47:17 52:20	70:25 75:10,12 80:7	oversimplification 19:3
33:2 36:5,10 45:7,10	100:16 101:14	58:17 74:20,20 79:18	84:25 100:15 108:12	47:4
46:6,9,13 50:9,14	GB-GYN 47:7	82:21 90:14 93:14,15	111:4 112:17 113:3	ovulatory 105:23
61:24 65:1 69:2 82:14	occult 83:2 103:19	101:6 105:10 109:11	114:12,24 116:5	107:24
91:24 118:24 121:25	occurred 72:4	110:6 112:4,5,15	117:12 119:19	own 25:1636:1839:18
node 89:11,16,16	off 10:15 47:11,13	113:25	ourselves 73:15	45:20 67:2,5 75:3
nodes 63:5	49:12 52:21 82:14,15	onto 72:9	out 8:21 20:7,19 21:24	76:24 80:3 94:18
nomenclature 42:6	offer 4:21	0004:3	27:6 28:9,15 29:16	105:16 109:16
81:17	office 13:21 14:1 54:25	oophorectomy 103:1	33:22 38:25 39:24	105.10 105.10
normal 21:25 24:19	officially 74:9	op 51:14,17,24 52:20	45:9,12,13 49:10	Р
64:22 65:23 66:16	often 7:11 22:16 48:5	53:22	59:20 60:10,24 64:21	P 2:1,1
69:13,14 86:25 99:13	oftentimes 38:7 43:18	open 105:3	65:7,23 66:16 68:6	page 3:5,14 31:16,17,23
105:23 117:25	Oh 5:14 7:6 18:14	open-ended 30:4	69:13,23 76:16 92:20	32:8 45:4 46:19,25
notary 122:22 123:7	44:14 59:21 93:5,18	operated 52:15 55:4	101:5,8 107:2,5	53:24 61:23,24,25
note 5 1:17,24 52:12,20	94:12 108:23 118:8	71:10 72:4,21 73:2	117:18 120:15,16,23	91:21 92:15 105:4
53:22 105:4	119:2	operating 40:4,6 73:16	121:2	108:16 122:10
noted 48:25	dhio 1:22:10 7:23 9:6,8	74:22 89:4,13	iutcome 23:10	pages 34:9 52:21
notes 12:5 33:18	9:22 10:5 11:1	operation 41:15,18	outright 84:9	pain 115:18 116:24
nothing 41:13 44:11	okay 7:18 11:1 18:8	105:6	outs 20:18	117:4,6,7,10,12 118:6
69:2 114:13	19:13 26:18 32:22	operative 33:18 51:13	outside 48:22 61:16	palpable 48:25
iotion 67:15 99:3	46:14 62:19 88:4 90:6	52:1253:4,25 54:3	62:11,20,25	paper 12:4
118:18	91:25 100:9,25	61:2 73:24	ovarian 5:11,15,19 6:2	papers 44: 18
1uclei 28:23	omental 89:10	opinion 12:2 16:20,21	6:7,10 12:20 13:3,9	paragraph 14:1147:2
nulli 107:21	omentum 103:16,17	17:10 20:3 23:12,13	30:16,20 34:20 35:2,6	97:25
1umber 48:5 99:16	omitted 70:7	25:4,12,22 26:21 27:9	35:15 37:15 38:4,9,17	parenthesis 97:10,12
101:4	once 7:13 9:23,24 16:19	27:1237:1064:15,20	38:24,25 39:1,17	parous 107:21
10meral 40:11	31:14 52:20	65:8,13,22 66:11,18	41:12,14,22,24 42:2,4	piart 6:5 22:16 23:14,15
iursing 5:5	oncologist 12:1225:5	67:8 68:1,20 69:13	49:2,4,6 50:5,18 51:1	23:17,20,25 37:12
N-U-L-L-I 107:21	27:6 35:1,15 37:6,6	80:24 83:10,14 84:6	52:1,3,8,14 59:23	39:16,23 54:1,10 65:2
	41:2 49:24 87:12	85:22 87:7 97:9,13	61:7 70:18,19 71:1,11	76:19 77:1 82:16,18
0	88:24 90:9 103:21	101:15,16 108:22	71:14,23 72:10,12,21	87:17 95:6 96:8
D 4:11 120:14	oncologists 11:17,20	109:10 111:2	73:17,18,19,23 74:3	particular 12:22,25
oath 4:7	48:8	opinions 4:20 5:23 12:6	74:23 76:9 78:21 79:8	22:4 40:17 45:17 61:6
		l		

Buell Realtime Reporting (206) 287-9066

		······································	T	
72:20 88:5	pause 10:10	107:23 108:1	plenty 59:21 99:9	107:14 116:18
particularly 21:6 82:19	paying 53:24	peritoneal 50:20 5 1:10	point 18:2 30:4 50:17	presents 64:1
104:6	pelvic 15:17 21:2 22:20	51:25 58:5,19 61:4	59:20 60:10,24 61:12	presume 87:11 105:22
partly 27:15 36:1,8	25:1,14 27:3 28:22,25	62:20,25 63:24 64:18	64:3 73:20,25 91:25	presumed 110:2 115:11
37:25 96:2	29:21 30:1,9 50:24	65:12 70:17,25 71:3	100:10,24 102:7	Presumedly 103:18
passed 94:3	51:4,25 53:9 54:4,13	71:17 72:9 74:1,9,11	112:25 113:10	presumption 63:7
path 120:15,23 121:2	54:15,19 55:3,6,8	79:17 80:6 89:24	pointed 28:9	presumptive 97:7
pathologic 38:16 39:4	57:4 58:5,18 59:10,18	90:19 97:8 99:12,15	pointing 107:2,5	presumptively 102:14
39:1462:9	59:22,23 60:11,23	100:3,14,17 101:18	Polito 2:8	104:1
pathological 24:20	61:4 63:23 65:9 68:3	101:25 103:6,7,14	poor 43:23	pretty 13:12 18:20
pathologically 103:19	70:7,12,24,25 72:9,25	104:7 105:25	poorer 43:19 44:13	108:24
pathologist 19:20 20:5	74:1,7,9,23 75:22	peritoneum 53:10,12	poorly 35:17,20 43:16	previously 8:22,24
26:2,22 46:1 66:3	79:16 81:11 83:15,18	70:24 72:25 74:7,24	80:1983:399:3	primary 35:5 70:25
67:12,13,21 68:9,15	83:21 84:3,14,20,24	75:23 81:12,13	portion 52:22	73:18 79:16 80:5
69:22 94:22 121:13	85:8.19 87:14 89:23	103:20 105:13 108:15	positive 51:4,9 63:4	88:1889:291:5
pathologists 12:15 47:6	89:25 95:2 97:6,8,14	person 27:23 28:10	90:19,20 97:6,14	102:13 103:25 104:3
64:17 65:11,19 66:20	100:16,20 101:7	109:2	99:14 100:3,5,20	104:6,8
67:3,7,18 69:20 85:1	102:12103:7,19,24	personal 102:15 109:14	101:17,22,25 102:32	principle 96:14
103:22	104:7 105:13,25	personally 11:16 22:17	103:14,24	principles 35:23
pathology 16:10 19:1	108:15 111:5 115:2	89:5 109:19	possible 72:13 89:15	print 45:13
20:18 22:3,19 25:19	117:4,9 119:25	phase 87:1	possibly 52:9 73:1	prior 16:15 17:23 18:13
26:8 27:8,18 44:16	pelvic-peri 75:16	phone 41 :1,17,21	80:18 81:5 85:20	26:21 48:19 52:9
45:1849:1155:157:2	pelvis 32:17 38:10,16	121:13	106:17	62:14 92:15 113:14
63:1067:2574:11	39:3 45:3 48:22 58:15	phonetic 41:20	postmenopausal 107:3	115:21 116:11,11
77:15 84:12 85:10	60:17 62:20,25 73:20	phrase 30:7 31:14	postoperative 53:2	probably 5:1 7:6,13
87:25 88:6 89:21	73:22 90:1	33:20 53:3 57:2 58:1	postulate 120:7	9:25 18:18 19:3 20:2
94:10 110:8 117:17	penetrating 73:25	61:1 68:13 121:2,12	post-status 94:9	20:6 34:5 36:6 42:10
117:24	people 6: 12 58:6 84:25	phrased 21:19 69:5	potential 44:23 56:12	55:22 58:5 68:4,7
patient 23:1 27:7 35:2	per 7:13	121:7	potentially 61:14 88:8	73:20 83:12 84:16
35:11,15 38:24 39:6	percent 40:8,14 43:13	phraseology 51:15	practice 22: 1627:2	85:24 86:16 94:5
39:11,16 41:3,4,5,11	43:1445:447:17,24	physical 48: 1849:6	48:10 74:22 93:20	98:21 101:12 102:9
42:17 54:17 55:3,11	47:25 48:1 77:10	113:18	102:16	102:24 104:3 109:25
58:23 59:16,19 60:12	78:14 79:2,4 80:14,15	physician 117:14	practicing 20:4 25:5	112:4 119:24 121:12
63:1,5,21 66:9,21	80:18 81:4 82:13	physicians 12:22,25	45:25	problem 21:25 40:17
70:13 72:15 74:4 75:5	86:10 97:19,21 98:15	pick 41:1,16,21 92:20	Prayson 14:1824:2,10	50:18 59:13
76:1479:2381:19	98:19 102:3,6,10	picked 68:2,2	24:15	procedure 52:10 54:3,7
82:19,23,24 83:6,17	108:25 109:6,7,7,12	picture 25:20	preceding 115:14	procedures 40:6 77:23
83:24 85:6 87:15	109:13,20 110:15	pills 105:10,12	precise 73:25 119:16	112:18 113:4
88:13,25 90:7,21	111:8,11	place 73:2 92:17 118:20	precisely 19:19 59:25	process 6: 17 24:20
100:15,16 103:8,18	percentage 7:1442:1	119:12,16	precision 72:7	25:17 50:23 76:24
103:24 104:1 106:16	42:15 43:2 47:19,20	placed 89:23 115:12	predict 69:23	86:17 87:18 89:23
111:4 112:18 114:14	81:24 82:21 102:2,3	places 52:24,25	predominantly 27:5	96:8
115:4 116:7,23 117:1	percentages 78:15 79:5	placing 120:9	prefer 96:17	prognoses 40:24 44:2
118:2 120:10	80:13 108:24 109:2	plaintiff 1:72:3 5:10,22	premalignant 60:1	prognosis 35:11 43:19
patients 38:18 40:9,15	pierfect 33:23 51:24	8:12,25 11:8,9 12:22	61:14 83:13,20 84:19	43:23 44:13 47:9 75:8
42:1 45:2 48:9 65:19	61:177:3	23:6,9,22,24 66:16	85:20 87:1 112:5	76:1 8 1:20
67:2 71:4,10,22,25 72:3 73:3,5 78:16	performed 71:25	69:20	premise 112:5	prognostic 81:18
79:12 80:9 81:18 82:5	perhaps 29:7 72:23 103:3 112:5 117:12	plaintiffs 11:2	prepared 65:16 66:7	108:23
99:24 100:11 101:6,8		plaintiff's 12:19 13:2,7 26:7 97:11 110:8	presence 51:25 54:16 55:10 65:13 97:7	progression 114:8
	perimenopausal 107:4 108:2	plan 87:22	100:2	118:19 proper 68:12
101:17,23,24 102:11 102:19 103:3 104:11	perimenopause 106:6	planes 36:2,9 38:1,7		proper 68:13
111:6 121:10	107:7,11	F'LEAS 1:1	present 29:21 30:10	properly 42:18
patient's 39:21 72:6	period 26:10,11 53:6,12	please 4: 14 24:6 36:4	40:10,15,16 55:16 56:162:2 87:4 119:1	prophylactic 103:1,8 propose 67:17
85:13	54:4,6,7 73:1 105:22	*	119:9	
pattern 95:24 96:21	108:2 115:7,10	52:23 53:19 59:4,6,20 73:9	presentation 117:14	Prospect 2:3 protective 105:12,14
patterns 74:3	periods 106:21 107:1	plentiful 30:23	presented 67:25 106:2	protective 105:12,14 prove 74:7
Putter in a start	PULIOUS 100.21 10/.1	prominui 30.23	presented 07.23 100.2	Prove / 7. /

Howard Muntz, M.D.

Page 11

$ \begin{array}{c} \mbox{provided } 9:12 83:15,22 \\ 84:5 \\ \mbox{provided } 9:19 11:25 \\ 14:8,13,14,15:9,16 \\ 14:8,13,14,15:9,16 \\ 15:5 \\ \mbox{provided } 9:19 11:25 \\ 15:5 \\ 15:5 \\ \mbox{provided } 9:19 11:25 \\ 15:5 \\ 15:5 \\ \mbox{provided } 9:19 11:25 \\ 15:6 \\ \mbox{provided } 9:19 11:25 \\ 15:6 \\ \mbox{provided } 9:19 11:25 \\ 11:8 9:112,24 102:9 \\ 11:78:11 \\ \mbox{provided } 9:11 \\ 9:118 9:112,24 102:9 \\ 11:78:11 \\ \mbox{provided } 9:11 \\ 9:112 9:115 \\ \mbox{put} 9:115 \\ \mbox{put} 9:11 \\ 9:112 9:116 \\ \mbox{put} 9:115 \\ \mbox{put} 9:11 \\ 9:112 9:116 \\ \mbox{put} 9:1$			
	36:12,14	5 94:1 99:3 101:8 refers 96:21 109:19 represent	ation 42:12
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			ations 115.1
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		-	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		1	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			1116 1 4.4
			s 6.9 73.21
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			3 0.7 70.221
		,	α 45 ·14
$ \begin{array}{ $	•		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1	-	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			+.5 10.2,15
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			14.7 16.1
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			
P-A-T-H 12:9 10:25 requirements 76 Q range 42:5 47:23 48:12 received 14:21,23 15:20 reloked 88:11 requirements 76 qualifiers 38:11 46:18 82:4,5,13 received 14:21,23 15:20 reloked 88:11 reloked 88:11 qualifiers 38:11 46:18 82:4,5,13 receiving 15:11 receiving 15:11 reloked 88:11 reserve 49:23 quantary 67:25 rate 45:3 81:2 82:19 104:8 recognize 94:23 95:26 reserve 49:23 residen 17:22:11 residen 12:20 residen 47:7 quarter 67:22 95:25 109:12 recognize 94:23 95:26 remember 8:1,3,14 responde 46:23 23:21 26:18 28:8 29:3 reaction 74:18 recollect 94:7 95:15,19 90:13:15 50:9 62:13 responde 46:23 39:11 40:17 42:19 26:21 27:1,15,19 31:5 recollecting 102:22 recollecting 102:22 responde 46:23 responde 14:20 39:11 40:17 42:19 26:21 27:1,15,19 31:5 recollecting 102:22 responde 14:20 39:11 40:17 42:19 26:12 7:1,15,19 31:5 recollecting 102:21 remember 8:1,3,14 response 31:21 6 39:11 40:17 42:19 26:12 7:7, 40:13			11.11 50.9
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			n 140:13
			0.10
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			
$ \begin{array}{l l l l l l l l l l l l l l l l l l l $			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	1		
$ \begin{array}{c} \mbox{question} 6:21\ 7:1\ 9:10 & \mbox{rather} 58:9\ 73:14 & \mbox{reach} 73:22 & \mbox{reach} 73:22 & \mbox{reach} reach 73:23 & \mbox{reach} reach 73:24 & \mbox{reach} reach 73:25 & \mbox{reach} reach 73:24 & \mbox{reach} reach 73:25 & \mbox{reach} reach 73:25 & \mbox{reach} reach 73:24 & \mbox{reach} reach 73:25 & \mbox{reach} reach 73:25 & \mbox{reach} reac$		e	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			
62:13 64:24 68:2450:15 52:19,22 53:1347:11,13 50:15 52:19render 25:11 58:23retained 69:2069:3 71:7,18,19 75:153:19,25 57:19,2053:19,25 59:7 65:464:4 67:8 77:7retina 17:1478:12,25 79:7,15 80:759:7 61:22 62:1773:10 82:14,15 98:9rendered 68:8 70:1retroperitoneal 681:24 82:6,16,2164:21,25 65:1,4,6,23105:4 106:17 110:25103:25 104:1189:1684:10 88:2 92:1066:16 69:13,23 73:9114:15,25 116:15repeat 6:24 24:8,14retrospect 67:8 996:16,17 112:173:10 87:25 91:21120:2459:4 71:19retrospect 67:8 9questionable 94:995:10,17 98:7,9records 14:1416:3,6,7repetitively 52:959:14 60:14 94questioning 78:19110:25 117:18 121:1625:2 59:18 60:10,22rephrase 6:24 31:13retrospectively 197:17 119:17122:762:23 113:1 115:20rait447:25reveal 94:8question-and-answer33:1,5 45:1 52:1137:1451:13,14 53:25 61:2reversed 67:2373:1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,2,2,5 19quickly 88:14 119:13reads 51:2427:20 95:1382:8 108:1659:14 67:2,4 84quickly 88:14 119:13reads 51:2427:20 95:13report 77:1817:18 22:7 169:15realize 21:6 82:1794:15review 71:21:2394:8,10,20 114review 21:5 16review 51:2477:20 95:13report 77:1817:18 21:7 51:1			
69:3 71:7,18,19 75:153:19,25 57:19,2053:19,25 59:7 65:464:4 67:8 77:7retina 17:1478:12,25 79:7,15 80:759:7 61:22 62:1773:10 82:14,15 98:9rendered 68:8 70:1retroperitoneal 681:24 82:6,16,2164:21,25 65:1,4,6,23105:4 106:17 110:25103:25 104:1189:1684:10 88:2 92:1066:16 69:13,23 73:9114:15,25 116:15repeat 6:24 24:8,14retrospect 67:8 996:16,17 112:173:10 87:25 91:21120:2459:4 71:19retrospect 67:8 9questionable 94:995:10,17 98:7,9records 14:1416:3,6,7reptitively 52:959:14 60:14 94questions 8:23 10:20reading 21:2324:7115:25report 17:19 18:2,9,11reveal 94:8question-and-answer33:1,5 45:1 52:1137:1451:13,14 53:25 61:2reversed 67:2373:1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,2,2,5 19quick 19:8:14 119:13reads 51:2427:20 95:1376:12,16,23 81:1620:18 22:3,17 23quick 19:8:14 119:13reads 51:2427:20 95:13report 32:14 123:6review d12:5 1689:15realize 21:6 82:1794:15references 52:24 94:8report 32:14 123:6review d12:5 16			
78:12,25 79:7,15 80:759:7 61:22 62:1773:10 82:14,15 98:9rendered 68:8 70:1metroperitoneal 681:24 82:6,16,2164:21,25 65:1,4,6,23105:4 106:17 110:25103:25 104:1189:1684:10 88:2 92:1066:16 69:13,23 73:9114:15,25 116:15repeat 6:24 24:8,14metrospect 67:8 996:16,17 112:173:10 87:25 91:21120:2459:4 71:19metrospect 67:8 9questionable 94:995:10,17 98:7,9records 14:1416:3,6,7repetitively 52:959:14 60:14 9497:17 119:17122:762:23 113:1 115:2033:1447:25metrospectively 1questions 8:23 10:20reading 21:2324:7115:25report 17:19 18:2,9,11mevesds 60:22question-and-answer33:1,5 45:1 52:1137:1451:13,14 53:25 61:2mevesd 67:2373:1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,22,25 19quick 89:994:22 95:1reference 10:7 16:882:8 108:1659:14 67:2,4 84quickly 88:14 119:13meads 51:2427:20 95:13REPORTED 1:2394:8,10,20 114quick 23:1130:23 35:22meads 51:2427:20 95:13reporter 32:14 123:6reviewd 12:5 1689:15mealize 21:6 82:1794:1594:1517:18 21:7 51:1			
81:24 82:6,16,2164:21,25 65:1,4,6,23105:4 106:17 110:25103:25 104:1189:1684:10 88:2 92:1066:16 69:13,23 73:9114:15,25 116:15repeat 6:24 24:8,14retrospect 67:8 996:16,17 112:173:10 87:25 91:21120:2459:4 71:19retrospective 39questionable 94:995:10,17 98:7,9records 14:1416:3,6,7repetitively 52:959:14 60:14 9497:17 119:17122:762:23 113:1 115:2033:1447:25reveal 94:8questions 8:23 10:20reading 21:2324:7115:25report 17:19 18:2,9,11reveals 60:2246:23 55:23 60:2025:25 28:15 29:25recut 28:17 31:6 37:420:8 29:16 49:11reveals 60:2273:1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,22,25 19quibble 49:24 97:369:15 91:8 92:1261:6 70:7 80:4 106:2076:12,16,23 81:1620:18 22:3,17 3quick 89:994:22 95:1reference 10:7 16:882:8 108:1659:14 67:2,4 84quickly 88:14 119:13reads 51:2427:20 95:13reporter 32:14 123:6reviewed 12:5 1689:15realize 21:6 82:1794:1594:15reporting 76:7 77:1817:18 21:7 51:1			
84:10 88:2 92:1066:16 69:13,23 73:9114:15,25 116:15repeat 6:24 24:8,14retrospect 67:8 996:16,17 112:173:10 87:25 91:21120:2459:4 71:19retrospective 39questionable 94:995:10,17 98:7,9records 14:1416:3,6,7repetitively 52:959:14 60:14 94questioning 78:19110:25 117:18 121:1625:2 59:18 60:10,22rephrase 6:24 31:13retrospectively 197:17 119:17122:762:23 113:1 115:2033:1447:25reveal 94:8questions 8:23 10:20reading 21:23 24:7115:25report 17:19 18:2,9,11reveals 60:2246:23 55:23 60:2025:25 28:15 29:25recut 28:17 31:6 37:420:8 29:16 49:11reveals 60:22question-and-answer33:1,5 45:1 52:1137:1451:13,14 53:25 61:2review 7:12 10:273:1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,22,25 19quible 49:24 97:369:15 91:8 92:1261:6 70:7 80:4 106:2076:12,16,23 81:1620:18 22:3,17 3quickly 88:14 119:13reads 51:2427:20 95:13references 52:24 94:8reporter 32:14 123:6reviewed 12:5 16guite 23:1130:23 35:22ready 18:15 35:22references 52:24 94:8reporter 32:14 123:6reviewed 12:5 1689:15realize 21:6 82:1794:15retor 55:24 94:8reporter 32:14 123:6reviewed 12:5 16			oneal 63:4
96:16,17 112:173:10 87:25 91:21120:2459:4 71:19retrospective 39questionable 94:995:10,17 98:7,9records 14:1416:3,6,7repetitively 52:959:14 60:14 94questioning 78:19110:25 117:18 121:1625:2 59:18 60:10,22rephrase 6:24 31:13retrospectively 197:17 119:17122:762:23 113:1 115:2033:1447:25reveal 94:8questions 8:23 10:20reading 21:2324:7115:25recut 28:17 31:6 37:420:8 29:16 49:11reveals 60:2246:23 55:23 60:2025:25 28:15 29:25recut 28:17 31:6 37:420:8 29:16 49:11reveals 60:2273:1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,22,25 19quibble 49:24 97:369:15 91:8 92:1261:6 70:7 80:4 106:2076:12,16,23 81:1620:18 22:3,17 3quick 89:994:22 95:1referenced 10:7 16:882:8 108:1659:14 67:2,4 84quick 23:1130:23 35:22ready 18:15 35:22references 52:24 94:8reporter 32:14 123:6reviewed 12:5 1689:15realize 21:6 82:1794:1594:15reporting 76:7 77:1817:18 21:7 51:1			
questionable 94:9 questioning 78:19 97:17 119:1795:10,17 98:7,9 110:25 117:18 121:16 122:7records 14:1416:3,6,7 25:2 59:18 60:10,22 62:23 113:1 115:20repetitively 52:9 rephrase 6:24 31:13 33:1447:2559:14 60:14 94 retrospectively 1 reveal 94:8questions 8:23 10:20 46:23 55:23 60:20 question-and-answer 73:14reading 21:2324:7 25:25 28:15 29:25115:25 recut 28:17 31:6 37:4 37:14report 17:19 18:2,9,11 20:8 29:16 49:11reveal 94:8 reveal 94:8question-and-answer 73:1433:1,5 45:1 52:11 69:15 91:8 92:1237:1451:13,14 53:25 61:2 61:6 70:7 80:4 106:20review 7:12 10:2 68:8 70:5,6 74:11quick 89:9 quick 89:994:22 95:1 94:22 95:1referenced 10:7 16:8 27:20 95:1382:8 108:1659:14 67:2,4 84 14:10,22,2 519quickly 88:14 119:13 quite 23:1130:23 35:22 89:15reads 51:24 realize 21:6 82:1727:20 95:13 94:15reporter 32:14 123:6 reporting 76:7 77:1817:18 21:7 51:1			
questioning 78:19 97:17 119:17110:25 117:18 121:1625:2 59:18 60:10,22 62:23 113:1 115:20rephrase 6:24 31:13 33:1447:25retrospectively 1 reveal 94:8questions 8:23 10:20 46:23 55:23 60:20 question-and-answer 73:14reading 21:2324:7 25:25 28:15 29:25115:25 recut 28:17 31:6 37:4report 17:19 18:2,9,11 20:8 29:16 49:11reveals 60:22 reveal 94:8question-and-answer 73:1433:1,5 45:1 52:11 62:13,15,16,18 68:637:1451:13,14 53:25 61:2 68:8 70:5,6 74:11reversed 67:23 review 7:12 10:2quibble 49:24 97:3 quick 89:969:15 91:8 92:12 94:22 95:161:6 70:7 80:4 106:20 referenced 10:7 16:8 27:20 95:13 references 52:24 94:876:12,16,23 81:16 82:8 108:1620:18 22:3,17 32 94:8,10,20 114quick 19:88 report 13:10:23 35:22 89:15reads 51:24 realize 21:6 82:1727:20 95:13 94:15REPORTED 1:23 reporting 76:7 77:1894:8,10,20 114 17:18 21:7 51:1			
97:17 119:17122:762:23 113:1 115:2033:1447:25reveal 94:8questions 8:23 10:20reading 21:2324:7115:25recut 28:17 31:6 37:420:8 29:16 49:11reveals 60:2246:23 55:23 60:2025:25 28:15 29:25recut 28:17 31:6 37:451:13,14 53:25 61:2reveals 60:22question-and-answer33:1,5 45:1 52:1137:1451:13,14 53:25 61:2review 7:12 10:273:1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,22,25 19quibble 49:24 97:369:15 91:8 92:1261:6 70:7 80:4 106:2076:12,16,23 81:1620:18 22:3,17 3quick 89:994:22 95:1referenced 10:7 16:882:8 108:1659:14 67:2,4 84quickly 88:14 119:13reads 51:2427:20 95:13references 52:24 94:8reporter 32:14 123:6quite 23:1130:23 35:22ready 18:15 35:22references 52:24 94:8reporter 32:14 123:6reviewed 12:5 1689:15realize 21:6 82:1794:1594:1517:18 21:7 51:1			
questions 8:23 10:20 46:23 55:23 60:20reading 21:2324:7 25:25 28:15 29:25115:25 recut 28:17 31:6 37:4report 17:19 18:2,9,11 20:8 29:16 49:11reveals 60:22 reversed 67:23question-and-answer 73:1433:1,5 45:1 52:11 62:13,15,16,18 68:637:1451:13,14 53:25 61:2 61:6 70:7 80:4 106:20 reference 49:22 53:2058:8 70:5,6 74:11 68:8 70:5,6 74:1114:10,22,25 19 14:10,22,25 19quibble 49:24 97:3 quick 89:969:15 91:8 92:12 94:22 95:161:6 70:7 80:4 106:20 reference 10:7 16:876:12,16,23 81:16 82:8 108:1620:18 22:3,17 32 14:10,22,25 19quickly 88:14 119:13 quite 23:1130:23 35:22 89:15reads 51:24 references 52:24 94:827:20 95:13 references 52:24 94:8 94:15REPORTED 1:23 reporting 76:7 77:1894:8,10,20 114 reviewed 12:5 16			
46:23 55:23 60:2025:25 28:15 29:25recut 28:17 31:6 37:420:8 29:16 49:11reversed 67:23question-and-answer33:1,5 45:1 52:1137:1451:13,14 53:25 61:2review 7:12 10:273: 1462:13,15,16,18 68:6reference 49:22 53:2068:8 70:5,6 74:1114:10,22,25 19quible 49:24 97:369:15 91:8 92:1261:6 70:7 80:4 106:2076:12,16,23 81:1620:18 22:3,17 2quick 89:994:22 95:1reference 10:7 16:882:8 108:1659:14 67:2,4 84quickly 88:14 119:13reads 51:2427:20 95:13references 52:24 94:8reporter 32:14 123:6quite 23:1130:23 35:22ready 18:15 35:22references 52:24 94:8reporter 32:14 123:6reviewed 12:5 1689:15realize 21:6 82:1794:1594:1517:18 21:7 51:1			
question-and-answer 73:1433:1,5 45:1 52:11 62:13,15,16,18 68:637:14 reference 49:22 53:2051:13,14 53:25 61:2 68:8 70:5,6 74:11review 7:1210:2 14:10,22,25 19quibble 49:24 97:369:15 91:8 92:1261:6 70:7 80:4 106:20 reference 10:7 16:876:12,16,23 81:1620:18 22:3,17 2 20:18 22:3,17 2quick 89:994:22 95:1reference 10:7 16:8 27:20 95:1382:8 108:1659:14 67:2,4 84 94:8,10,20 114quick 23:1130:23 35:22ready 18:15 35:22 realize 21:6 82:17references 52:24 94:8 94:15reporter 32:14 123:6 reporting 76:7 77:18reviewed 12:5 16 17:18 21:7 51:1		1	
73: 14 quibble 49:24 97:3 quick 89:9 quickly 88:14 119:13 quite 23: 1130:23 35:2262:13,15,16,18 68:6 69:15 91:8 92:12reference 49:22 53:20 61:6 70:7 80:4 106:20 referenced 10:7 16:8 27:20 95:1368:8 70:5,6 74:11 76:12,16,23 81:16 82:8 108:1614:10,22,25 19 20:18 22:3,17 32quick 89:9 quickly 88:14 119:13 quite 23: 1130:23 35:22 89:1594:22 95:1 reads 51:24references 52:24 94:8 94:1582:8 108:16 REPORTED 1:23 reporter 32:14 123:6 reporting 76:7 77:1859:14 67:2,4 84 14:10,20 114			
quibble 49:24 97:3 quick 89:969:15 91:8 92:12 94:22 95:161:6 70:7 80:4 106:20 referenced 10:7 16:8 27:20 95:1376:12,16,23 81:16 82:8 108:1620:18 22:3,17 32 59:14 67:2,4 84 59:14 67:2,4 84 94:8,10,20 114quick 19:894:22 95:1 reads 51:24referenced 10:7 16:8 27:20 95:1382:8 108:1659:14 67:2,4 84 94:8,10,20 114quice 23:1130:23 35:22 89:15ready 18:15 35:22 realize 21:6 82:17references 52:24 94:8 94:15reporter 32:14 123:6 reporting 76:7 77:18reviewed 12:5 16 17:18 21:7 51:1			,
quick 89:9 quickly 88:14 119:13 quite 23:1130:23 35:22 89:1594:22 95:1 reads 51:24referenced 10:7 16:8 27:20 95:13 references 52:24 94:882:8 108:16 REPORTED 1:23 reporter 32:14 123:6 reporting 76:7 77:1859:14 67:2,4 84 94:8,10,20 114 reviewed 12:5 16 17:18 21:7 51:1			
quickly 88:14 119:13reads 51:2427:20 95:13 REPORTED 1:2394:8,10,20 114quite 23:1130:23 35:22ready 18:15 35:22references 52:24 94:8reporter 32:14 123:6reviewed 12:5 1689:15realize 21:6 82:1794:1517:18 21:7 51:1			
quite 23:1130:23 35:22 89:15ready 18:15 35:22 realize 21:6 82:17references 52:24 94:8 94:15reporter 32:14 123:6 reporting 76:7 77:18reviewed 12:5 16 17:18 21:7 51:13			
89:15 realize 21:6 82:17 94:15 reporting 76:7 77:18 17:18 21:7 51:1			
		1	
		94:15 reporting 76:7 77:18 17:18 21	.:7 51:17
		referencing 61:21 reports 17:2,17 27:16 87:16	
quote 24:11,13,16 26:6 really 27:7 43:16 67:10 referring 30:1444:2 33:18 77:15 82:2 reviewing 7:15			7:15
26: 1128: 3,4 30: 12, 13 67: 19 72: 8 75: 15 81: 8 46: 20 69: 6 93: 16 110: 8 reviews 116: 1, 12			
33:5,7,15 36:6,10,11 81:10 82:25 86:8,15 97:15 113:1 represent 37:11 revised 37:10			

Buell Realtime Reporting (206) 287-9066

		1		
revolving 18:16 20:20	68:8 69:7,12 71:2	119:24	84:13 87:3 104:17	someplace 85:16
re-explored 103:15	84:7 93:9 99:1 122:8	sent 6:2 58:13 110:20	108:7 121:20	something 6:23 56:22
riddled 38:6	sampling 39:24,25 40:6	113:2 116:19	site 102:13 104:6,8	74:13
right 7:2,3 23:4 41:23	samplings 103:16	sentence 33:22	sitting 54:25 68:6,21	sometime 86:17119:3
43:13 44:12 49:4,15	satisfied 87:25	separate 114:6	120:25	sometimes 39:8 44:8
49:23 53:9 54:4 58:12			situation 5:25 57:2 58:2	117:7
	save 116:13 122:8	separately 74:25		
58:16,20 61:4 66:9	saw 31:7 92:4,24 93:2	sequence 53:22 112:20	66:167:1072:23	somewhere 85:13
88:3 91:2 101:3,19	106:16 112:10 120:2	113:12	76:10 80:11 102:15	106:11
106:18 117:20 119:4	saying 26: 1528:6 30:18	SER 76:20,20	103:10	soon 50:22 81:11
right-sided 52:1	32:14 46:155:15	series 48:15	situations 10:5 34:4	sorry 11:5 53:21 54:1
rind 52:4	65:25 66:5 99:20	serious 69:25 72:23	103:23	55:2 57:1960:8,9,20
risk 89:11,24 104:15,25	100:19,21 101:12	81:22	sizable 119:20	76:25 90:17 91:19
105:9,17,24 106:10	109:19 110:17 119:6	seriously 9:16	size 96:18,25	99:21 111:10
106:25 107:16,19,25	119:23 120:22	set 66:15 123:12	skill 123:11	sort 99:25
108:2,6,12	says 32:19,20 33:2 53:4	setting 64:19 99:11	skilled 103:21	sorting 20:19
Robboy 18:22,24 19:2	54:3 55:2 56:22 61:25	settled 11:9	skip 65:2	sotto 29:9
19:4,12,22 21:1,22	62:8,9,10 66:11 82:24	several 15:20 39:19	slash 120:14	sound 43:13
28:22 29:1,11 46:16	85:11 93:5	52:24 118:20 119:6,9	slide 27:25 37:2 66:14	sounded 77:10
46:23	scan 88:17116:25	severe 39:10 51:24	68:17 69:7 93:17,18	sounds 36:18 107:2
Robboy's 19:17 20:10	scenario 55:6,8 85:6,7	shared 93:9 102:17	93:20,24 94:2	121:13
20:15,21 21:10,16	102:18	shares 56:4 57:6	slides 16:10 21:23,24	sources 49:18
22:4,8,10 29:4 44:16	scenarios 10:1 79:10	sharp 54:5 61:10	22:17,21 24:25 25:1,3	space 120:14
roles 67:22	schedule 88:15	shed 83:20	25:14,14,18,18,20,24	space-time 68:5 69:22
Roman 40: 10	scheduled 117:15 118:4	shoes 120:9	25:25 26:13,23 27:1,3	speak 6:24 18:23 41:2
room 6:1 40:4,7 89:5,13	118:12	Shorie 15:21	27:4,13,14,18 37:7	speaking 20:9 92:2
116:18	scheduling 18:16	Shorthand 123:6	54:13,15 57:4 64:15	special 41:13
Rosenberg 42:21	science 119:14	shortly 57:16,23	65:9,14 66:6,15 67:2	specific 13:4,4 49:25
rotation 115:12	scientific 72:7	show 28:3,4 31:1 46:19	67:3,11 68:3,7 84:24	53:19 119:13
routine 13:25 115:13	seal 123:13	60:11 61:17 91:10	87:16,24 88:10 92:19	specifically 5:3,19 19:9
115:15 118:4 119:21	Seattle 1:18 4:1 48:15	showed 17:7 37:17	94:8 95:2,17 114:5	61:21 77:12 108:4
119:25	76:21	showing 62:14	slightly 33:19	specifics 13:11 38:23
routinely 103:6	second 10:2 17:1,19	shown 39:19	slow 24:8 96:15	specimen 24:25 27:3
RPR 1:23 123:16	39:16 45:6 46:6 88:6	side 39:25 49:5,9 99:20	slowly 57:21	66:4 70:5,6 94:21
rule 39:24 120:14,16,23	90:18 108:16 112:8		snowly 37.21 small 7:1627:24 28:11	specimens 22:20 30:19
121:2		99:21,22		
	second-look 63:1490:2	ssides 27:10	30:8,24 43:24 44:4,5	55:24 65:9 69:15 92:6
rules 51:6 76:10	90:5	sidewall 53:9 74:1	44:1056:257:568:19	94:23 95:11
run 52:24 88:14	section 34:9 39:25	srigned 20:7 21:24 29:16	69:10 96:4 103:16	speculate 86:16 87:10
running 88:15	44:20,24 52:1970:5	significance 37:5 39:14	smaller 96:7,12 110:12	speculation 77:24
run-of-the-mill 41:24	sectioning 103:12	significant 38:16,20	111:23 118:17	speculative 77:25
rupture 6:3 51:19,22	sections 74:15,20	39:20	smallest 35:11	speculum 121:1
52:22 75:20	see 14:1,3 15:25 16:13	similar 56:1 63:24	small-cell 43:22 44:7	speeches 7:19
ruptured 51:4,9,11	17:16 21:8 27:2,14	67:25 70:23 74:23	snapshot 47:6	srpell 4:13
52:14,17 53:14 54:6	28:25 59:18 61:3,3,6	105:12,25 108:14	SNOHOMISH123.4	srpend 116:14
72:1,10,18,2173:4,6	62:23 87:18 106:8	121:9	solely 25:1	spoke 18:25 19:9,12,16
75:2 90:16 100:18,19	111:21	simple 29:1233:20	srolid 35:9 96:10,11	spoken 13:24 18:12
101:6	seed 71:5,12 72:1	simplistic 36:23	some 6:17 10:20 14:24	56:15
ruptures 71:5,11,23	seeing 55:5 65:14	simply 6:9 16:5 25:5	14:25 18:2,14 20:6	sipontaneous 75:21
100:12	seem 97:5 100:4	34:6 49:2 76:7 93:6	23:7 28:1 33:19 40:23	spontaneously 72:18
rupturing 52:8 53:20	seemed 79:4	94:4 96:7 104:9 118:3	43:1754:464:1168:5	73:4 75:3
	seen 5:25 16:10 17:11	since 12:9 22:25 25:3	69:21 70:3 74:6 84:25	spread 74:3,11 96:13
S	20:3 25:3,13,15,25	25:19 27:1,11 33:17	85:20 106:1,3 115:15	96:21
S 2:1	29:4,13 64:21 66:6,14	36:18 53:24 64:15	115:24 117:10	spring 86:17 119:3
sad 23:10	66:15 120:11	104:7	somebody 65:1772:21	ss 122:4 123:3
sake 94:18	sees 37:13	single 69:19	73:16 92:24	stack 48:6.8
same 6:22 9:2,18 23:4	send 16:1 47:7	sit 19:21 20:25 28:21	somebody's 94:6	staff 14:167:24 69:22
35:5 41:4 56:4 57:7	sense 27:6 33:23 41:9	31:22 32:4 49:8 63:20	somehow 97:14 116:6	stage 40:10,16,22 41:12
65:22 66:1867:23	66:23 100:22 113:19	67:271:24 82:11	someone 13:21 88:11	41:22,24 42:2,4,12
00.100/140		للنشاب سنبات	JUNE 13.41 00.11	الملاوا وسودهما المسوسيعين
	I water a second se			

				-
43:3,9,15 44:7,7 45:2	strain 110:23	53:20 55:1 57:17,24	talk 41:17,21 53:16	113:17
50:19,22 62:6,8 74:4	Street 2:3	62:3 63:14 71:5,6,12	99:2	text 26:5 42:21 45:6,9
74:1075:8,877:22	stroma 36:19,20,22,25	71:13,23,25 72:3,18	talked 26:1	45:12,16 46:3,7,10,12
78:16 79:1,6 80:9	37:18 38:4,14	73:6 75:4,4,21 89:6	talking 9:25 10:23 18:3	textbook 40:20 42:3,11
81:9,14 82:10,22 83:2	stromal 36:2,9 37:1,3,5	89:18 90:2,5 100:12	19:20 28:6 36:25 38:4	44:18 45:18,18 47:8
89:14,20 91:5 97:16	38:1,7	103:9 105:7 106:2	41:4 44:21 58:3,6	49:25
97:18 98:22 99:4,13	strong 103:2	113:6 117:18	70:1973:1778:20,24	textbooks 49:22
99:24 100:13 101:2	structured 73:13	surgical 22:20 24:25	80:1 82:23 85:14	texts 44:16 49:17 50:2
staged 6:1178:3,6,11	struggling 72:7	25:1427:3 30:1938:8	96:10,18,19 104:19	Thank 46:13 50:11
78:13 79:25 82:5	stuck 101:10	44:8 52:10 55:24 65:9	109:1114:7	54:8,12 73:11 104:14
stages 40:23 44:5 50:6	studies 39:19 99:10	69:15 70:5 75:15	talks 7:1952:25 54:9	their 13:5,11 23:14 75:3
76:11,13	study 88:19	77:23 89:1194:23	target 91:1	81:17 100:12,13
staging 6:5,6 38:17	studying 45:20	surgically 62:7	taxol 91:3 104:12	103:8
51:6 72:16 73:8 75:15	stutter 33:13	surprised 121:3	technicality 73:12	Thencorsi 41:20
76:5,6 77:23 79:11,20	subject 47:5	survival 39:21 42:4,7,8	Telephonic 10:13	theory 96:2 97:11
79:25 80:5 81:17	submit 74:24	42:12 43:3,5,8 45:3	tell 6:20 7:17 15:6	98:22
stand 116:10	submits 43:6	50:475:6,977:10	18:21,24 19:7 46:12	therapy 64:8 89:25
standard 41:1449:21	submitted 18:11 22:21	78:16,22 79:3,21 80:9	51:7 55:2 77:9 81:19	91:3
73:18 90:23,25 93:25	SUBSCRIBED 122:18	81:4,8,25 82:4,4,7,9	82:24 87:3 121:6	thing 34:24 45:6 58:17
115:12	subsection 44:22	82:19,22,25 97:18,20	telling 9:3 110:14	61:20 65:17 88:9
standpoint 27:7	subsequent 14:23 15:3	98:2,14 99:8,15,18,21	117:16 118:10	106:8 112:16 113:25
start 32:3 37:1 55:17	20:5 59:23 67:9 84:18	101:1,4 102:4,5	ten 48:1096:25	things 53:1,23 66:9
86:25	102:23 111:13 112:6	108:21 109:2,12	Tench 14:17 19:7,10,12	98:25 104:21
started 34: 13 64: 11	116:8,20	110:15	26:6 37:2,17 67:20,23	think 9:23 10:16,21
105:19 107:23 112:15	substantive 17:16	survivals 42:5	68:1,5,20 69:13	13:25 15:23 17:5 18:1
113:1 114:12 117:9	22:15	survive 6:1442:2	Tench's 17:1 19:16	20:24 21:5 22:2,14
starting 9:18	substantively 17:9	survives 111:12	20:14,20 37:13	23:22 24:9,19 26:17
state 4:13 9:5 25:23	substitute 31:12,14	suspect 72:5 117:8	tends 50:5	27: 11 28: 1 29: 12 3 1:3
30:12 52:16,18 61:20	substrata 6:12	121:11	teratoma 5:156:5,8	31:19 32:9 33:10,11
85:5 93:24 97:6	subtleties 75:14	suspected 58:8	tterm 38:19 95:20	33:15,21 39:6 41:10
108:16 109:10 122:3	subtlety 107:5	suspicious 39:22 94:24	tterminology 25:19	47:14 48:6,9 49:5
122:23 123:3,7	subtypes 43:16	95:3 115:3	terms 10:21 29:8 41:5	50:16 51:16 54:10
stated 33:11 105:1	suggest 57:6 93:8	Switzer 2:8	56:12,25 108:9 112:6	56:10,11 57:1 60:25
116:4	108:21	sworn 4:7 122:18 123:9	itest 88:16	60:25 61:11,19 63:23
statement 14:16,17	suggested 56:4	symptom 117:14	testified 4:8 11:3,12,13	66:25 68:13,14,22
20:24 24:19 34:15	suggesting 46:3	symptomatology	18:24 19:2,8,22 21:1	70:171:1876:478:7
35:13 37:24 46:4	suggestive 53:6	114:22	21:22 23:3 27:22	78:8,10,14,23 80:6,13
50:1657:2070:15,20	suggests 75:19	symptoms 115:14,17	28:22 29:1,11,20 31:8	81:6 83:12,21 85:19
70:22 73:14 75:9 81:6	Suite 2:4,9	116:5,5 118:3	43:9,10,12 58:20	86:10,13 87:4 89:8
85:21 98:1 109:18,25	summaries 94:7	syndrome 6:2	61:15 69:9 84:25	91:1,12 93:11,18
110:9 115:6 116:22	summary 14:1622:2	synopsis 47:6	121:21	94: 1297:5 98:14,17
states 28:17 31:18,24	summer 86:18 summertime64:13	syntax 34:4 99:22	testify 5:20 11:7,11	98:18,21 99:25
32:9 62:24 stating 29:6 56:10	Superior 2:9	system 6:5,6,11 40:22	45:22 91:19	100:20 101:11,14,15
	-	43:3 72:16 73:8 75:19	testifying 28:9	102:2,4,5,15,24
114:17	support 96:2	76:5,6 79:11,25 80:5	testimony 9:8,11,15,22	104:24 106:24 108:23
114:17 statistics 78:22 79:21	support 96:2 suppose 5:7	76:5,6 79:11,25 80:5 80:10 82:1,9	testimony 9:8,11,15,22 10:6,21,22,23 18:22	104:24 106:24 108:23 114:3 115:6 116:2,18
114:17 statistics 78:22 79:21 81:9 97:18	support 96:2 suppose 5:7 sure 12:8 13:6 37:21	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22	76:5,6 79:11,25 80:5 80:10 82:1,9	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23 sticking 109:18	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15 86:15 91:16 95:13	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20 S-H-O-R-I-E 15:22 T	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9 22:10 25:2 29:22,25	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19 120:18,25
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23 sticking 109:18 still 59:1 60:13 83:14	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15 86:15 91:16 95:13 114:16 120:3	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20 S-H-O-R-I-E 15:22 T 4:11 122:1 123:1,1	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9 22:1025:2 29:22,25 31:5 32:11,13 61:17	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19 120:18,25 thin-prep 30:17
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23 sticking 109:18 still 59:1 60:13 83:14 84:6 99:7 106:1 107:3	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15 86:15 91:16 95:13 114:16 120:3 surface 34: 18 70:18,23	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20 S-H-O-R-I-E 15:22 T T 4:11 122:1 123:1,1 take 37:9 61:8,9,9 77:5	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9 22:10 25:2 29:22,25 31:5 32:11,13 61:17 61:18 79:11,14,16,23	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19 120:18,25 thin-prep 30:17 third 11:10 88:6
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23 sticking 109:18 still 59:1 60:13 83:14 84:6 99:7 106:1 107:3 stop 118:24	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15 86:15 91:16 95:13 114:16 120:3 surface 34:18 70:18,23 71:1 72:9 79:19	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20 S-H-O-R-I-E 15:22 T 4:11 122:1 123:1,1 take 37:9 61:8,9,9 77:5 89:4 92:7	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9 22:10 25:2 29:22,25 31:5 32:11,13 61:17 61:18 79:11,14,16,23 81:3 85:4 91:9,14	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19 120:18,25 thin-prep 30:17 third 11:10 88:6 thoroughly 89:14
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23 sticking 109:18 still 59:1 60:13 83:14 84:6 99:7 106:1 107:3 stop 118:24 stories 102:17,22	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15 86:15 91:16 95:13 114:16 120:3 surface 34:18 70:18,23 71:1 72:9 79:19 surgeon 22:19 74:2	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20 S-H-O-R-I-E 15:22 T 4:11 122:1 123:1,1 take 37:9 61:8,9,9 77:5 89:4 92:7 taken 1:17,22 4:23	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9 22:10 25:2 29:22,25 31:5 32:11,13 61:17 61:18 79:11,14,16,23 81:3 85:4 91:9,14 92:12,13,25 110:10	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19 120:18,25 thin-prep 30:17 third 11:10 88:6 thoroughly 89:14 though 25:24 41:6,8
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23 sticking 109:18 still 59:1 60:13 83:14 84:6 99:7 106:1 107:3 stop 118:24 stories 102:17,22 story 89:12	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15 86:15 91:16 95:13 114:16 120:3 surface 34: 18 70:18,23 71:1 72:9 79:19 surgeon 22:19 74:2 Surgeons 76:23	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20 S-H-O-R-I-E 15:22 T T 4:11 122:1 123:1,1 take 37:9 61:8,9,9 77:5 89:4 92:7 taken 1:17,22 4:23 30:19 89:9 92:6	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9 22:10 25:2 29:22,25 31:5 32:11,13 61:17 61:18 79:11,14,16,23 81:3 85:4 91:9,14 92:12,13,25 110:10 120:4 121:8,17	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19 120:18,25 thin-prep 30:17 third 11:10 88:6 thoroughly 89:14 though 25:24 41:6,8 44:4 50:2 71:22 84:24
114:17 statistics 78:22 79:21 81:9 97:18 status 75:16,17 77:21 step 69:18 70:21 93:23 sticking 109:18 still 59:1 60:13 83:14 84:6 99:7 106:1 107:3 stop 118:24 stories 102:17,22	support 96:2 suppose 5:7 sure 12:8 13:6 37:21 42:23 44:17 55:22 62:17 71:8 76:15 86:15 91:16 95:13 114:16 120:3 surface 34:18 70:18,23 71:1 72:9 79:19 surgeon 22:19 74:2	76:5,6 79:11,25 80:5 80:10 82:1,9 S-E-R 76:20 S-H-O-R-I-E 15:22 T 4:11 122:1 123:1,1 take 37:9 61:8,9,9 77:5 89:4 92:7 taken 1:17,22 4:23	testimony 9:8,11,15,22 10:6,21,22,23 18:22 19:5,16,17,24,25 20:10,13,14,15,20,22 21:4,7,10,16 22:5,9 22:10 25:2 29:22,25 31:5 32:11,13 61:17 61:18 79:11,14,16,23 81:3 85:4 91:9,14 92:12,13,25 110:10	104:24 106:24 108:23 114:3 115:6 116:2,18 118:9,12 119:2,9,11 121:8,18 thinking 55:18 77:19 120:18,25 thin-prep 30:17 third 11:10 88:6 thoroughly 89:14 though 25:24 41:6,8

[]	/#	1		1
thought 23: 1340:2,3	20:21 21:21 34:19,23	trusted 117:24	67:6 70:2 94:14	variable 102:21
46:15 53:23 58:6,17	87:13 109:7 115:8	try 6:21 27:6 72:13	100:24 113:21	variety 41:12
60:18 74:20 77:10	117:24 121:21	88:14,21 93:7 119:12	understood 7:2	various 42:4
104:18 106:25 110:24	top 49:13 52:21	trying 34:7 46:11 56:13	undertaken 63:10	veer 119:13
118:23,25 120:1,3	tortured 32:1334:4	56:17 60:19 80:4	112:18 113:4,15,17	verbalized 33:12
thoughts 10:11	total 8:2100:23108:6	91:13	underway 60:2	versus 20:19 35:17,21
three 6:9 10:1 11:1,6	totally 43:25 79:10	tubes 57:18,25 103:13	unfair 67:20	42:8 67:10 73:5 74:17
55:22	town 48: 15	Tuesday 19:23	unfortunate 115:18	75:2,4 90:16
threshold 86:8	toxic 88:8	tumor 35:10 49:2,4,14	116:4	very 20:2 21:22 25:20
through 6:17 14:15	track 15:5 49:5	55:25 57:18,24 59:11	unfortunately 106:13	26:3,23 27:9 30:8
25:11 27:16 48:6,9	tracks 76:8	59:19,22 60:12,23	111:13 116:23	31:3,5 33:18 35:4
52:25 53:22 62:10	tract 48:24	61:16 62:11 72:14	unhappy 12:22,23 23:7	38:3 40:3 41:23,24
68:5 69:21 70:18	training 95:6,10,16	73:23 76:17,23 77:18	23:9,22,24	43:23 47:4 50:12,21
73:25 76:24 86:25	transcribed 15:2 56:23	95:21 96:4,6,9,12,18	uniformity 40:23	52:7,13 59:8 66:19
88:14 115:25 116:15	transcript 22:9 29:4,14	96:20,25 97:23 110:4	unimportant 34:6 49:3	67:6 68:13 70:22 81:1
throughout 70:16	33:8,9,25 34:7,9,12	110:11 111:23 118:16	unique 109:15	81:2,21 86:7 88:14
96:22	77:2 123:8	118:20	unknown 72:25 104:3	90:13 93:24 94:12,17
throwing 88:3 101:5,8	transcription 34:5	tumors 6:13 35:9,25	unquote 66:17	98:4 100:10 103:12
tilt 33:19	transcriptionist 33:19	36:1,7,8 37:24,25	unrecognizable 103:20	106:9 109:4,4,5
time 7:14 14:5 16:2	transcripts 16:3 19:5	40:9,15 44:23,23,24	unrecognized 98:21	112:20 113:12,19
17:18 21:24 22:18	34:2 37:20	70:16 96:10,11 104:7	unresponsive 109:15	115:6 121:14
23:1939:2355:14	transferring 41:19	turn 117:22		vesicouterine 53:10,11
60:15 61:12,16 62:3,7	transformation 47:15	turns 38:25	until 63:21,25 68:25	view 104:4
62:11,19 63:24 64:1,3	47:18 60:1	two 9:7 11:1 13:18 16:6	111:18 112:25 113:23	viewed 84:18
	treat 70:12 90:21 91:2	17:17 25:16 26:1,19	115:19 116:8,17	violation 68:5 69:21
89:18 95:10,17 98:8	96:4,6,9,11 97:2	26:21 76:4 79:10 82:6	upper 48:12 77:21	Virginia 7:17 12:12
102:7 103:8 105:5,22	102:13 110:11	96:15,24 97:198:4,25	80:15 88:19 89:7	67:4
106:2,6 107:14 111:6	treatable 111:2,5	104:21 112:1	upset 119:15	virtually 57:4
112:9,19,25 113:8,14	treated 48:9 71:4 97:24	Itwo-part 82:17	upstage 100:6	visible 48:25 visit 117:15 118:4,13,21
113:19,24 114:11,22	102:11,19 111:1,18	ttype 5:13,15 29:20 90:8 98:23 104:10 110:22	upwards 48:11	Vitae 3: 15
115:7,10 116:13,14 118:22 119:8	treating 87:12,15 104:9 treatment 40:24 47:9	itypes 80:21 106:7	urinary 114:21 use 43:157:1476:6	vice 3.15
timely 13:8	58:23 62:5 77:7 81:22	120:11	93:12 105:11 106:23	volumes 16:6
times 4:25 5:1 7:4,8	87:22 89:2 103:25	typical 33: 12 41:24	121:12	volumes 10.0 vs 1:8
9:21 16:18 48:3,5	104:10 111:7 114:20	92:1 99:11 107:7	used 7: 14 49:22 80:25	V-E-S-I-C-0-U-T-E
-	treatments 64:12	117:3	90:24 93:14 96:2	53:11
tiny 96:24	trial 4:22 8:9 10:6,8,22	typically 24:3,12,17	uses 76:4	55.11
tired 91:20	11:7,10,11,11	typographical 92:3	using 30:6 45:24 56:12	W
	tried 119:16	cypographical 72.5	74:5 79:20 80:10	wait 6:20 32:24 87:21
	triggering 107:8	U	81:16,25	115:8 118:10
	triggers 106:7	unable 102:12	usual 13:25 88:16,23	waited 115:19 116:6
	tripped 73:15	inambiguously 90:19	uterus 57:18,25	want 6:17 10:17 17:11
,	trouble 109:1	unclear 21:5	utilization 18:12	32:25 36:17 38:23
	true 25:15 26:2,19,25	under 37:14 38:13 43:3	utilize 82:3	57:11 59:4 65:1 71:19
tissues 58:6,19 61:5	35:25 36:7 44:9,10	53:2,4 54:3 74:7	itilized 79:12	80:12 82:7 96:9,11
74:12 97:8	50:16 51:5 58:24 59:8	underestimation 48:1		97:2 104:22 118:14
today 4:18 11:23 16:15	59:11 63:9 64:10	undergoes 47:18	<u> </u>	wanted 31:25 39:24
17:18 18:10 19:21	66:10,12 70:8,9,13,14	undergoing 102:25	W122:1	94:17
20:13,25 28:21 31:22	70:15,20,22 71:22	underrepresentative	vaginal 56:1 58:5 61:7	wanting 43:7 55:6
32:5,5 49:8 87:3	72:19,20 73:18 74:15	31:7	64:1,13,20 65:6,22,25	wants 87:21
121:20	75:24 76:3,11 84:21	urnderstand 6:23 12:23	66:14 69:1,7 91:9	wash 28:25 54:13,15,19
today's 17:23	84:22 85:12 90:25	13:6,7,10 14:25 21:9	93:1112:16,23114:1	55:6 57:4 59:23 83:18
together 17:21 36:23	96:5 98:23 111:19,20	38:3 41:7 74:2	114:11,22 115:17,21	84:24 95:2
48:13 61:22 67:4	111:24 112:14,19	understandably 23:9	115:24 116:8,9,11,17	washing 2 1:2 22:2 1
96:1697:198:25	113:5 114:14,23	understanding 12:18	116:20,23 118:16	25:1,14 27:4 68:3
112:21	117:10 122:8 123:10	12:21 13:4 21:21 23:6	119:21 120:21	70:7 100:20
	1		1 45 0	1. 15 10 00 00
told 17:24 18:1 19:2	truly 98:2 120:7	23:8 36:20 43:8 66:25	value 47:8	washings 15:18 28:22

Howard Muntz, M.D.

Page 15

			· · · · · · · · · · · · · · · · · · ·	·····
29:22 30:1,9 51:4	113:22,23 115:7	wrong 99:20,21,22	86:18,20,22 92:19,22	99 14:15 24:25 57:4,15
55:3,8 64:18 65:9,12	weren't 76: 15 118:22	118:9	94:8 108:20 110:2,5	57:17,24 58:7,8 59:9
	1	wrote 25:22	110:21 111:3 112:9	59:22 62:24 67:24
70:12 75:23 83:15,22	we're 4:18,19 38:4	wrote 25.22		
84:3,14,21 85:8,19	46:25 54:19,20 55:5	X	112:23 113:8,14,23	68:6,10 69:16 78:7,8
87:14 97:6,14 100:3,6	55:20 60:14,15 72:13		117:1 119:10,19	78:9,13 83:11 84:14
100:14,16 101:7,18	73:12,15 76:18,19	X 4:11	121:23	86:9,18 87:12 92:22
101:22,24,25 102:12	77:1278:23 80:11	X-ray 88:17	2002 1:22 4:1 13:16,18	92:24 94:21 102:4
103:6,25 115:2	85:14 99:1 100:19,21		25:23 32:5 122:19	117:18 119:3
Washington 1:18 4:1	104:2,7 109:1114:6	<u> </u>	123:10,13	
122:3,23 123:3,7	we've 78:22 101:13	year 7:11,13 13:16	2006 123:18	
wasn't 7:17 21:15	104:11	105:10 110:2 115:5	22 1:22 4:1 123:10	
26:15 53:18 63:21	WHEREOF 123:12	117:17,23 118:10	24th 123:13	
68:25 78:3,5 111:2,21	whole 59:13 60:13	years 7:9 42:2 44:17	27 13:18 25:23	
way 5:7 10:19 21:18	77:25 90:15 94:16	45:19 48:10 52:9	28 123:18	
25:4,9 28:5 29:7	96:8	yesterday 17:8,21,25	29 31:23 51:20 54:15	
36:16,24 38:1239:20	widespread 111:19	18:5,6,7,13,21 21:11	55:25 57:15,22 77:8	
41:10 48:4 49:17	william 2:7 14:16	21:17 22:5,12	84:4,7 86:5	
50:23,24 51:22 57:1	willing 45:23 101:5	yesterday's 18:4	29th 31:932:6	
-	witness 4:6 5:7,10 7:5	yielded 11:6	· · · · · · · · · · · · · · · · · · ·	
58:1 61:1 64:15 67:1	-	young 5:14 105:21	3	
68:13 69:4 71:2 81:19	8:25 9:11 19:13 33:4	107:24	331:18 32:8	
86:15 98:8 101:4	45:17 65:2 98:16	107.24		
104:3,15 114:24	116:1,12 119:15	Z	30 40:8,14 79:1 80:17	
121:16	123:12		81:4	
ways 82:6	witnesses 86:8	zero 108:22 109:4	37 91:21	
Wednesday 19:8	woman 5:14,25 74:22	110:15	38 31:23 34:9	
week 15:1 19:23 20:15	88:7 102:25 121:14	1	39 31:17,24 32:8 34:10	
20:23 22:11	woman's 76:11		61:25	
weeks 73:1	women 39:10 47:22,23	1 3:15 4:4 14:2 52:21		
Weiss 14:17 26:6 97:5,7	50:5 82:9 83:4 104:19	75:20 82:6	4	
97:13 99:6 100:1	106:3,4 109:20 117:6	11 62:10 105:20	43:7,15	
101:1	wonder 90:14 120:22	11:55 121:25	- 3th 32:5	
welcome 116:14	wondering 55:13	1200 2:3	· 30 61:24 80:18 81:4	
well 24:25 25:2,18 27:9	word 31:12,13 53:12	13 62:10	· 339194 1:8	
28:24 30:16 39:18	56:7,12,19 57:9,14	1326 1:17	44114-1491 2:10	
51:15 56:20 68:24	80:24 93:12,14,14,15	1400 2:9		
70:6,1175:2177:24	106:23 109:9	19 44:20	5	
87:23 92:7 101:13,22	words 20:7 21:7 67:15	1976 105:8	50 48:16 82:13 102:9	
108:14 119:8	70:25 75:12 100:15	1999 20:4 26:9 30:16	109:6,7,12	
well-differentiated	111:4	30:17 31:9,23 32:6	51 86:10	
35:17 83:5	worked 7:22 8:169:22	34:21 51:20 54:16	:52 104:17 105:1 107:3	
went 11:6,9,10 32:2	working 8:11 12:8	55:25 57:22 58:11	\$26 2:9	
48:9 91:15 118:5	103:21	59:12,15 60:22 65:8	532 45:4	
were 5:2,13,24 7:25	workup 75:16 88:23	69:23 77:9 79:2 83:11	\$\$50 2:4	
8:11 9:2 13:14 14:14	90:7	84:4,7 85:23,25 86:5		
15:1,8,16 17:4 18:3	worried 83:1	9 1:2 98:3,12,14,24	6	
18:15 19:20 20:20	worse 77:23 82:25	102:6 106:3 108:19	60 82:13 97:21 98:15	
21:2 25:24 26:2,13,22	100:6 101:12	108:22 109:5,11,23		
37:3,4 39:22 40:2,4	worst 39:9	110:3,6,16 112:4	8	
53:23 54:10,14 63:7	worst 39.9 worth 34:7	1101090910 11417	8 91:24	
	worth 34.7 wouldn't 27:1143:24	2	4th 115:22 116:11,17	
64:16 65:10 66:7,17		2 14:2 52:21 82:16,18	80 43:12 45:4 77:10	
74:20 75:12,12,13	45:22 100:21	20 10:19 48:12 98:18	78:1479:4 80:13	
78:13,20,21 83:22	wrap 109:3		97:19,21 98:15	
84:16 87:11,13,19,25	write 74:14	102:3,6 108:25 109:6	91.17,41 70.13	
90:6 92:4,8,9,10,11	writing 13:17 26:21	109:6,12,20 111:8,11	9	
100:14 102:12 104:24	written 18:9 26:6 44:16	2000 14:16 56:2,3 57:6		
108:22 110:5,6	44:19 45:24 56:19	63:22,25 64:2,5,13,21	9:00 4:2	
112:18 113:4,15,17	68:8 74:10	65:6,23 66:13 68:18	\$,2037 2:4	
112.10 115.7,15,17				

Buell Realtime Reporting (206) 287-9066

,